Patent Application
20130303533
Provided herein are compounds that are modulators of JAK kinases, compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention, or amelioration of a disease or disorder related to JAK, including JAK2, JAK3 or TYK2 kinases, or one or more symptoms associated with such diseases or disorders. Further provided are methods for treatment of cancer, including blood borne and solid tumors.
The JAK kinase family is a cytoplasmic protein kinase family comprising the members JAK1, JAK2, JAK3 and TYK2. Growth factor or cytokine receptors that recruit JAK kinases include the interferon receptors, interleukin receptors (receptors for the cytokines IL-2 to IL-7, IL-9 to IL-13, IL-15, IL-23), various hormone receptors (erythropoietin (Epo) receptor, the thrombopoietin (Tpo) receptor, the leptin receptor, the insulin receptor, the prolactin (PRL) receptor, the Granulocyte Colony-Stimulating Factor (G-CSF) receptor and the growth hormone receptor, receptor protein tyrosine kinases (such as EGFR and PDGFR), and receptors for other growth factors such as leukemia inhibitory factor (LIF), Oncostatin M (OSM), IFNα/β/γ, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) (See, Rane, S. G. and Reddy E. P., Oncogene 2000 19, 5662-5679).
Phosphorylated receptors serve as docking sites for other SH-2 domain containing signaling molecules that interact with JAKs such as the STAT family of transcription factors, Src family of kinases, MAP kinases, PI3 kinase and protein tyrosine phosphatases (Rane S. G. and Reddy E. P., Oncogene 2000 19, 5662-5679). The family of latent cytoplasmic transcription factors, STATs, is the most well characterized downstream substrates for JAKs. The STAT proteins bind to phosphorylated cytokine receptors through their SH2 domains to become phosphorylated by JAKs, which leads to their dimerization and release and eventual translocation to the nucleus where they activate gene transcription. The various members of STAT which have been identified thus far, are STAT1, STAT2, STAT3, STAT4, STATS (including STAT5a and STAT5b) and STATE.
Since the JAK kinases may play an important signaling role via such receptors, disorders of fat metabolism, growth disorders and disorders of the immune system are all potential therapeutic targets.
The JAK kinases and JAK2 mutations are implicated in myeloproliferative disorders, cancers, including blood borne and solid tumors. Exemplary disorders include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), chronic myelomonocytic leukemia (CMML) and systemic mastocytosis (SM). Myeloproliferative disorders are believed to arise from either gain-of-function mutations to JAK itself or from activation by the oncoprotein BCR-ABL, which specifically activates the JAK2 pathway. Several literature reports describe role of JAK2 mutations in various disorders. See, Samanta et al. Cancer Res 2006, 66(13), 6468-6472, Sawyers et al. Cell, 1992, 70, 901-910, Tefferi N. Eng. J. Med. (2007) 356(5): 444-445) Baxter et al. Lancet (2005) 365:1054-1056, Levine et al. Blood (2006, Jones et al. Blood (2005) 106:2162-2168) 107:4139-4141, Campbell et al. Blood (2006) 107(5): 2098-2100, Scott et al. N Eng J Med 2007 356(5): 459-468, Mercher et al. Blood (2006) 108(8): 2770-2778, Lacronique et al. Science (1997) 278:1309-1312, Lacronique et al. Blood (2000) 95:2535-2540, Griesinger F. et al. Genes Chromosomes Cancer (2005) 44:329-333, Bousquet et al. Oncogene (2005) 24:7248-7252, Schwaller et al. Mol. Cell. 2000 6, 693-704, Zhao et al. EMBO 2002 21(9), 2159-2167.
Literature indicates that JAK may also serve as a target for prostate cancer, including androgen-resistant prostate cancer. See, Barton et al. Mol. Canc. Ther. 2004 3(1), 11-20, Blume-Jensen et al. Nature (2001) 411(6835):355-356 and Bromberg J Clin Invest. (2002) 109(9):1139-1142, Rane Oncogene (2000) 19(49):5662-5679. JAK as a prominent mediator of the cytokine signaling pathway, is considered to be a therapeutic target for inflammation and transplant rejections. See, Borie et al., Transplantation (2005) 79(7):791-801 and Milici et al., Arthritis Research (2008) 10(R14):1-9
Given the multitude of diseases attributed to the dysregulation of JAK signaling, many small molecule inhibitors of JAK are currently being developed. Examples of compounds in preclinical development include TG101209 (TargeGen). Examples of compounds being investigated in clinical studies include INCB018424 (Incyte), XL019 (Exelixis) and TG101348 (TargeGen). See, Pardanani et al. Leukemia 2007, 21:1658-1668; and Pardanai, A. Leukemia 2008 22:23-20.
There is, however, an ever-existing need to provide novel classes of compounds that are useful as inhibitors of enzymes in the JAK signaling pathway.
Provided herein are compounds of formula (I)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A is azolyl;
B is aryl or heteroaryl;
A3 and A4 are each independently N or CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
each R3 is independently hydrogen, deutero, halo, alkyl, cyano, haloalkyl, deuteroalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen, alkyl, alkenyl or alkynyl;
each R6 is independently selected from hydrogen, deutero, halo, nitro, cyano, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz, —RxS(O)qRv, —RxNR19C(O)R18, —RxC(O)OR18 and —RxNR19S(O)X; where the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one, two or three halo, oxo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl groups;
each R6a is independently hydrogen, cyano or alkyl;
each R7 is independently halo, alkyl, haloalkyl or —RxORw;
Rx is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or —C(O)OR8;
R12 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)Rv, —C(O)ORw or —C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, —C(O)Rv, —C(O)ORw, —C(O)NRyRw or —S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl are substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)NRyRz or —NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently selected from alkyl, hydroxyl, halo, oxo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, carboxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
R19 and R20 are selected as follows:
R21 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl;
each R22 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; or both R22, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted with oxo;
R23 is alkyl, alkenyl, alkynyl or haloalkyl;
R24 is hydrogen or alkyl;
each Rx is independently alkylene, alkenylene, alkynylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
r is 1-3;
p is 0-4; and
each q is independently 0, 1 or 2.
In certain embodiments, the compounds have activity as JAK kinase, including JAK2 kinase, modulators. The compounds are useful in medical treatments, pharmaceutical compositions and methods for modulating the activity of JAK kinase, including wildtype and/or mutated forms of JAK kinase. In certain embodiments, the compounds provided herein have activity as JAK2 kinase modulators. In certain embodiments, the compounds are inhibitors of JAK kinase, including JAK2 kinase.
In one embodiment, the compounds for use in the compositions and methods provided herein are compounds of formula (I).
In one embodiment, the compound provided herein is a compound of formula (I). In one embodiment, the compound provided herein is a pharmaceutically acceptable salt of the compound of formula (I). In one embodiment, the compound provided herein is a solvate of the compound of formula (I). In one embodiment, the compound provided herein is a hydrate of compound of formula (I).
Also provided are pharmaceutical compositions formulated for administration by an appropriate route and means containing effective concentrations of one or more of the compounds provided herein, or pharmaceutically acceptable salts, solvates and hydrates thereof, and optionally comprising at least one pharmaceutical carrier.
Such pharmaceutical compositions deliver amounts effective for the treatment, prevention, or amelioration of diseases or disorders that include without limitation, myeloproliferative disorders such as polycythemia vera (PCV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic eosinophilic leukemia (CEL), chronic myelomonocytic leukemia (CMML), systemic mastocytosis (SM) and idiopathic myelofibrosis (IMF); leukemia such as myeloid leukemia including chronic myeloid leukemia (CML), imatinib-resistant forms of CML, acute myeloid leukemia (AML), and a subtype of AML, acute megakaryoblastic leukemia (AMKL); lymphoproliferative diseases such as myeloma; cancer such as cancer of the head and neck, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancers, brain tumors, pancreatic cancer and renal cancer; and inflammatory diseases or disorders related to immune dysfunction, immunodeficiency, immunomodulation, autoimmune diseases, tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease, diabetic neuropathy, multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, psoriasis, allergic rhinitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis (UC), systemic lupus erythematosis (SLE), arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma chronic obstructive pulmonary disease (COPD) and dry eye syndrome (or keratoconjunctivitis sicca (KCS)). In one embodiment, such diseases or disorders are modulated or otherwise affected by the JAK kinases, including JAK2, JAK3 or TYK2.
Also provided herein are combination therapies using one or more compounds or compositions provided herein, or pharmaceutically acceptable salts, solvates or hydrates thereof, in combination with other pharmaceutically active agents for the treatment of the diseases and disorders described herein.
In one embodiment, such additional pharmaceutical agents include one or more chemotherapeutic agents, anti-proliferative agents, anti-inflammatory agents, immunomodulatory agents or immunosuppressive agents.
The compounds or compositions provided herein, or pharmaceutically acceptable salts, solvates or hydrates thereof, may be administered simultaneously with, prior to, or after administration of one or more of the above agents. Pharmaceutical compositions containing a compound provided herein and one or more of the above agents are also provided.
In certain embodiments, provided herein are methods of treating, preventing or ameliorating a disease or disorder that is modulated or otherwise affected by JAK kinases, including JAK2 kinase such as wild type and/or mutant JAK2 kinase, or one or more symptoms or causes thereof. In another embodiment, provided herein are methods of treating, preventing or ameliorating a disease or disorder by modulating the JAK2 kinase selectively over JAK3 kinase. In yet another embodiment, provided herein are methods of treating, preventing or ameliorating a disease or disorder by modulating the JAK3 kinase selectively over JAK2 kinase. In another embodiment, provided herein are methods of treating, preventing or amerliorating a disease or disorder by modulating both JAK2 and JAK3. In one embodiment, provided are methods for treatment of cancer, including blood borne and solid tumors.
In practicing the methods, effective amounts of the compounds or compositions containing therapeutically effective concentrations of the compounds, which are formulated for systemic delivery, including parenteral, oral, or intravenous delivery, or for local or topical application are administered to an individual exhibiting the symptoms of the disease or disorder to be treated. The amounts are effective to ameliorate or eliminate one or more symptoms of the disease or disorder.
These and other aspects of the subject matter described herein will become evident upon reference to the following detailed description.
Provided herein are compounds of formula (I) that have activity as JAK kinase, including JAK2 kinase, modulators. Further provided are methods of treating, preventing or ameliorating diseases that are modulated by JAK kinases, including JAK2 kinase, and pharmaceutical compositions and dosage forms useful for such methods. The methods and compositions are described in detail in the sections below.
In certain embodiments, the compounds provided herein are JAK2 selective, i.e., the compounds bind or interact with JAK2 at substantially lower concentrations than they bind or interact with other JAK receptors, including JAK3 receptor, at that same concentration. In certain embodiments, the compounds bind to JAK3 receptor at a binding constant at least about 3-fold higher, about 5-fold higher, about 10-fold higher, about 20-fold higher, about 25-fold higher, about 50-fold higher, about 75-fold higher, about 100-fold higher, about 200-fold higher, about 225-fold higher, about 250 fold higher, or about 300 fold higher than they bind JAK2 receptor.
In certain embodiments, the compounds provided herein are JAK3 selective, i.e., the compounds bind or interact with JAK3 at substantially lower concentrations than they bind or interact with other JAK receptors, including JAK2 receptor, at that same concentration. In certain embodiments, the compounds bind to JAK2 receptor at a binding constant at least about 3-fold higher, about 5-fold higher, about 10-fold higher, about 20-fold higher, about 25-fold higher, about 50-fold higher, about 75-fold higher, about 100-fold higher, about 200-fold higher, about 225-fold higher, about 250 fold higher, or about 300 fold higher than they bind with JAK3 receptor.
In certain embodiments, the compounds provided herein have Kd of greater than about 10 nM, 20 nM, 25 nM, 40 nM, 50 nM, or 70 nM against Aurora B kinase. Methods for determining binding constant against Aurora B kinase are known to one of skill in the art. Exemplary methods are described in U.S. provisional application No. 61/294,413, and Fabian et al., Nature Biotechnology 2005, 23, 329-336.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.
“Alkyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to ten, one to eight, one to six or one to four carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1-methylethyl (iso-propyl), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), and the like.
“Alkenyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one double bond, in certain embodiment, having from 2 to 10 carbon atoms, from 2 to 8 carbon atoms, or from 2 to 6 carbon atoms, and which is attached to the rest of the molecule by a single bond or a double bond, e.g., ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.
“Alkynyl” refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, having from two to ten carbon atoms, and which is attached to the rest of the molecule by a single bond or a triple bond, e.g., ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-ynyl, pent-3-ynyl and the like.
“Alkylene” and “alkylene chain” refer to a straight or branched divalent hydrocarbon chain consisting solely of carbon and hydrogen, containing no unsaturation and having from one to eight carbon atoms, e.g., methylene, ethylene, propylene, n-butylene and the like. The alkylene chain may be attached to the rest of the molecule through any two carbons within the chain.
“Alkoxy” refers to the group having the formula —OR wherein R is alkyl or haloalkyl, where the alkyl may be optionally substituted by one or more substituents, in one embodiment, one, two or three substitutents independently selected from the group consisting of nitro, halo, hydroxyl, alkoxy, oxo, thioxo, amino, carbony, carboxy, azido, cyano, cycloalkyl, heteroaryl, and heterocyclyl.
“Alkoxyalkyl” refers to a group having the formula —RhOR wherein Rh is a straight or branched alkylene chain and OR is alkoxy as defined above.
“Alkylthio” refers to a group having the formula —SR wherein R is alkyl or haloalkyl.
“aryloxy” refers to the group —OR, in which R is aryl, including lower aryl, such as phenyl.
“Amine” or “amino” refers to a group having the formula —NR′R″ wherein R′ and R″ are each independently hydrogen, alkyl, haloalkyl, hydroxyalkyl or alkoxyalkyl or wherein R′ and R″, together with the nitrogen atom to which they are attached form a heterocyclyl optionally substituted with halo, oxo, hydroxy or alkoxy.
“Aminoalkyl” refers to a group having the formula —RhNR′R″ wherein Rh is a straight or branched alkylene chain and wherein NR′R″ is amino as defined above.
“Aminocarbonyl” refers to a group having the formula —C(O)NR′R″ wherein —NR′R″ is amino as defined above.
“Aryl” refers to a group of carbocylic ring system, including monocyclic, bicyclic, tricyclic, tetracyclic C6-C18 ring systems, wherein at least one of the rings is aromatic. The aryl may be fully aromatic, examples of which are phenyl, naphthyl, anthracenyl, acenaphthylenyl, azulenyl, fluorenyl, indenyl and pyrenyl. The aryl may also contain an aromatic ring in combination with a non-aromatic ring, examples of which are acenaphene, indene, and fluorene. The term includes both substituted and unsubstituted moieties. The aryl group can be substituted with any described moiety, including, but not limited to, one or more moieties selected from the group consisting of halo (fluoro, chloro, bromo or iodo), alkyl, hydroxyl, amino, alkoxy, aryloxy, nitro and cyano.
“Cycloalkyl” refers to a stable monovalent monocyclic or bicyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having from three to ten carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, decalinyl, norbornane, norbornene, adamantyl, bicyclo[2.2.2]octane and the like.
“Cycloalkylalkyl” refers to a group of the formula —RaRd where Ra is an alkyl group as defined above and Rd is a cycloalkyl group as defined above. The alkyl group and the cylcoalkyl group may be optionally substituted as defined herein.
“Deutero” or “deuterium” refers to the hydrogen isotope deuterium having the chemical symbol D.
“Deuteroalkyl” refers to an isotopically enriched alkyl group in which one or more of the hydrogen atoms are replaced by deuterium.
“Halo”, “halogen” or “halide” refers to F, Cl, Br or I.
“Haloalkyl” refers to an alkyl group, in certain embodiments, C1-6alkyl group in which one or more of the hydrogen atoms are replaced by halogen. Such groups include, but are not limited to, chloromethyl, trifluoromethyl, 1-chloro-2-fluoroethyl, 2,2-difluoroethyl, 2-fluoropropyl, 2-fluoropropan-2-yl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, 1,3-difluoro-2-methylpropyl, 2,2-difluorocyclopropyl, (trifluoromethyl)cyclopropyl, 4,4-difluorocyclohexyl and 2,2,2-trifluoro-1,1-dimethyl-ethyl.
“Heterocyclyl” refers to a stable 3- to 15-membered ring group which consists of carbon atoms and from one to five heteroatoms selected from a group consisting of nitrogen, oxygen and sulfur. In one embodiment, the heterocyclic ring system group may be a monocyclic, bicyclic or tricyclic ring or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen or sulfur atoms in the heterocyclic ring system group may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl group may be partially or fully saturated or aromatic. The heterocyclic ring system may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Exemplary heterocylic radicals include, azetidinyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, chromanyl, chromonyl, coumarinyl, decahydroisoquinolinyl, dibenzofuranyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydropyranyl, dioxolanyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrazolyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1,4 dithianyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isochromanyl, isocoumarinyl, benzo[1,3]dioxol-5-yl, benzodioxolyl, 1,3-dioxolan-2-yl, dioxolanyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, tetrahydrofuran, oxazolidin-2-onyl, oxazolidinonyl, piperidinyl, piperazinyl, pyranyl, tetrahydrofuryl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydrothienyl, pyrrolidinonyl, oxathiolanyl, and pyrrolidinyl.
“Heteroaryl” refers to a heterocyclyl group as defined above which is aromatic. The heteroaryl group may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound. Examples of such heteroaryl groups include, but are not limited to: acridinyl, benzimidazolyl, benzindolyl, benzisoxazinyl, benzo[4,6]imidazo[1,2-α]pyridinyl, benzofuranyl, benzonaphthofuranyl, benzothiadiazolyl, benzothiazolyl, benzothiophenyl, benzotriazolyl, benzothiopyranyl, benzoxazinyl, benzoxazolyl, benzothiazolyl, β-carbolinyl, carbazolyl, cinnolinyl, dibenzofuranyl, furanyl, imidazolyl, imidazopyridinyl, imidazothiazolyl, indazolyl, indolizinyl, indolyl, isobenzothienyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, naphthyridinyl, octahydroindolyl, octahydroisoindolyl, oxazolidinonyl, oxazolidinyl, oxazolopyridinyl, oxazolyl, isoxazolyl, oxiranyl, perimidinyl, phenanthridinyl, phenathrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyridopyridinyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazinyl and triazolyl.
“Azolyl” refers to a 5-membered heterocyclic or heteroaryl ring system containing at least one nitrogen atom. Exemplary azolyl rings include pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, diazolyl, and triazolyl.
“Aralkyl” refers to a group of the formula —RaRb where Ra is an alkyl group as defined above, substituted by Rb, an aryl group, as defined above, e.g., benzyl. Both the alkyl and aryl groups may be optionally substituted as defined herein.
“Heteroaralkyl” refers to a group of the formula —RaRf where Ra is an alkyl group as defined above and Rf is a heteroaryl group as defined herein. The alkyl group and the heteroaryl group may be optionally substituted as defined herein.
“Heterocyclylalkyl” refers to a group of the formula —RaRe, wherein Ra is an alkyl group as defined above and Re is a heterocyclyl group as defined herein, where the alkyl group Ra may attach at either the carbon atom or the heteroatom of the heterocyclyl group Re. The alkyl group and the heterocyclyl group may be optionally substituted as defined herein.
“Alkoxycarbonyl” refers to a group having the formula —C(O)OR in which R is alkyl, including lower alkyl.
The term “dioxacycloalkyl” as used herein means a heterocyclic group containing two oxygen ring atoms and two or more carbon ring atoms.
“Oxo” refers to the group ═O attached to a carbon atom.
“Thioalkyl” refers to a group having the formula —RhSRi, where the Rh is a straight or branched alkylene chain and Ri is alkyl or haloalkyl.
“Thioxo” refers to the group ═S attached to a carbon atom.
“IC50” refers to an amount, concentration or dosage of a particular test compound that achieves a 50% inhibition of a maximal response, such as cell growth or proliferation measured via any the in vitro or cell based assay described herein.
Unless stated otherwise specifically described in the specification, it is understood that the substitution can occur on any atom of the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group.
Pharmaceutically acceptable salts include, but are not limited to, amine salts, such as but not limited to N,N′-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methylglucamine, procaine, N-benzylphenethylamine, 1-para-chlorobenzyl-2-pyrrolidin-F-ylmethylbenzimidazole, diethylamine and other alkylamines, piperazine and tris(hydroxymethyl)aminomethane; alkali metal salts, such as but not limited to lithium, potassium and sodium; alkali earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, such as but not limited to zinc; and inorganic salts, such as but not limited to, sodium hydrogen phosphate and disodium phosphate; and also including, but not limited to, salts of mineral acids, such as but not limited to hydrochlorides, hydrobromides, phosphates and sulfates; and salts of organic acids, such as but not limited to acetates, lactates, malates, tartrates, citrates, ascorbates, succinates, butyrates, valerates, mesylates, esylates, tosylates, besylates, trifluoroacetates, benzoates, fumarates, maleates, and oxalates.
As used herein and unless otherwise indicated, the term “hydrate” means a compound provided herein or a salt thereof, that further includes a stoichiometric or non-stoichiometeric amount of water bound by non-covalent intermolecular forces.
As used herein and unless otherwise indicated, the term “solvate” means a solvate formed from the association of one or more solvent molecules to a compound provided herein. The term “solvate” includes hydrates (e.g., mono-hydrate, dihydrate, trihydrate, tetrahydrate and the like).
As used herein, “substantially pure” means sufficiently homogeneous to appear free of readily detectable impurities as determined by standard methods of analysis, such as thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC) and mass spectrometry (MS), used by those of skill in the art to assess such purity, or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, such as enzymatic and biological activities, of the substance. Methods for purification of the compounds to produce substantially chemically pure compounds are known to those of skill in the art. A substantially chemically pure compound may, however, be a mixture of stereoisomers. In such instances, further purification might increase the specific activity of the compound.
Unless specifically stated otherwise, where a compound may assume alternative tautomeric, regioisomeric and/or stereoisomeric forms, all alternative isomers are intended to be encompassed within the scope of the claimed subject matter. For example, where a compound is described as having one of two tautomeric forms, it is intended that the both tautomers be encompassed herein. Thus, the compounds provided herein may be enantiomerically pure, or be stereoisomeric or diastereomeric mixtures.
It is to be understood that the compounds provided herein may contain chiral centers. Such chiral centers may be of either the (R) or (S) configuration, or may be a mixture thereof.
Optically active (+) and (−), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as reverse phase HPLC or by crystallization.
As used herein, the term “enantiomerically pure” or “pure enantiomer” denotes that the compound comprises more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight or more than 99.9% by weight, of the desired enantiomer.
Where the number of any given substituent is not specified (e.g., haloalkyl), there may be one or more substituents present. For example, “haloalkyl” may include one or more of the same or different halogens.
In the description herein, if there is any discrepancy between a chemical name and chemical structure, the structure preferably controls.
As used herein, “isotopic composition” refers to the amount of each isotope present for a given atom, and “natural isotopic composition” refers to the naturally occurring isotopic composition or abundance for a given atom. Atoms containing their natural isotopic composition may also be referred to herein as “non-enriched” atoms. Unless otherwise designated, the atoms of the compounds recited herein are meant to represent any stable isotope of that atom. For example, unless otherwise stated, when a position is designated specifically as “H” or “hydrogen”, the position is understood to have hydrogen at its natural isotopic composition.
As used herein, “isotopically enriched” refers to an atom having an isotopic composition other than the natural isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom.
As used herein, “isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope at a given atom in a molecule in the place of that atom's natural isotopic abundance. For example, deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The isotopic enrichment of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.
In certain embodiments, compounds herein having one or more deutero substituents have an isotopic enrichment factor for each designated deuterium atom of from about 50% to about 99.5%, 60% to about 99.5%, 70% to about 99.5% deuterium incorporation.
In certain embodiments, compounds herein having one or more deutero substituents have an isotopic enrichment factor for each designated deuterium atom of at least about 3500 (about 52.5% deuterium incorporation), at least about 4000 (about 60% deuterium incorporation), at least about 4500 (about 67.5% deuterium incorporation), at least about 5000 (about 75% deuterium incorporation), at least about 5500 (82.5% deuterium incorporation), at least about 6000 (about 90% deuterium incorporation), at least about 6466.7 (about 97% deuterium incorporation), at least about 6600 (about 99% deuterium incorporation), or at least about 6633.3 (99.5% deuterium incorporation).
In certain embodiments, compounds herein having one or more deutero substituents have an isotopic enrichment factor for each designated deuterium atom of about 3500 (about 52.5% deuterium incorporation), about 4000 (about 60% deuterium incorporation), about 4500 (about 67.5% deuterium incorporation), about 5000 (about 75% deuterium incorporation), about 5500 (82.5% deuterium incorporation), about 6000 (about 90% deuterium incorporation), about 6466.7 (about 97% deuterium incorporation), about 6600 (about 99% deuterium incorporation), or about 6633.3 (99.5% deuterium incorporation).
“Anti-cancer agents” refers to anti-metabolites (e.g., 5-fluoro-uracil, methotrexate, fludarabine), antimicrotubule agents (e.g., vinca alkaloids such as vincristine, vinblastine; taxanes such as paclitaxel, docetaxel), alkylating agents (e.g., cyclophosphamide, melphalan, carmustine, nitrosoureas such as bischloroethylnitrosurea and hydroxyurea), platinum agents (e.g. cisplatin, carboplatin, oxaliplatin, JM-216 or satraplatin, CI-973), anthracyclines (e.g., doxrubicin, daunorubicin), antitumor antibiotics (e.g., mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitors (e.g., etoposide, camptothecins), anti-angiogenesis agents (e.g. Sutent® and Bevacizumab) or any other cytotoxic agents, (estramustine phosphate, prednimustine), hormones or hormone agonists, antagonists, partial agonists or partial antagonists, kinase inhibitors, and radiation treatment.
“Anti-inflammatory agents” refers to methotrexate, matrix metalloproteinase inhibitors, inhibitors of pro-inflammatory cytokines (e.g., anti-TNF molecules, TNF soluble receptors, and IL1) non-steroidal anti-inflammatory drugs (NSAIDs) such as prostaglandin synthase inhibitors (e.g., choline magnesium salicylate, salicylsalicyclic acid), COX-1 or COX-2 inhibitors), or glucocorticoid receptor agonists such as corticosteroids, methylprednisone, prednisone, or cortisone.
As used herein, the abbreviations for any protective groups, amino acids and other compounds, are, unless indicated otherwise, in accord with their common usage or recognized abbreviations including abbreviations found in J. Org. Chem. 2007 72(1): 23A-24A or abbreviations established by the IUPAC-IUB Commission on Biochemical Nomenclature (see, Biochem. 1972, 11:942-944).
Provided herein are compounds of formula (I)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A is azolyl;
B is aryl or heteroaryl;
A3 and A4 are each independently N or CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
each R3 is independently hydrogen, deutero, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen, alkyl, alkenyl or alkynyl;
each R6 is independently hydrogen, deutero, halo, nitro, cyano, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv; where the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups are each optionally substituted with one, two or three halo, oxo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl groups;
each R6a is independently hydrogen, cyano or alkyl;
each R7 is independently halo, alkyl, haloalkyl or —RxORw;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or —C(O)OR8;
R12 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)Rv, —C(O)ORw or —C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, —C(O)Rv, —C(O)ORw, —C(O)NRyRw or —S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl are substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)NRyRz or —NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently selected from alkyl, hydroxyl, halo, oxo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, carboxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
R19 and R20 are selected as follows:
R21 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl;
each R22 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; or both R22, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted with oxo;
R23 is alkyl, alkenyl, alkynyl or haloalkyl;
R24 is hydrogen or alkyl;
each Rx is independently alkylene, alkenylene, alkynylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
r is 1-3;
p is 0-4; and
each q is independently 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (II)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A is azolyl;
A1 and A2 are each independently selected from N and CR7a;
A3 and A4 are each independently N or CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
(c) A7 is N or NR6 and A5 and A6 are each independently CR6, N, NR6, S, or O;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii), (iv) and (v) as follows:
R3 is hydrogen, deutero, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
each R6 is independently selected from hydrogen, deutero, halo, cyano, nitro, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, —RxOR18, —RxNR19R26, —RxC(O)NRyRz and —RxS(O)qRv; where the alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups are optionally substituted with one, two or three halo, oxo, hydroxy, alkoxy, alkyl, alkenyl, alkynyl, haloalkyl, or cycloalkyl groups;
R6a is hydrogen, cyano or, alkyl;
each R7 is independently halo, alkyl, haloalkyl or —RxORw;
R7a is hydrogen or alkyl;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or —C(O)OR8;
R12 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)Rv, —C(O)ORw or —C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, —C(O)Rv, —C(O)ORw, —C(O)NRyRz or —S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl are substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)NRyRv or —NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently alkyl, hydroxyl, halo, oxo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, carboxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl or amino;
R19 and R20 are selected as follows:
each R22 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; or both R22, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted with oxo;
R23 is alkyl, alkenyl, alkynyl or haloalkyl;
R24 is hydrogen or alkyl;
each Rx is independently alkylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
r is 1-3;
p is 0-4; and
each q is independently 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (II) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (II) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N, NR6, S or O;
A6 is N or NR6;
A7 is CR6, N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (II) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N or NR6;
A6 is CR6, N, NR6, S or O;
A7 is N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (III)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein R4 is hydrogen, alkyl or haloalkyl and the other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A1 and A2 are each independently selected from N and CH;
A3 and A4 are selected from N and CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen, deutero, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R4 is hydrogen, alkyl or haloalkyl
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, cyano, nitro, halo, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, —RxOR18, RxNR19R20, or —RxS(O)qRv;
R6a is hydrogen, cyano or alkyl;
each R7 is independently halo, alkyl, or haloalkyl;
R8 is alkyl, alkenyl or alkynyl;
R9 is hydrogen, alkyl, haloalkyl, hydroxy, alkoxy or amino;
R10 is hydrogen or alkyl;
R11 is hydrogen, alkyl, haloalkyl or —C(O)OR8;
R12 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)Rv, —C(O)ORw or —C(O)NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R13 and R14 are selected as follows:
(i) R13 is hydrogen or alkyl; and R14 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, —C(O)Rv, —C(O)ORw, —C(O)NRyRw or —S(O)qRv, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio; or
(ii) R13 and R14, together with the nitrogen atom to which they are attached, form heterocyclyl or heteroaryl wherein the heterocyclyl or heteroaryl are substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, alkyl, hydroxy, alkoxy, amino and alkylthio and wherein the heterocyclyl is optionally substituted with oxo;
R15 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, —C(O)NRyRz or —NRyRz, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl are each optionally substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one, two or three, substituents independently selected from halo, oxo, alkyl, hydroxy, alkoxy, amino and alkylthio;
R18 is hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl; wherein R18 is optionally substituted with 1 to 3 groups Q1, each Q1 independently selected from alkyl, hydroxyl, halo, oxo, haloalkyl, alkoxy, aryloxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, carboxyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, haloaryl and amino;
R19 and R20 are selected as follows:
R21 is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl;
each R22 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl or cycloalkyl; or both R22, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted with oxo;
R23 is alkyl, alkenyl, alkynyl or haloalkyl;
R24 is hydrogen or alkyl;
each Rx is independently alkylene, alkenylene, alkynylene or a direct bond;
Rv is hydrogen, alkyl, alkenyl or alkynyl;
Rw is independently hydrogen, alkyl, alkenyl, alkynyl or haloalkyl;
Ry and Rz are selected as follows:
p is 0-4;
each q is independently 0, 1 or 2; and
r is 1 or 2.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N, NR6, S or O;
A6 is N or NR6;
A7 is CR6, N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N or NR6;
A6 is CR6, N, NR6, S or O;
A7 is N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 and A7 are each independently CR6, N, NR6, S, or O;
L1 is —C(R1)(R2)— or —S(O)1-2—;
R1 and R2 are selected as follows:
R3 is hydrogen, alkyl or cycloalkyl,
R4 and R5 are each independently hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —Rx(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
p is 1;
each q is independently 0, 1 or 2; and
r is 1 or 2.
In certain embodiments, provided herein are compounds of formula (III) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 and A7 are each independently CR6, N, NR6, S, or O;
L1 is —C(R1)(R2)— or —S(O)1-2—;
R1 and R2 are selected as follows:
R3 is hydrogen, alkyl or cycloalkyl,
R4 and R5 are each independently hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRw or —RxS(O)qRv;
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
p is 1;
each q is independently 0, 1 or 2; and
r is 1 or 2.
In certain embodiments, provided herein are compounds of formula (IV)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (IV) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A1 and A2 are each independently selected from N and CH;
A3 and A4 are each independently N or CH, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —Rx(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
each R7 is independently halo, alkyl, or haloalkyl;
p is 0-4; and
each q is independently 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (IV) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A1 and A2 are each independently selected from N and CH;
A3 and A4 are each independently N or CH, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
each R7 is independently halo, alkyl, or haloalkyl;
p is 0-4; and
each q is independently 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (V)
wherein the variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (V) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O;
L1 is —C(R1)(R2)— or —S(O)1-2—;
R1 and R2 are selected as follows:
R3 is hydrogen, alkyl or cycloalkyl,
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, dutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo; and
q is 0-2.
In certain embodiments, provided herein are compounds of formula (V) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O; and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (V) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N, NR6, S or O;
A6 is N or NR6;
A7 is CR6, N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (V) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N or NR6;
A6 is CR6, N, NR6, S or O;
A7 is N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (V) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O;
L1 is —C(R1)(R2)— or —S(O)1-2—;
R1 and R2 are selected as follows:
R3 is hydrogen, alkyl or cycloalkyl,
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, dutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo; and
q is 0-2.
In certain embodiments, provided herein are compounds of formula (VI)
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (VI) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
R6a is hydrogen, cyano or alkyl;
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo; and
q is 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (VI) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CR6a, such that at least one of A3 or A4 is N;
A5, A6, and A7 are selected as follows:
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
R6a is hydrogen, cyano or alkyl;
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo; and
q is 0, 1 or 2.
In certain embodiments, provided herein are compounds of formula (VI) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is N or NR6;
A6 is CR6, N or NR6;
A7 is CR6, N, NR6, S or O;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (VI) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N, NR6, S or O;
A6 is N or NR6;
A7 is CR6, N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (VI) or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein
A3 and A4 are selected from N and CH such that at least one of A3 or A4 is N;
A5 is CR6, N or NR6;
A6 is CR6, N, NR6, S or O;
A7 is N or NR6;
and other variables are as described elsewhere herein.
In certain embodiments, provided herein are compounds of formula (VII):
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (VII), wherein A is pyrazolyl, imidazolyl, or thiazolyl; B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described herein. In certain embodiments, provided herein are compounds of formula (VII), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
A6 and A7 are selected as follows:
(i) A6 is N or CR6, and A7 is CR6; or
(ii) A6 is CR6, and A7 is S;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (VII), wherein A is pyrazolyl, imidazolyl, or thiazolyl; B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described herein. In certain embodiments, provided herein are compounds of formula (VII), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
A6 and A7 are selected as follows:
(i) A6 is N or CR6, and A7 is CR6; or
(ii) A6 is CR6, and A7 is S;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (VIII):
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (VIII), wherein A is pyrazolyl, imidazolyl, or thiazolyl; B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described herein. In certain embodiments, provided herein are compounds of formula (VIII), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
A6 and A7 are selected as follows:
(i) A6 is NR6 or CR6, and A7 is CR6; or
(ii) A6 is CR6, and A7 is S;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (VIII), wherein A is pyrazolyl, imidazolyl, or thiazolyl; B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described herein. In certain embodiments, provided herein are compounds of formula (VIII), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
A6 and A7 are selected as follows:
(i) A6 is NR6 or CR6, and A7 is CR6; or
(ii) A6 is CR6, and A7 is S;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv,
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In one embodiment, A is pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, or triazolyl. In one embodiment, A is pyrazolyl. In one embodiment, A is imidazolyl.
In one embodiment, A is
wherein each R3 is independently hydrogen, deutero, halo, alkyl, cyano, haloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy or alkoxy; and each R4 is independently hydrogen, or alkyl.
In one embodiment, A is
wherein each R3 is independently hydrogen, deutero, halo, alkyl, hydroxy or alkoxy; and each R4 is independently hydrogen, or alkyl.
In one embodiment, A is
wherein X1, X2 and X3 are selected from (i)-(iv) as follows
In one embodiment, A is
wherein X1, X2 and X3 are selected from (i) and (ii) as follows
In one embodiment, A is
where R3 is hydrogen or alkyl. In one embodiment, R3 is hydrogen or methyl.
In one embodiment, A1 is CH and A2 is CH. In one embodiment, A1 is CH and A2 is N. In one embodiment, A1 is N and A2 is CH. In one embodiment, A1 is N and A2 is N.
In one embodiment, A3 is CH and A4 is N. In one embodiment, A3 is N and A4 is CH. In one embodiment, A3 is N and A4 is N.
In one embodiment, L is S, SO or SO2.
In one embodiment, R1 and R2 together form ═O.
In one embodiment, R1 and R2, together with the carbon atom to which they are attached, form cycloalkyl or heterocyclyl wherein the cycloalkyl is substituted with one or more, in one embodiment, one to four, in one embodiment, one to three, in one embodiment, one or two, substitutents selected from halo, deutero, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, cyano, ═O, ═N—OR21, —RxOR21, —RxN(R22)2, RxS(O)qR23, —C(O)R21, —C(O)OR21 and —C(O)N(R22)2 and wherein the heterocyclyl contains one to two heteroatoms and/or heterogroups each independently selected from O, NR24, S, S(O) and S(O)2.
In one embodiment, R1 and R2 are both halo. In one embodiment, R1 and R2 are both fluoro.
In one embodiment, R1 is hydroxy or alkoxy, and R2 is hydrogen or alkyl. In one embodiment, R1 is hydroxy, and R2 is hydrogen or methyl.
In one embodiment, R3 is hydrogen, deutero or alkyl. In another embodiment, R3 is hydrogen or methyl. In another embodiment, R3 is hydrogen. In one embodiment, R4 is hydrogen. In one embodiment, R5 is hydrogen.
In one embodiment, each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl; and
q is 0-2.
In one embodiment, each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl, —RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene; and
R18, R19, R20, Ry, Rz and Rv are each independently hydrogen or alkyl;
In one embodiment, R7 is halo. In one embodiment, R7 is fluoro.
In one embodiment, r is 1, 2 or 3. In one embodiment, r is 1 or 2.
In one embodiment, p is 1 or 2. In one embodiment, p is 1.
In certain embodiments, provided herein are compounds of formula (IXa), (IXb), (IXc) or (IXd):
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (IXa), (IXb), (IXc) or (IXd), wherein B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (IXa), (IXb), (IXc) or (IXd), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (IXa), (IXb), (IXc) or (IXd), wherein B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (IXa), (IXb), (IXc) or (IXd), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
A3 and A4 are selected from N and CH, such that at least one of A3 or A4 is N;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected from (i), (ii), (iii) and (iv) as follows:
R3 is hydrogen, alkyl or cycloalkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd):
or pharmaceutically acceptable salts, solvates or hydrates thereof, wherein the variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen or alkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein B is phenyl, pyridinyl or pyrimidinyl, and the other variables are as described elsewhere herein. In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein
A is azolyl;
B is phenyl, pyridinyl or pyrimidinyl;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen or alkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 0-2; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein
A is pyrazolyl;
B is phenyl;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen or alkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, cycloalkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 1; and
r is 1-3.
In certain embodiments, provided herein are compounds of formula (Xa), (Xb), (Xc) or (Xd), wherein
A is pyrazolyl;
B is phenyl;
L1 is —C(R1)(R2)— or —S(O)q—;
R1 and R2 are selected as follows:
R3 is hydrogen or alkyl;
R5 is hydrogen or alkyl;
each R6 is independently hydrogen, deutero, halo, cyano, alkyl, alkoxyalkyl, hydroxyalkyl, cyanoalkyl, alkoxy, haloalkoxy, heterocyclyl, heterocyclylalkyl, aryl,
—RxOR18, —RxNR19R20, —RxC(O)NRyRz or —RxS(O)qRv;
Rx is direct bond or alkylene;
Ry and Rz are each independently hydrogen or alkyl;
R18, R19 and R20 are each independently hydrogen or alkyl;
Rv is hydrogen or alkyl;
R7 is halo;
q is 0, 1 or 2;
p is 1; and
r is 1-3.
In one embodiment, provided herein is a compound selected from
2-((4-fluorophenyl)sulfonyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine;
Also provided herein are isotopically enriched analogs of the compounds provided herein. Isotopic enrichment (for example, deuteration) of pharmaceuticals to improve pharmacokinetics (“PK”), pharmacodynamics (“PD”), and toxicity profiles, has been demonstrated previously with some classes of drugs. See, for example, Lijinsky et. al., Food Cosmet. Toxicol., 20: 393 (1982); Lijinsky et. al., J. Nat. Cancer Inst., 69: 1127 (1982); Mangold et. al., Mutation Res. 308: 33 (1994); Gordon et. al., Drug Metab. Dispos., 15: 589 (1987); Zello et. al., Metabolism, 43: 487 (1994); Gately et. al., J. Nucl. Med., 27: 388 (1986); Wade D, Chem. Biol. Interact. 117: 191 (1999).
Isotopic enrichment of a drug can be used, for example, to (1) reduce or eliminate unwanted metabolites, (2) increase the half-life of the parent drug, (3) decrease the number of doses needed to achieve a desired effect, (4) decrease the amount of a dose necessary to achieve a desired effect, (5) increase the formation of active metabolites, if any are formed, and/or (6) decrease the production of deleterious metabolites in specific tissues and/or create a more effective drug and/or a safer drug for combination therapy, whether the combination therapy is intentional or not.
Replacement of an atom for one of its isotopes often will result in a change in the reaction rate of a chemical reaction. This phenomenon is known as the Kinetic Isotope Effect (“KIE”). For example, if a C—H bond is broken during a rate-determining step in a chemical reaction (i.e. the step with the highest transition state energy), substitution of a deuterium for that hydrogen will cause a decrease in the reaction rate and the process will slow down. This phenomenon is known as the Deuterium Kinetic Isotope Effect (“DKIE”). (See, e.g, Foster et al., Adv. Drug Res., vol. 14, pp. 1-36 (1985); Kushner et al., Can. J. Physiol. Pharmacol., vol. 77, pp. 79-88 (1999)).
Tritium (“T”) is a radioactive isotope of hydrogen, used in research, fusion reactors, neutron generators and radiopharmaceuticals. Tritium is a hydrogen atom that has 2 neutrons in the nucleus and has an atomic weight close to 3. It occurs naturally in the environment in very low concentrations, most commonly found as T2O. Tritium decays slowly (half-life=12.3 years) and emits a low energy beta particle that cannot penetrate the outer layer of human skin. Internal exposure is the main hazard associated with this isotope, yet it must be ingested in large amounts to pose a significant health risk. As compared with deuterium, a lesser amount of tritium must be consumed before it reaches a hazardous level. Substitution of tritium (“T”) for hydrogen results in yet a stronger bond than deuterium and gives numerically larger isotope effects. Similarly, substitution of isotopes for other elements, including, but not limited to, 13C or 14C for carbon, 33S, 34S, or 36S for sulfur, 15N for nitrogen, and 17O or 18O for oxygen, will provide a similar kinetic isotope effects.
Provided herein are pharmaceutical compositions comprising a compound provided herein, e.g., a compound of Formula I, as an active ingredient, or a pharmaceutically acceptable salt, solvate or hydrate thereof; in combination with a pharmaceutically acceptable vehicle, carrier, diluent, or excipient, or a mixture thereof.
The compound provided herein may be administered alone, or in combination with one or more other compounds provided herein. The pharmaceutical compositions that comprise a compound provided herein, e.g., a compound of Formula I, can be formulated in various dosage forms for oral, parenteral, and topical administration. The pharmaceutical compositions can also be formulated as modified release dosage forms, including delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. These dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy, supra; Modified-Release Drug Deliver Technology, Rathbone et al., Eds., Drugs and the Pharmaceutical Science, Marcel Dekker, Inc.: New York, N.Y., 2003; Vol. 126).
In one embodiment, the pharmaceutical compositions are provided in a dosage form for oral administration, which comprise a compound provided herein, e.g., a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
In another embodiment, the pharmaceutical compositions are provided in a dosage form for parenteral administration, which comprise a compound provided herein, e.g., a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
In yet another embodiment, the pharmaceutical compositions are provided in a dosage form for topical administration, which comprise a compound provided herein, e.g., a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof; and one or more pharmaceutically acceptable excipients or carriers.
The pharmaceutical compositions provided herein can be provided in a unit-dosage form or multiple-dosage form. A unit-dosage form, as used herein, refers to physically discrete a unit suitable for administration to a human and animal subject, and packaged individually as is known in the art. Each unit-dose contains a predetermined quantity of an active ingredient(s) sufficient to produce the desired therapeutic effect, in association with the required pharmaceutical carriers or excipients. Examples of a unit-dosage form include an ampoule, syringe, and individually packaged tablet and capsule. A unit-dosage form may be administered in fractions or multiples thereof A multiple-dosage form is a plurality of identical unit-dosage forms packaged in a single container to be administered in segregated unit-dosage form. Examples of a multiple-dosage form include a vial, bottle of tablets or capsules, or bottle of pints or gallons.
The pharmaceutical compositions provided herein can be administered at once, or multiple times at intervals of time. It is understood that the precise dosage and duration of treatment may vary with the age, weight, and condition of the patient being treated, and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test or diagnostic data. It is further understood that for any particular individual, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the formulations.
In one embodiment, the therapeutically effective dose is from about 0.1 mg to about 2,000 mg per day of a compound provided herein. The pharmaceutical compositions therefore should provide a dosage of from about 0.1 mg to about 2000 mg of the compound. In certain embodiments, pharmaceutical dosage unit forms are prepared to provide from about 1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 20 mg to about 500 mg or from about 25 mg to about 250 mg of the essential active ingredient or a combination of essential ingredients per dosage unit form. In certain embodiments, the pharmaceutical dosage unit forms are prepared to provide about 10 mg, 20 mg, 25 mg, 50 mg, 100 mg, 250 mg, 500 mg, 1000 mg or 2000 mg of the essential active ingredient.
Oral Administration
The pharmaceutical compositions provided herein can be provided in solid, semisolid, or liquid dosage forms for oral administration. As used herein, oral administration also includes buccal, lingual, and sublingual administration. Suitable oral dosage forms include, but are not limited to, tablets, fastmelts, chewable tablets, capsules, pills, troches, lozenges, pastilles, cachets, pellets, medicated chewing gum, bulk powders, effervescent or non-effervescent powders or granules, solutions, emulsions, suspensions, wafers, sprinkles, elixirs, and syrups. In addition to the active ingredient(s), the pharmaceutical compositions can contain one or more pharmaceutically acceptable carriers or excipients, including, but not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, coloring agents, dye-migration inhibitors, sweetening agents, and flavoring agents.
Binders or granulators impart cohesiveness to a tablet to ensure the tablet remaining intact after compression. Suitable binders or granulators include, but are not limited to, starches, such as corn starch, potato starch, and pre-gelatinized starch (e.g., STARCH 1500); gelatin; sugars, such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums, such as acacia, alginic acid, alginates, extract of Irish moss, panwar gum, ghatti gum, mucilage of isabgol husks, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone (PVP), Veegum, larch arabogalactan, powdered tragacanth, and guar gum; celluloses, such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline celluloses, such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, Pa.); and mixtures thereof. Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof. The binder or filler may be present from about 50 to about 99% by weight in the pharmaceutical compositions provided herein.
Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents, such as mannitol, lactose, sorbitol, sucrose, and inositol, when present in sufficient quantity, can impart properties to some compressed tablets that permit disintegration in the mouth by chewing. Such compressed tablets can be used as chewable tablets.
Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses, such as methylcellulose and carboxymethylcellulose; wood products; natural sponge; cation-exchange resins; alginic acid; gums, such as guar gum and Veegum HV; citrus pulp; cross-linked celluloses, such as croscarmellose; cross-linked polymers, such as crospovidone; cross-linked starches; calcium carbonate; microcrystalline cellulose, such as sodium starch glycolate; polacrilin potassium; starches, such as corn starch, potato starch, tapioca starch, and pre-gelatinized starch; clays; aligns; and mixtures thereof. The amount of a disintegrant in the pharmaceutical compositions provided herein varies upon the type of formulation, and is readily discernible to those of ordinary skill in the art. The pharmaceutical compositions provided herein may contain from about 0.5 to about 15% or from about 1 to about 5% by weight of a disintegrant.
Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glycerol behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oil, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laureate; agar; starch; lycopodium; silica or silica gels, such as AEROSIL® 200 (W.R. Grace Co., Baltimore, Md.) and CAB-O-SIL® (Cabot Co. of Boston, Mass.); and mixtures thereof. The pharmaceutical compositions provided herein may contain about 0.1 to about 5% by weight of a lubricant.
Suitable glidants include colloidal silicon dioxide, CAB-O-SIL® (Cabot Co. of Boston, Mass.), and asbestos-free talc. Coloring agents include any of the approved, certified, water soluble FD&C dyes, and water insoluble FD&C dyes suspended on alumina hydrate, and color lakes and mixtures thereof. A color lake is the combination by adsorption of a water-soluble dye to a hydrous oxide of a heavy metal, resulting in an insoluble form of the dye. Flavoring agents include natural flavors extracted from plants, such as fruits, and synthetic blends of compounds which produce a pleasant taste sensation, such as peppermint and methyl salicylate. Sweetening agents include sucrose, lactose, mannitol, syrups, glycerin, and artificial sweeteners, such as saccharin and aspartame. Suitable emulsifying agents include gelatin, acacia, tragacanth, bentonite, and surfactants, such as polyoxyethylene sorbitan monooleate (TWEEN® 20), polyoxyethylene sorbitan monooleate 80 (TWEEN® 80), and triethanolamine oleate. Suspending and dispersing agents include sodium carboxymethylcellulose, pectin, tragacanth, Veegum, acacia, sodium carbomethylcellulose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Preservatives include glycerin, methyl and propylparaben, benzoic add, sodium benzoate and alcohol. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether. Solvents include glycerin, sorbitol, ethyl alcohol, and syrup. Examples of non-aqueous liquids utilized in emulsions include mineral oil and cottonseed oil. Organic acids include citric and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.
It should be understood that many carriers and excipients may serve several functions, even within the same formulation.
The pharmaceutical compositions provided herein can be provided as compressed tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, or enteric-coating tablets, sugar-coated, or film-coated tablets. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric-coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Sugar-coated tablets are compressed tablets surrounded by a sugar coating, which may be beneficial in covering up objectionable tastes or odors and in protecting the tablets from oxidation. Film-coated tablets are compressed tablets that are covered with a thin layer or film of a water-soluble material. Film coatings include, but are not limited to, hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000, and cellulose acetate phthalate. Film coating imparts the same general characteristics as sugar coating. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, and press-coated or dry-coated tablets.
The tablet dosage forms can be prepared from the active ingredient in powdered, crystalline, or granular forms, alone or in combination with one or more carriers or excipients described herein, including binders, disintegrants, controlled-release polymers, lubricants, diluents, and/or colorants. Flavoring and sweetening agents are especially useful in the formation of chewable tablets and lozenges.
The pharmaceutical compositions provided herein can be provided as soft or hard capsules, which can be made from gelatin, methylcellulose, starch, or calcium alginate. The hard gelatin capsule, also known as the dry-filled capsule (DFC), consists of two sections, one slipping over the other, thus completely enclosing the active ingredient. The soft elastic capsule (SEC) is a soft, globular shell, such as a gelatin shell, which is plasticized by the addition of glycerin, sorbitol, or a similar polyol. The soft gelatin shells may contain a preservative to prevent the growth of microorganisms. Suitable preservatives are those as described herein, including methyl- and propyl-parabens, and sorbic acid. The liquid, semisolid, and solid dosage forms provided herein may be encapsulated in a capsule. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils, or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Pat. Nos. 4,328,245; 4,409,239; and 4,410,545. The capsules may also be coated as known by those of skill in the art in order to modify or sustain dissolution of the active ingredient.
The pharmaceutical compositions provided herein can be provided in liquid and semisolid dosage forms, including emulsions, solutions, suspensions, elixirs, and syrups. An emulsion is a two-phase system, in which one liquid is dispersed in the form of small globules throughout another liquid, which can be oil-in-water or water-in-oil. Emulsions may include a pharmaceutically acceptable non-aqueous liquid or solvent, emulsifying agent, and preservative. Suspensions may include a pharmaceutically acceptable suspending agent and preservative. Aqueous alcoholic solutions may include a pharmaceutically acceptable acetal, such as a di(lower alkyl) acetal of a lower alkyl aldehyde, e.g., acetaldehyde diethyl acetal; and a water-miscible solvent having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs are clear, sweetened, and hydroalcoholic solutions. Syrups are concentrated aqueous solutions of a sugar, for example, sucrose, and may also contain a preservative. For a liquid dosage form, for example, a solution in a polyethylene glycol may be diluted with a sufficient quantity of a pharmaceutically acceptable liquid carrier, e.g., water, to be measured conveniently for administration.
Other useful liquid and semisolid dosage forms include, but are not limited to, those containing the active ingredient(s) provided herein, and a dialkylated mono- or poly-alkylene glycol, including, 1,2-dimethoxymethane, diglyme, triglyme, tetraglyme, polyethylene glycol-350-dimethyl ether, polyethylene glycol-550-dimethyl ether, polyethylene glycol-750-dimethyl ether, wherein 350, 550, and 750 refer to the approximate average molecular weight of the polyethylene glycol. These formulations can further comprise one or more antioxidants, such as butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), propyl gallate, vitamin E, hydroquinone, hydroxycoumarins, ethanolamine, lecithin, cephalin, ascorbic acid, malic acid, sorbitol, phosphoric acid, bisulfate, sodium metabisulfite, thiodipropionic acid and its esters, and dithiocarbamates.
The pharmaceutical compositions provided herein for oral administration can be also provided in the forms of liposomes, micelles, microspheres, or nanosystems. Micellar dosage forms can be prepared as described in U.S. Pat. No. 6,350,458.
The pharmaceutical compositions provided herein can be provided as non-effervescent or effervescent, granules and powders, to be reconstituted into a liquid dosage form. Pharmaceutically acceptable carriers and excipients used in the non-effervescent granules or powders may include diluents, sweeteners, and wetting agents. Pharmaceutically acceptable carriers and excipients used in the effervescent granules or powders may include organic acids and a source of carbon dioxide.
Coloring and flavoring agents can be used in all of the above dosage forms.
The pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
The pharmaceutical compositions provided herein can be co-formulated with other active ingredients which do not impair the desired therapeutic action, or with substances that supplement the desired action.
Parenteral Administration
The pharmaceutical compositions provided herein can be administered parenterally by injection, infusion, or implantation, for local or systemic administration. Parenteral administration, as used herein, include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrastemal, intracranial, intramuscular, intrasynovial, intravesical, and subcutaneous administration.
The pharmaceutical compositions provided herein can be formulated in any dosage forms that are suitable for parenteral administration, including solutions, suspensions, emulsions, micelles, liposomes, microspheres, nanosystems, and solid forms suitable for solutions or suspensions in liquid prior to injection. Such dosage forms can be prepared according to conventional methods known to those skilled in the art of pharmaceutical science (see, Remington: The Science and Practice of Pharmacy, supra).
The pharmaceutical compositions intended for parenteral administration can include one or more pharmaceutically acceptable carriers and excipients, including, but not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, cryoprotectants, lyoprotectants, thickening agents, pH adjusting agents, and inert gases.
Suitable aqueous vehicles include, but are not limited to, water, saline, physiological saline or phosphate buffered saline (PBS), sodium chloride injection, Ringers injection, isotonic dextrose injection, sterile water injection, dextrose and lactated Ringers injection. Non-aqueous vehicles include, but are not limited to, fixed oils of vegetable origin, castor oil, corn oil, cottonseed oil, olive oil, peanut oil, peppermint oil, safflower oil, sesame oil, soybean oil, hydrogenated vegetable oils, hydrogenated soybean oil, and medium-chain triglycerides of coconut oil, and palm seed oil. Water-miscible vehicles include, but are not limited to, ethanol, 1,3-butanediol, liquid polyethylene glycol (e.g., polyethylene glycol 300 and polyethylene glycol 400), propylene glycol, glycerin, N-methyl-2-pyrrolidone, N,N-dimethylacetamide, and dimethyl sulfoxide.
Suitable antimicrobial agents or preservatives include, but are not limited to, phenols, cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoates, thimerosal, benzalkonium chloride (e.g., benzethonium chloride), methyl- and propyl-parabens, and sorbic acid. Suitable isotonic agents include, but are not limited to, sodium chloride, glycerin, and dextrose. Suitable buffering agents include, but are not limited to, phosphate and citrate. Suitable antioxidants are those as described herein, including bisulfite and sodium metabisulfite. Suitable local anesthetics include, but are not limited to, procaine hydrochloride. Suitable suspending and dispersing agents are those as described herein, including sodium carboxymethylcelluose, hydroxypropyl methylcellulose, and polyvinylpyrrolidone. Suitable emulsifying agents include those described herein, including polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monooleate 80, and triethanolamine oleate. Suitable sequestering or chelating agents include, but are not limited to EDTA. Suitable pH adjusting agents include, but are not limited to, sodium hydroxide, hydrochloric acid, citric acid, and lactic acid. Suitable complexing agents include, but are not limited to, cyclodextrins, including α-cyclodextrin, β-cyclodextrin, hydroxypropyl-β-cyclodextrin, sulfobutylether-β-cyclodextrin, and sulfobutylether 7-β-cyclodextrin (CAPTISOL®, CyDex, Lenexa, Kans.).
The pharmaceutical compositions provided herein can be formulated for single or multiple dosage administration. The single dosage formulations are packaged in an ampoule, a vial, or a syringe. The multiple dosage parenteral formulations must contain an antimicrobial agent at bacteriostatic or fungistatic concentrations. All parenteral formulations must be sterile, as known and practiced in the art.
In one embodiment, the pharmaceutical compositions are provided as ready-to-use sterile solutions. In another embodiment, the pharmaceutical compositions are provided as sterile dry soluble products, including lyophilized powders and hypodermic tablets, to be reconstituted with a vehicle prior to use. In yet another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile suspensions. In yet another embodiment, the pharmaceutical compositions are provided as sterile dry insoluble products to be reconstituted with a vehicle prior to use. In still another embodiment, the pharmaceutical compositions are provided as ready-to-use sterile emulsions.
The pharmaceutical compositions provided herein can be formulated as immediate or modified release dosage forms, including delayed-, sustained, pulsed-, controlled, targeted-, and programmed-release forms.
The pharmaceutical compositions can be formulated as a suspension, solid, semi-solid, or thixotropic liquid, for administration as an implanted depot. In one embodiment, the pharmaceutical compositions provided herein are dispersed in a solid inner matrix, which is surrounded by an outer polymeric membrane that is insoluble in body fluids but allows the active ingredient in the pharmaceutical compositions diffuse through.
Suitable inner matrixes include polymethylmethacrylate, polybutyl-methacrylate, plasticized or unplasticized polyvinylchloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, ethylene-vinyl acetate copolymers, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, hydrophilic polymers, such as hydrogels of esters of acrylic and methacrylic acid, collagen, cross-linked polyvinyl alcohol, and cross-linked partially hydrolyzed polyvinyl acetate.
Suitable outer polymeric membranes include polyethylene, polypropylene, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, ethylene/vinyl acetate copolymers, silicone rubbers, polydimethyl siloxanes, neoprene rubber, chlorinated polyethylene, polyvinylchloride, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer.
Topical Administration
The pharmaceutical compositions provided herein can be administered topically to the skin, orifices, or mucosa. The topical administration, as used herein, includes (intra)dermal, conjunctival, intracorneal, intraocular, ophthalmic, auricular, transdermal, nasal, vaginal, urethral, respiratory, and rectal administration.
The pharmaceutical compositions provided herein can be formulated in any dosage forms that are suitable for topical administration for local or systemic effect, including emulsions, solutions, suspensions, creams, gels, hydrogels, ointments, dusting powders, dressings, elixirs, lotions, suspensions, tinctures, pastes, foams, films, aerosols, irrigations, sprays, suppositories, bandages, dermal patches. The topical formulation of the pharmaceutical compositions provided herein can also comprise liposomes, micelles, microspheres, nanosystems, and mixtures thereof.
Pharmaceutically acceptable carriers and excipients suitable for use in the topical formulations provided herein include, but are not limited to, aqueous vehicles, water-miscible vehicles, non-aqueous vehicles, antimicrobial agents or preservatives against the growth of microorganisms, stabilizers, solubility enhancers, isotonic agents, buffering agents, antioxidants, local anesthetics, suspending and dispersing agents, wetting or emulsifying agents, complexing agents, sequestering or chelating agents, penetration enhancers, cryoprotectants, lyoprotectants, thickening agents, and inert gases.
The pharmaceutical compositions can also be administered topically by electroporation, iontophoresis, phonophoresis, sonophoresis, or microneedle or needle-free injection, such as POWDERJECT™ (Chiron Corp., Emeryville, Calif.), and BIOJECT™ (Bioject Medical Technologies Inc., Tualatin, Oreg.).
The pharmaceutical compositions provided herein can be provided in the forms of ointments, creams, and gels. Suitable ointment vehicles include oleaginous or hydrocarbon vehicles, including lard, benzoinated lard, olive oil, cottonseed oil, and other oils, white petrolatum; emulsifiable or absorption vehicles, such as hydrophilic petrolatum, hydroxystearin sulfate, and anhydrous lanolin; water-removable vehicles, such as hydrophilic ointment; water-soluble ointment vehicles, including polyethylene glycols of varying molecular weight; emulsion vehicles, either water-in-oil (W/O) emulsions or oil-in-water (O/W) emulsions, including cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid (see, Remington: The Science and Practice of Pharmacy, supra). These vehicles are emollient but generally require addition of antioxidants and preservatives.
Suitable cream base can be oil-in-water or water-in-oil. Cream vehicles may be water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase is also called the “internal” phase, which is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation may be a nonionic, anionic, cationic, or amphoteric surfactant.
Gels are semisolid, suspension-type systems. Single-phase gels contain organic macromolecules distributed substantially uniformly throughout the liquid carrier. Suitable gelling agents include crosslinked acrylic acid polymers, such as carbomers, carboxypolyalkylenes, CARBOPOL®; hydrophilic polymers, such as polyethylene oxides, polyoxyethylene-polyoxypropylene copolymers, and polyvinylalcohol; cellulosic polymers, such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, and methylcellulose; gums, such as tragacanth and xanthan gum; sodium alginate; and gelatin. In order to prepare a uniform gel, dispersing agents such as alcohol or glycerin can be added, or the gelling agent can be dispersed by trituration, mechanical mixing, and/or stirring.
The pharmaceutical compositions provided herein can be administered rectally, urethrally, vaginally, or perivaginally in the forms of suppositories, pessaries, bougies, poultices or cataplasm, pastes, powders, dressings, creams, plasters, contraceptives, ointments, solutions, emulsions, suspensions, tampons, gels, foams, sprays, or enemas. These dosage forms can be manufactured using conventional processes as described in Remington: The Science and Practice of Pharmacy, supra.
Rectal, urethral, and vaginal suppositories are solid bodies for insertion into body orifices, which are solid at ordinary temperatures but melt or soften at body temperature to release the active ingredient(s) inside the orifices. Pharmaceutically acceptable carriers utilized in rectal and vaginal suppositories include bases or vehicles, such as stirrening agents, which produce a melting point in the proximity of body temperature, when formulated with the pharmaceutical compositions provided herein; and antioxidants as described herein, including bisulfite and sodium metabisulfite. Suitable vehicles include, but are not limited to, cocoa butter (theobroma oil), glycerin-gelatin, carbowax (polyoxyethylene glycol), spermaceti, paraffin, white and yellow wax, and appropriate mixtures of mono-, di- and triglycerides of fatty acids, hydrogels, such as polyvinyl alcohol, hydroxyethyl methacrylate, polyacrylic acid; glycerinated gelatin. Combinations of the various vehicles may be used. Rectal and vaginal suppositories may be prepared by the compressed method or molding. The typical weight of a rectal and vaginal suppository is about 2 to about 3 g.
The pharmaceutical compositions provided herein can be administered ophthalmically in the forms of solutions, suspensions, ointments, emulsions, gel-forming solutions, powders for solutions, gels, ocular inserts, and implants.
The pharmaceutical compositions provided herein can be administered intranasally or by inhalation to the respiratory tract. The pharmaceutical compositions can be provided in the form of an aerosol or solution for delivery using a pressurized container, pump, spray, atomizer, such as an atomizer using electrohydrodynamics to produce a fine mist, or nebulizer, alone or in combination with a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. The pharmaceutical compositions can also be provided as a dry powder for insufflation, alone or in combination with an inert carrier such as lactose or phospholipids; and nasal drops. For intranasal use, the powder can comprise a bioadhesive agent, including chitosan or cyclodextrin.
Solutions or suspensions for use in a pressurized container, pump, spray, atomizer, or nebulizer can be formulated to contain ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active ingredient provided herein, a propellant as solvent; and/or a surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
The pharmaceutical compositions provided herein can be micronized to a size suitable for delivery by inhalation, such as about 50 micrometers or less, or about 10 micrometers or less. Particles of such sizes can be prepared using a comminuting method known to those skilled in the art, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.
Capsules, blisters and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the pharmaceutical compositions provided herein; a suitable powder base, such as lactose or starch; and a performance modifier, such as l-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate. Other suitable excipients or carriers include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose, and trehalose. The pharmaceutical compositions provided herein for inhaled/intranasal administration can further comprise a suitable flavor, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium.
The pharmaceutical compositions provided herein for topical administration can be formulated to be immediate release or modified release, including delayed-, sustained-, pulsed-, controlled-, targeted, and programmed release.
Modified Release
The pharmaceutical compositions provided herein can be formulated as a modified release dosage form. As used herein, the term “modified release” refers to a dosage form in which the rate or place of release of the active ingredient(s) is different from that of an immediate dosage form when administered by the same route. Modified release dosage forms include delayed-, extended-, prolonged-, sustained-, pulsatile-, controlled-, accelerated- and fast-, targeted-, programmed-release, and gastric retention dosage forms. The pharmaceutical compositions in modified release dosage forms can be prepared using a variety of modified release devices and methods known to those skilled in the art, including, but not limited to, matrix controlled release devices, osmotic controlled release devices, multiparticulate controlled release devices, ion-exchange resins, enteric coatings, multilayered coatings, microspheres, liposomes, and combinations thereof. The release rate of the active ingredient(s) can also be modified by varying the particle sizes and polymorphorism of the active ingredient(s).
Examples of modified release include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,739,108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,197,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; and 6,699,500.
1. Matrix Controlled Release Devices
The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using a matrix controlled release device known to those skilled in the art (see, Takada et al in “Encyclopedia of Controlled Drug Delivery,” Vol. 2, Mathiowitz Ed., Wiley, 1999).
In one embodiment, the pharmaceutical compositions provided herein in a modified release dosage form is formulated using an erodible matrix device, which is water-swellable, erodible, or soluble polymers, including synthetic polymers, and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
Materials useful in forming an erodible matrix include, but are not limited to, chitin, chitosan, dextran, and pullulan; gum agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenans, gum ghatti, guar gum, xanthan gum, and scleroglucan; starches, such as dextrin and maltodextrin; hydrophilic colloids, such as pectin; phosphatides, such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; and cellulosics, such as ethyl cellulose (EC), methylethyl cellulose (MEC), carboxymethyl cellulose (CMC), CMEC, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), CAP, CAT, hydroxypropyl methyl cellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methyl cellulose acetate trimellitate (HPMCAT), and ethylhydroxy ethylcellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethacrylic acid or methacrylic acid (EUDRAGIT®, Rohm America, Inc., Piscataway, N.J.); poly(2-hydroxyethyl-methacrylate); polylactides; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(−)-3-hydroxybutyric acid; and other acrylic acid derivatives, such as homopolymers and copolymers of butylmethacrylate, methylmethacrylate, ethylmethacrylate, ethylacrylate, (2-dimethylaminoethyl)methacrylate, and (trimethylaminoethyl)methacrylate chloride.
In further embodiments, the pharmaceutical compositions are formulated with a non-erodible matrix device. The active ingredient(s) is dissolved or dispersed in an inert matrix and is released primarily by diffusion through the inert matrix once administered. Materials suitable for use as a non-erodible matrix device included, but are not limited to, insoluble plastics, such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethylmethacrylate, polybutylmethacrylate, chlorinated polyethylene, polyvinylchloride, methyl acrylate-methyl methacrylate copolymers, ethylene-vinyl acetate copolymers, ethylene/propylene copolymers, ethylene/ethyl acrylate copolymers, vinyl chloride copolymers with vinyl acetate, vinylidene chloride, ethylene and propylene, ionomer polyethylene terephthalate, butyl rubber epichlorohydrin rubbers, ethylene/vinyl alcohol copolymer, ethylene/vinyl acetate/vinyl alcohol terpolymer, and ethylene/vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubbers, polydimethylsiloxanes, silicone carbonate copolymers, and; hydrophilic polymers, such as ethyl cellulose, cellulose acetate, crospovidone, and cross-linked partially hydrolyzed polyvinyl acetate; and fatty compounds, such as carnauba wax, microcrystalline wax, and triglycerides.
In a matrix controlled release system, the desired release kinetics can be controlled, for example, via the polymer type employed, the polymer viscosity, the particle sizes of the polymer and/or the active ingredient(s), the ratio of the active ingredient(s) versus the polymer, and other excipients or carriers in the compositions.
The pharmaceutical compositions provided herein in a modified release dosage form can be prepared by methods known to those skilled in the art, including direct compression, dry or wet granulation followed by compression, melt-granulation followed by compression.
2. Osmotic Controlled Release Devices
The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated using an osmotic controlled release device, including one-chamber system, two-chamber system, asymmetric membrane technology (AMT), and extruding core system (ECS). In general, such devices have at least two components: (a) the core which contains the active ingredient(s); and (b) a semipermeable membrane with at least one delivery port, which encapsulates the core. The semipermeable membrane controls the influx of water to the core from an aqueous environment of use so as to cause drug release by extrusion through the delivery port(s).
In addition to the active ingredient(s), the core of the osmotic device optionally includes an osmotic agent, which creates a driving force for transport of water from the environment of use into the core of the device. One class of osmotic agents water-swellable hydrophilic polymers, which are also referred to as “osmopolymers” and “hydrogels,” including, but not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinylpyrrolidone (PVP), crosslinked PVP, polyvinyl alcohol (PVA), PVA/PVP copolymers, PVA/PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, sodium croscarmellose, carrageenan, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), carboxymethyl cellulose (CMC) and carboxyethyl, cellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.
The other class of osmotic agents is osmogens, which are capable of imbibing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts, such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphates, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars, such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids, such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof.
Osmotic agents of different dissolution rates can be employed to influence how rapidly the active ingredient(s) is initially delivered from the dosage form. For example, amorphous sugars, such as MANNOGEM™ EZ (SPI Pharma, Lewes, Del.) can be used to provide faster delivery during the first couple of hours to promptly produce the desired therapeutic effect, and gradually and continually release of the remaining amount to maintain the desired level of therapeutic or prophylactic effect over an extended period of time. In this case, the active ingredient(s) is released at such a rate to replace the amount of the active ingredient metabolized and excreted.
The core can also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to promote stability or processing.
Materials useful in forming the semipermeable membrane include various grades of acrylics, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water-permeable and water-insoluble at physiologically relevant pHs, or are susceptible to being rendered water-insoluble by chemical alteration, such as crosslinking. Examples of suitable polymers useful in forming the coating, include plasticized, unplasticized, and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, CA p-toluene sulfonate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, acetaldehyde dimethyl acetate, triacetate of locust bean gum, hydroxylated ethylene-vinylacetate, EC, PEG, PPG, PEG/PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic) acids and esters and poly-(methacrylic) acids and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyalkenes, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
Semipermeable membrane can also be a hydrophobic microporous membrane, wherein the pores are substantially filled with a gas and are not wetted by the aqueous medium but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798,119. Such hydrophobic but water-vapor permeable membrane are typically composed of hydrophobic polymers such as polyalkenes, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
The delivery port(s) on the semipermeable membrane can be formed post-coating by mechanical or laser drilling. Delivery port(s) can also be formed in situ by erosion of a plug of water-soluble material or by rupture of a thinner portion of the membrane over an indentation in the core. In addition, delivery ports can be formed during coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Pat. Nos. 5,612,059 and 5,698,220.
The total amount of the active ingredient(s) released and the release rate can substantially by modulated via the thickness and porosity of the semipermeable membrane, the composition of the core, and the number, size, and position of the delivery ports.
The pharmaceutical compositions in an osmotic controlled-release dosage form can further comprise additional conventional excipients or carriers as described herein to promote performance or processing of the formulation.
The osmotic controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see, Remington: The Science and Practice of Pharmacy, supra; Santus and Baker, J. Controlled Release 1995, 35, 1-21; Verma et al., Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et al., J. Controlled Release 2002, 79, 7-27).
In certain embodiments, the pharmaceutical compositions provided herein are formulated as AMT controlled-release dosage form, which comprises an asymmetric osmotic membrane that coats a core comprising the active ingredient(s) and other pharmaceutically acceptable excipients or carriers. See, U.S. Pat. No. 5,612,059 and WO 2002/17918. The AMT controlled-release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation, and a dip-coating method.
In certain embodiments, the pharmaceutical compositions provided herein are formulated as ESC controlled-release dosage form, which comprises an osmotic membrane that coats a core comprising the active ingredient(s), a hydroxylethyl cellulose, and other pharmaceutically acceptable excipients or carriers.
3. Multiparticulate Controlled Release Devices
The pharmaceutical compositions provided herein in a modified release dosage form can be fabricated as a multiparticulate controlled release device, which comprises a multiplicity of particles, granules, or pellets, ranging from about 10 μm to about 3 mm, about 50 μm to about 2.5 mm, or from about 100 μm to about 1 mm in diameter. Such multiparticulates can be made by the processes known to those skilled in the art, including wet- and dry-granulation, extrusion/spheronization, roller-compaction, melt-congealing, and by spray-coating seed cores. See, for example, Multiparticulate Oral Drug Delivery; Marcel Dekker: 1994; and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989.
Other excipients or carriers as described herein can be blended with the pharmaceutical compositions to aid in processing and forming the multiparticulates. The resulting particles can themselves constitute the multiparticulate device or can be coated by various film-forming materials, such as enteric polymers, water-swellable, and water-soluble polymers. The multiparticulates can be further processed as a capsule or a tablet.
4. Targeted Delivery
The pharmaceutical compositions provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated, including liposome-, resealed erythrocyte-, and antibody-based delivery systems. Examples include, but are not limited to, U.S. Pat. Nos. 6,316,652; 6,274,552; 6,271,359; 6,253,872; 6,139,865; 6,131,570; 6,120,751; 6,071,495; 6,060,082; 6,048,736; 6,039,975; 6,004,534; 5,985,307; 5,972,366; 5,900,252; 5,840,674; 5,759,542; and 5,709,874.
Standard physiological, pharmacological and biochemical procedures are available for testing the compounds to identify those that possess biological activities that modulate the activity of JAK kinases, including wild type and mutant JAK kinases. Such assays include, for example, biochemical assays such as binding assays, see, Fabian et al., Nature Biotechnology 2005, 23, 329-336, radioactivity incorporation assays, as well as a variety of cell based assays.
Exemplary cell based assay methodologies include measurement of STAT5A phosphorylation, for example, by ELISA or the measurement of proliferation in leukemic cell lines such as TF-1 or HEL-2, for example, by BrdU incorporation, by fluorescent staining or by a reporter assay activated by the transcription factor STAT5. Cells useful in the assays include cells with wildtype JAK such as TF-1 or mutated JAK such as the cell line HEL-2 which express a constitutively active JAK2 carrying the V617F mutation. Suitable cells include those derived through cell culture from patient samples as well as cells derived using routine molecular biology techniques, e.g., retroviral transduction, transfection, mutagenesis, etc.
Also provided herein are methods of using the disclosed compounds and compositions, or pharmaceutically acceptable salts, solvates or hydrates thereof, for the treatment, prevention, or amelioration of a disease or disorder that is mediated or otherwise affected via JAK kinase, including JAK2 kinase activity or one or more symptoms of diseases or disorders that are mediated or otherwise affected via JAK kinase, including JAK2 kinase, activity. JAK kinase can be wild type and/or mutant form of JAK2 kinase. Consistent with the description above, such diseases or disorders include without limitation: myeloproliferative disorders such as polycythemia vera (PCV), essential thrombocythemia and idiopathic myelofibrosis (IMF); leukemia such as myeloid leukemia including chronic myeloid leukemia (CML), imatinib-resistant forms of CML, acute myeloid leukemia (AML), and a subtype of AML, acute megakaryoblastic leukemia (AMKL); lymphoproliferative diseases such as myeloma; cancer including head and neck cancer, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancer, brain tumor, pancreatic cancer and renal carcinoma; and inflammatory diseases or disorders related to immune dysfunction, immunodeficiency, immunomodulation, autoimmune diseases, tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease, multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, psoriasis, allergic rhinitis, inflammatory bowel disease including Crohn's disease and ulcerative colitis (UC), systemic lupus erythematosis (SLE), arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma and chronic obstructive pulmonary disease (COPD) and dry eye syndrome (or keratoconjunctivitis sicca (KCS)).
In certain embodiments, provided herein are methods of using the disclosed compounds and compositions, or pharmaceutically acceptable salts, solvates or hydrates thereof, for the treatment, prevention, or amelioration of a disease or disorder selected from myeloproliferative disorders such as polycythemia vera (PCV), essential thrombocythemia and idiopathic myelofibrosis (IMF) and hypereosinophilic syndrome (HES); leukemia such as myeloid leukemia including chronic myeloid leukemia (CML), imatinib-resistant forms of CML, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and a subtype of AML, acute megakaryoblastic leukemia (AMKL); lymphoproliferative diseases such as myeloma; cancer including head and neck cancer, prostate cancer, breast cancer, ovarian cancer, melanoma, lung cancer, brain cancer, pancreatic cancer, gastric cancer, thyroid cancer, renal carcinoma, Kaposi's sarcoma, Castleman's disease, melanoma; and inflammatory diseases or disorders related to immune dysfunction, immunodeficiency or immunomodulation, such as tissue transplant rejection, graft-versus-host disease, wound healing, kidney disease including diabetic neuropathy; autoimmune diseases such as multiple sclerosis, thyroiditis, type 1 diabetes, sarcoidosis, psoriasis, allergic rhinitis, atopic dermatitis, myasthenia gravis, inflammatory bowel disease including Crohn's disease and ulcerative colitis (UC), systemic lupus erythematosis (SLE), arthritis, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma and chronic obstructive pulmonary disease (COPD), inflammatory diseases of the eye including conjunctivitis, uveitis, iritis, scleritis, inflammatory diseases of the respiratory tract including the upper respiratory tract such as rhinitis and sinusitis and inflammatory diseases of the lower repiratory tract including bronchitis; inflammatory myopathy such as myocarditis, other inflammatory diseases such as ischemia reperfusion injuries related to an inflammatory ischemic event such as a stroke or cardiac arrest, and other inflammatory conditions such as systemic inflammatory response syndrome (SIRS) and sepsis.
In certain embodiments, JAK-mediated diseases and disorders include restenosis, fibrosis and scleroderma. In certain embodiments, JAK-mediated diseases include viral diseases such as Epstein Barr virus (EBV), hepatitis (hepatitis B or hepatitis C), human immunodeficiency virus (HIV), Human T-lymphotropic virus type 1 (HTLV-1), varicella-zoster virus and the human papilloma virus (HPV).
Furthermore, it will be understood by those skilled in the art that the compounds, isomers, and pharmaceutically acceptable salts, solvates or hydrates provided herein, including pharmaceutical compositions and formulations containing these compounds, can be used in a wide variety of combination therapies to treat the conditions and diseases described above. Thus, also contemplated herein is the use of compounds, isomers and pharmaceutically acceptable salts, solvates or hydrates provided herein in combination with other active pharmaceutical agents for the treatment of the disease/conditions described herein.
In one embodiment, such additional pharmaceutical agents include without limitation anti-cancer agents, including chemotherapeutic agents and anti-proliferative agents; anti-inflammatory agents and immunomodulatory agents or immunosuppressive agents.
In certain embodiments, the anti-cancer agents include anti-metabolites (e.g., 5-fluoro-uracil, cytarabine, methotrexate, fludarabine and others), antimicrotubule agents (e.g., vinca alkaloids such as vincristine, vinblastine; taxanes such as paclitaxel and docetaxel), alkylating agents (e.g., cyclophosphamide, melphalan, carmustine, nitrosoureas such as bischloroethylnitrosurea and hydroxyurea), platinum agents (e.g. cisplatin, carboplatin, oxaliplatin, satraplatin and CI-973), anthracyclines (e.g., doxrubicin and daunorubicin), antitumor antibiotics (e.g., mitomycin, idarubicin, adriamycin and daunomycin), topoisomerase inhibitors (e.g., etoposide and camptothecins), anti-angiogenesis agents (e.g. Sutent®, sorafenib and Bevacizumab) or any other cytotoxic agents, (e.g. estramustine phosphate, prednimustine), hormones or hormone agonists, antagonists, partial agonists or partial antagonists, kinase inhibitors (such as imatinib), and radiation treatment.
In certain embodiments, the anti-inflammatory agents include matrix metalloproteinase inhibitors, inhibitors of pro-inflammatory cytokines (e.g., anti-TNF molecules, TNF soluble receptors, and IL1) non-steroidal anti-inflammatory drugs (NSAIDs) such as prostaglandin synthase inhibitors (e.g., choline magnesium salicylate and salicylsalicyclic acid), COX-1 or COX-2 inhibitors, or glucocorticoid receptor agonists such as corticosteroids, methylprednisone, prednisone, or cortisone.
The compound or composition provided herein, or pharmaceutically acceptable salts, solvates or hydrates thereof, may be administered simultaneously with, prior to, or after administration of one or more of the above agents.
Pharmaceutical compositions containing a compound provided herein or pharmaceutically acceptable salts, solvates or hydrates thereof, and one or more of the above agents are also provided.
Also provided is a combination therapy that treats or prevents the onset of the symptoms, or associated complications of cancer and related diseases and disorders comprising the administration to a subject in need thereof, of one of the compounds or compositions disclosed herein, or pharmaceutically acceptable salts, solvates or hydrates thereof, with one or more anti-cancer agents.
Starting materials in the synthesis examples provided herein are either available from commercial sources or via literature procedures (e.g., March Advanced Organic Chemistry Reactions, Mechanisms, and Structure, (1992) 4th Ed.; Wiley Interscience, New York). All commercially available compounds were used without further purification unless otherwise indicated. Proton (1H) nuclear magnetic resonance (NMR) spectra were typically recorded at 300 MHz on a Bruker Avance 300 NMR spectrometer unless otherwise noted. Significant peaks are tabulated and typically include: number of protons, and multiplicity (s, singlet; d, double; t, triplet; q, quartet; m, multiplet; br s, broad singlet). Chemical shifts are reported as parts per million (δ) relative to tetramethylsilane. Unless otherwise noted, low resolution mass spectra (MS) were obtained as electrospray ionization (ESI) mass spectra, which were typically recorded on a Shimadzu HPLC/MS instrument using reverse-phase conditions using a mobile phase gradients of either acetonitrile/water containing 0.05% acetic acid or MeOH/water containing 0.2% formic acid. Preparative reverse phase HPLC was typically performed using a Varian HPLC system equipped with a Phenomenex phenylhexyl, a Phenomenex Luna C18, or a Varian Pursuit diphenyl reverse phase column; typical elution conditions utilized a gradient of acetonitrile/water containing 0.05% acetic acid. Silica gel chromatography was either performed manually, typically following the published procedure for flash chromatography (Still et al. (1978) J. Org. Chem. 43:2923), or on an automated system (for example, on a Biotage SP instrument) using pre-packed silica gel columns.
It is understood that in the following description, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds under standard conditions.
It will also be appreciated by those skilled in the art that in the process described below the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include —C(O)—R (where R is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or aralkyl esters.
Protecting groups may be added or removed in accordance with standard techniques, which are well-known to those skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T. W. and P. G. M. Wutz, Protective Groups in Organic Synthesis (1991), 2nd Ed., Wiley-Interscience.
One of ordinary skill in the art could readily ascertain which choices for each substituent are possible for the reaction conditions of each Scheme. Moreover, the substituents are selected from components as indicated in the specification heretofore, and may be attached to starting materials, intermediates, and/or final products according to schemes known to those of ordinary skill in the art.
Also it will be apparent that the compounds provided herein could exist as one or more isomers, that is E/Z isomers, enantiomers and/or diastereomers.
Compounds of formula (I) may be generally prepared as depicted in the following schemes, and unless otherwise noted, the various substituents are as defined elsewhere herein.
Standard abbreviations and acronyms as defined in J. Org. Chem. 2007 72(1): 23A-24A are used herein. Other abbreviations and acronyms used herein are as follows:
Compounds provided herein are synthesized according to the following schemes and descriptions.
As illustrated in Scheme 1, an appropriate substituted aminoheteroaryl-carboxamide 1 may be treated with phosgene or a phosgene equivalent (for example diphosgene, triphosgene, carbonyl diimidazole) to form the 2,4-dihydroxy heteroarylpyrimidine 2, which is then treated with an appropriate phosphorous or phosphoryl halide, for example phosphoryl chloride, to form the 2,4-dihalo derivative 3 (X=halo). Alternatively, X can be a different leaving group moiety, for example, sulfonate, which can be prepared by treatment of 2 with an appropriate sulfonyl halide in the presence of an organic base (such as DIEA or TEA). As a further alternative, 2 may also be transformed into 3 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. When 3 is treated with an azolyl amine in the presence of an organic base (such as DIEA or TEA), optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, preferential displacement of X at the pyrimidyl 4-position occurs to afford 4. Then 4 is treated with an appropriate thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent, to form 5. The pyrimidyl 2-sulfide moiety of 5 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 6. Sulfone 7 is formed either from further oxidation of 6 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 5 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
As illustrated in Scheme 2, an appropriate substituted aminoheteroarylcarboxylic ester 8 may be treated with benzoyl isothiocyanate at 0° C. to rt, in a suitable solvent such as acetone, DCM, THF, DMF, or DMA to afford 9. Intermediate 9 is first treated with a base such as sodium tert-butoxide, in a solvent such as MeOH or EtOH, at rt or with heating as necessary, and then acidified with an acid such as aq HCl, to afford 10. Treatment of 10 with an aryl or heteroaryl iodide or an aryl or heteroaryl bromide, in the presence of an inorganic base such as cesium carbonate, and in the presence of suitably activated copper (0) powder, in a suitable solvent such as DMF or DMA, and at an elevated temperature (heating between 100 to 250° C., in a conventional oil bath or in a microwave synthesizer), affords 11. Compound II is treated with an appropriate phosphorous or phosphoryl halide, for example phosphoryl chloride, to form the 4-halo derivative 12 (X=halo). Alternatively, X can be a different leaving group moiety, for example, sulfonate which can be prepared via treatment of 11 with an appropriate sulfonyl halide in the presence of an organic base (such as DIEA or TEA). As a further alternative, 11 may also be transformed into 12 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. Treatment of 12 with an azolyl amine in the presence of an organic base (such as DIEA or TEA), optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, affords 5. The pyrimidyl 2-sulfide moiety of 5 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 6. Sulfone 7 is formed either from further oxidation of 6 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 5 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
Scheme 3 illustrates synthetic methods for the preparation of substituted pyrrolopyrimidine derivatives 21 and 22 and associated intermediates. Compound 13 (which may be prepared as described in Bioorg. Med. Chem. 2007 15(19), 6336-6352) is treated with sodium acetate in water at elevated temperature, followed by treatment with chloroacetaldehyde in water at elevated temperature, to afford 14. The sulfide moiety of 14 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 15. Sulfone 16 is formed either from further oxidation of 15 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 14 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion. Compounds 15 or 16 may be treated with an appropriate thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent, to afford 17. Compound 17 is treated with an appropriate phosphorous or phosphoryl halide, for example phosphoryl chloride, to form the 4-halo derivative 18 (X=halo). Alternatively, X can be a different leaving group moiety, for example, sulfonate which can be prepared via treatment of 17 with an appropriate sulfonyl halide in the presence of an organic base (such as DIEA or TEA). The incorporation of a substituent at N-7 of pyrrolopyrimidine derivative 18 may be achieved via the treatment of 18 first with a base such as sodium hydride or sodium or potassium tert-butoxide at 0° C. to rt in a suitable solvent such as THF, DMF or DMA, followed by treatment with an appropriate electrophilic reagent, such as (but not restricted to) an alkyl, cycloalkyl, heteroalkyl, or heterocycloalkyl bromide, chloride, iodide, or sulfonate derivative optionally in the presence of a source of iodide ion, such as potassium iodide, at rt or elevated temperature as required to drive the reaction to substantial completion, to afford 19. Treatment of 19 with an azolyl amine in the presence of an organic base (such as DIEA or TEA), optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, affords 20. The sulfide moiety of 20 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 21. Sulfone 22 is formed either from further oxidation of 21 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 20 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
Scheme 4 illustrates synthetic methods for the preparation of substituted pyrazolopyrimidine derivatives 27 and 28 and associated intermediates. When compound 23 (when X1=Cl, this may be prepared as described in WO2008/39359 A2; when X1=SMe, this is available from commercial sources, alternatively it may be prepared as described in WO2007/147109 A2) is treated with an azolyl amine in the presence of an organic base such as DIEA or TEA, optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, preferential displacement of Cl at the pyrimidyl 4-position occurs to afford 24. Treatment of compound 24 with an appropriate mono-substituted hydrazine derivative 24a in the presence of an organic base such as DIEA or TEA in a suitable solvent such as dioxane, THF, DMF or DMA, at rt to an elevated temperature as necessary, affords pyrazolopyrimidine 25. Compound 25 (when X1=CO may be directly converted to the pyrimidyl 2-sulfonyl derivative 28 by treatment with an appropriate substituted sulfinate salt 25a, in a suitable solvent such as DMSO, DMF or DMA, at an elevated temperature, for example, heating between 100 to 250° C. in a conventional oil bath or in a microwave synthesizer. Alternatively, compound 25 (when X1=SMe) may be converted to the pyrimidyl 2-sulfonyl derivative 28 by initial treatment with an excess quantity of a suitable oxidizing agent such as meta-chloroperbenzoic acid in a suitable solvent such as DCM, followed by treatment with an appropriate substituted sulfinate salt 25a, in a suitable solvent such as DMSO, DMF or DMA, at an elevated temperature, for example, heating between 100 to 250° C. in a conventional oil bath or in a microwave synthesizer. Alternatively, compound 25 (when X1=CO may be treated with an appropriate thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent to afford 26. Alternatively, compound 25 (when X1=SMe) may be initially treated with an excess of an appropriate oxidizing agent such as meta-chloroperbenzoic acid, followed by treatment with a thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent to afford 26. The sulfide moiety of compound 26 may be oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 27. Sulfone 28 can also be formed either from further oxidation of 27 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 26 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
Scheme 5 illustrates synthetic methods for the preparation of substituted pyrazolopyrimidine derivatives 37 and 38, and associated intermediates. Treatment of para-methoxybenzaldehyde 29 with an appropriate mono-substituted hydrazine derivative 24a in a suitable solvent such as MeOH, EtOH, 2-propanol, or toluene at rt to an elevated temperature as necessary, and optionally in the presence of a water scavenger such as molecular sieves or anhydrous magnesium sulfate, or with removal of water via azeotropic distillation, affords a hydrazone derivative 30. Treatment of 30 with malononitrile and triethyl orthoformate in a suitable solvent such as MeOH, EtOH or 2-propanol, at rt to elevated temperature as required, followed by treatment with an acid such as aq HCl at rt to elevated temperature as necessary, affords substituted 5-amino-pyrazolopyrimidine-4-carbonitrile derivatives 31. Compounds 31 are converted to carboxamides 32 by standard methods, for example by treatment with concentrated sulfuric acid at 0° C. to rt or by reaction with potassium hydroxide and hydrogen peroxide in water at 0° C. to rt. A compound 32 is treated with phosgene or a phsogene equivalent such as diphosgene, triphosgene, carbonyl diimidazole to form the 2,4-dihydroxy heteroarylpyrimidine 33, which is then treated with an appropriate phosphorous or phosphoryl halide, for example phosphoryl chloride, to form the 2,4-dihalo derivative 34 (X=halo). Alternatively, X can be a different leaving group moiety, for example, sulfonate, which can be prepared via treatment of 33 with an appropriate sulfonyl halide in the presence of an organic base (such as DIEA or TEA). As a further alternative, 33 may also be transformed into 34 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. When 34 is treated with an azolyl amine in the presence of an organic base such as DIEA or TEA, optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, preferential displacement of X at the pyrimidyl 4-position occurs to afford 35. Subsequent treatment of 35 with an appropriate thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent, affords 36. The sulfide moiety of 36 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 37. Sulfone 38 is formed either from further oxidation of 37 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 36 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
Scheme 6 illustrates synthetic methods for the preparation of substituted thiazoloyrimidine derivatives 47 and 48, and associated intermediates. The treatment of 4-amino-thiazolopyrimidine-5-carbonitrile derivative 39, which may be prepared as described in Tetrahedron 2008, 64(39), 9309-9314, with either concentrated sulfuric acid at 0° C. to rt, or by reaction with potassium hydroxide and hydrogen peroxide in water at 0° C. to rt, affords 4-amino-thiazolopyrimidine-5-carboxamide derivative 40. The thiazole 2-sulfide moiety of 40 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 41. Subsequent reaction of 41 with appropriate nucleophiles, such as (but not restricted to) primary and secondary amines, alkoxides, alkylamgnesium halides, or metal cyanides, in appropriate solvents and at appropriate temperatures, will afford, respectively, 2-amino, 2-alkoxy, 2-alkyl, and 2-cyanothiazolopyrimidine derivatives as encompassed by structure 42. Thiazole derivative 42 is treated with phosgene or a phosgene equivalent such as diphosgene, triphosgene, or carbonyl diimidazole to form the 2,4-dihydroxy heteroarylpyrimidine 43, which is then treated with an appropriate phosphorous or phosphoryl halide, for example phosphoryl chloride, to form the 2,4-dihalo derivative 44 (X=halo). Alternatively, X can be a different leaving group moiety, for example, sulfonate which can be prepared via treatment of 43 with an appropriate sulfonyl halide in the presence of an organic base (such as DIEA or TEA). As a further alternative, 43 may also be transformed into 44 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. When 44 is treated with an azolyl amine in the presence of an organic base such as DIEA or TEA, optionally in the presence of an iodide source such as potassium iodide or tetrabutylammonium iodide, in a suitable solvent such as DMF or DMA with heating as necessary, preferential displacement of X at the pyrimidyl 4-position occurs to afford 45. Subsequent treatment of 45 with an appropriate thioalkoxide in a suitable solvent such as DMF, DMA, or an alcoholic solvent, affords 46. The pyrimidyl 2-sulfide moiety of 46 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 47. Sulfone 48 is formed either from further oxidation of 47 using additional equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required, or can be formed directly from 46 by treatment with two to four equivalents of an oxidant, such as a percarboxylic acid, at rt to elevated temperature as required to drive the reaction to substantial completion.
As illustrated in Scheme 7, an appropriate aminoheteroaryl-carboxamide 1, 32, or 42 may be transformed to a 2-carboxylate substituted heteroarylpyrimidine 49 with an activated oxalic acid derivative such as a dialkyl oxalate either neat or in a suitable solvent such as EtOH or HOAc with heating as required. Alternatively, 1, 32 or 42 is treated with an oxalic acid monoalkyl ester chloride in a suitable solvent such as DCM in the presence of a base such as TEA and optionally in the presence of a catalyst such as DMAP; or 1, 32, or 42 is treated with a cyano oxoacetate monoalkyl ester with heating in a suitable solvent such as acetonitrile or DMF in the presence of a base such as TEA. Subsequent treatment under dehydrating conditions, for example, heating with or without TMSC1 in the presence of a suitable base such as DIEA in a suitable solvent such as DCE affords the bicyclic product 49. Treatment of 49 with an appropriate phosphorous or phosphoryl halide reagent, for example phosphoryl chloride, forms the 4-halo derivative 50. Alternatively, 49 may be treated with a sulfonyl halide to form 50 (X=O-sulfonyl). As a further alternative, 49 may also be transformed into 50 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. Treatment of 50 with a metalloarene or metalloheteroarene, for example an aryl or heteroaryl lithium or an aryl or heteroaryl Grignard reagent in a suitable solvent such diethyl ether, THF, or other ether solvent, and at appropriate temperatures, produces ketone 51. Subsequent conversion of 51 to 52 is accomplished under conditions analogous to those described in Scheme 2 for conversion of 12 to 5.
As illustrated in Scheme 8, compounds 1, 32, or 42 may be condensed with a suitably activated carboxylic acid derivative 53 followed by dehydrative cyclization, promoted for example with heat or with TMSCl in the presence of a tertiary amine base such as TEA, DIEA, or pyridine to form 4-hydroxy derivatives 54. Alternatively, heating of 1, 32, or 42 with a carboxylic acid 53 (Y=OH) or its salt in the presence of trimethylsilyl polyphosphate affords 54. Treatment of 54 with an appropriate phosphorous or phosphoryl halide reagent, for example phosphoryl chloride, forms the 4-halo derivative 55. Alternatively, 54 may be treated with a sulfonyl halide in the presence of base to form 55 (X=O-sulfonyl). As a further alternative, 54 may also be transformed into 55 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. Subsequent conversion of 55 to 56 is accomplished under conditions analogous to those described in Scheme 2 for conversion of 12 to 5.
Scheme 9 illustrates synthetic methods for the preparation of substituted thiazolopyrimidine derivatives 61 and associated intermediates. Compound 40 may be condensed with a suitably activated carboxylic acid derivative 53 followed by dehydrative cyclization, promoted for example, with heat or with TMSCl in the presence of a tertiary amine base such as TEA, DIEA, or pyridine to form 4-hydroxy derivatives 57. Alternatively, heating of 40 with a carboxylic acid 53 (Y=OH) or its salt in the presence of trimethylsilyl polyphosphate affords 57. Treatment of 57 with an appropriate phosphorous or phosphoryl halide reagent, for example phosphoryl chloride, forms 58 (X=halo). Alternatively, 57 may be treated with a sulfonyl halide in the presence of base to form 58 (X=O-sulfonyl). As a further alternative, 57 may also be transformed into 58 (X=S(O)-alkyl or S(O)2-alkyl) by treatment with Lawesson's reagent or P2S5, followed by alkylation and subsequent oxidation. Subsequent conversion of 58 to 59 is accomplished under conditions analogous to those described in Scheme 2 for conversion of 12 to 5. The thiazolopyrimidine 2-sulfide moiety of 59 is then oxidized by treatment at 0° C. to rt with a stoichiometric or slight excess quantity of an oxidant such as a percarboxylic acid to give sulfoxide 60. Subsequent reaction of 60 with appropriate nucleophiles, such as but not restricted to primary and secondary amines, alkoxides, alkylmagnesium halides, or metal cyanides, in appropriate solvents and at appropriate temperatures, affords respectively, 2-amino, 2-alkoxy, 2-alkyl, and 2-cyanothiazolopyrimidine derivatives as encompassed by structure 61.
In Scheme 10 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 70. Treatment of an appropriate haloheteroaryl carboxylic acid 62 with acetoacetate ester and subsequent processing under conditions described in the literature (see Bender and Sarantakis, Org. Prep. Proc. Int. 1986, 18, 286-289 and references therein), 64 is formed. The hydroxyl groups of 64 are converted to leaving groups X in a fashion analogous to that described in Scheme 1 for conversion of 2 to 3, to form 65. Treatment of 65 with an aminoazole with heating as required in the presence of base or in the presence of a suitable Pd catalyst with added Pd ligands as required, affords 66. Treatment of 66 with a suitable thiolate reagent with heating as required forms an intermediate sulfide, which is oxidized to sulfoxides or sulfones 70 in a manner analogous to that described in Scheme 1 for conversion of 5 to 6 or 7. In some cases it may be advantageous to displace one of the X groups of 65 with a group “Prot” followed by reaction with a thiolate reagent to form 67. “Prot” is intended to be a group, for example alkoxy or thioalkoxy, which can be subsequently conveniently converted to a leaving group X, for example to afford 68. Conversion of 68 to 69 is effected under conditions analogous to, or if needed, more forcing than, those that used to effect conversion of 65 to 66. Conversion of 69 to 70 is carried out under conditions analogous to those described in Scheme 1 for the conversion of 5 to 6 or 7.
In Scheme 11 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 75. A suitable haloheteroaryl carboxylic ester 71 is treated with 2-acetamidoacrylate ester in the presence of a Pd catalyst, for example palladium acetate, with heating in a suitable solvent such as DMF to form 72. The hydroxyl group of 72 is converted to a leaving group X to form 73 in a fashion analogous to that described in Scheme 1 for conversion of 2 to 3. Treatment of 73 with a metalloarene or metalloheteroarene, for example an aryl or heteroaryl lithium or an aryl or heteroaryl Grignard reagent in a suitable solvent such diethyl ether, THF, or other ether solvent, and at appropriate temperatures, produces ketone 74. Treatment of 74 with an aminoazole with heating as required in the presence of acid or base or in the presence of a suitable Pd catalyst with added Pd ligands as required, affords 75.
In Scheme 12 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 80. A suitable methylheteroaryl carbonitrile 76 is deprotonated with strong base, and then treated with a suitably activated carboxylic acid 53, wherein Y may be alkoxy or —N(Me)OMe, to form ketone 77. Treatment of 77 with concentrated sulfuric acid and water effects ring closure to the fused hydroxypyridine derivative 78. The hydroxyl group of 78 is converted to a leaving group X to form 79 in a fashion analogous to that described in Scheme 1 for conversion of 2 to 3. Treatment of 79 with an aminoazole with heating as required, and in the presence of acid or base, or in the presence of a suitable Pd catalyst with added Pd ligands as required, affords 80.
In Scheme 13 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 85. As described by Barker, et al. (J. Chem. Res. 1985, 5, 214-215), treatment of a suitable aminoheteroaryl carboxylic ester 81 with a dialkyl malonate such as 81a affords amide 82. Alternatively, as described in WO2006/61642, treatment of 81 with an alkyl 3-chloro-3-oxopropanoate in the presence of a tertiary amine base such as DIEA or TEA affords 82. Treatment of 82 with a base such as sodium hydride or an alkoxide with heating effects ring closure, which is followed by ester hydrolysis and decarboxylation to afford 83. Conversion of 83 to 85 via 84 is effected using methodology analogous to that described in Scheme 10 for conversion of 64 to 70.
In Scheme 14 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 90. As described in U.S. Pat. No. 5,026,700, treatment of a suitable aminoheteroarene 86 with dialkyl acetylenedicarboxylate in refluxing alcohol solvent affords fused hydroxypyridine 87. Alternatively, dialkyl 2-oxosuccinate may be substituted for dialkyl acetylenedicarboxylate. Conversion of 87 to 90 via 88 and 89 may be effected using methodology analogous to that described in Scheme 11 for converting 72 to 75.
In Scheme 15 is illustrated synthetic methodology suitable for preparation of fused heteroaryl pyridines 94. A suitable aminoheteroarene 86 is acetylated under Friedel-Crafts conditions and then the amino group is acylated with a suitably activated carboxylic acid derivative 53 to afford amide 91. Ring closure to 92 is effected by treatment with a base such as hydroxide or alkoxide with heating as required. Conversion of 92 to 94 via 93 is effected using methodology analogous to that described in Scheme 12 for conversion of 78 to 80.
In Scheme 16 are illustrated representative examples by which the keto group in any of 52 (Scheme 7), 75 (Scheme 11), or 90 (Scheme 14) can be further modified to afford additional compounds of the invention. Treatment of ketone 52, 75, or 90 with Lawesson's reagent affords thioketones 95. Treatment of ketone 52, 75, or 90 with an amine, hydroxylamine, or alkoxylamine under dehydrating conditions optionally in the presence of acid with heating affords, respectively, imines, oximes, or O-alkyl oximes 96. Treatment of ketone 52, 75, or 90 with a Wittig reagent or Horner-Emmons reagent affords olefins 97. Treatment of ketone 52, 75, or 90 with a reducing agent such as sodium borohydride or lithium borohydride affords secondary alcohols 98. Treatment of ketone 52, 75, or 90 with an organometallic reagent such as a Grignard reagent or an organolithium compound affords tertiary alcohols 99. Heating ketone 52, 75, or 90 with an alcohol in the presence of acid with removal of water affords ketals 100. Heating ketone 52, 75, or 90 with a 1,2- 1,3- or 1,4-diol in the presence of acid with removal of water affords cyclic ketals 101.
In Scheme 17 is illustrated a useful method for preparing acids 53 used in Schemes 8, 9, and 15. A carboxylic acid derivative 102, where Y′ is for example alkoxy or a subsequently removable chiral auxiliary, is deprotonated at the alpha position with a strong base and treated with an alkylating agent to afford 103. The sequence is repeated with the same or a different alkylating agent to form 104. The Y′ group of 104 is then converted by procedures well known in the art to the Y group of 53 that is suitable for use in Scheme 8, 9, or 15.
In Scheme 18 is illustrated an alternative method for preparing acids 53 used in Schemes 8, 9, and 15. A suitable carboxylic acid derivative, following conversion with base to an enolate 105 or its equivalent is treated with an aryl halide, or more suitably with a heteroaryl halide to form 104. The Y′ group of 104 is then converted by procedures well known in the art to the Y group of 53 that is suitable for use in Scheme 8, 9, or 15.
It will be appreciated by one skilled in the art that standard functional group manipulations may be used to prepare additional compounds of the invention from products or intermediates prepared as described by the foregoing methods. In Schemes 19 through 23 are shown representative examples that are intended to illustrate, but in no way to limit the scope of, such standard functional group manipulations.
For example, as described in Scheme 19, imine 96 can be treated with a suitable reducing agent such as sodium borohydride in a suitable solvent such as MeOH, EtOH or THF, at 0° C. to rt or further elevated temperatures as required, to afford amine 107. Olefin 97 can be treated with hydrogen gas in the presence of a noble metal catalyst and in a solvent such as water, a lower alcohol, EtOAc, or DMF or mixtures thereof, at rt or elevated temperatures, to afford 108. Alcohol 98 can be treated with thionyl chloride, or carbon tetrabromide in the presence of triphenylphosphine, and in a suitable solvent such as THF or DCM, at rt to elevated temperatures, to afford, respectively, alkyl chlorides (X=Cl) or bromides 109 (X=Br). Or alcohol 98 can be treated with a fluorinating reagent such as diethylaminosulfur trifluoride, in a suitable solvent such as DCM, at 0° C. to rt, to afford alkyl fluorides 109 (X=F). Compound 110 can be treated with either boron tribromide in a suitable solvent such as DCM, at 0° C. to rt or elevated temperatures as required, or treated with trimethylsilyl iodide in a suitable solvent such as DCM, at 0° C. to rt or elevated temperatures as required to afford 111. Compound 107 can be treated with a suitable aryl or heteroaryl bromide or iodide, in the presence of a Pd catalyst with added Pd ligands, in the presence of an inorganic or organic base, and in a suitable solvent such as DMF, THF, or dioxane, and at rt or elevated temperatures as required, to afford 112 (where R13 is aryl or heteroaryl). Alternatively, compound 107 can be treated with an appropriate substituted acid chloride, or an appropriate substituted chloroformate, in a suitable solvent such as DCM, THF, or DMF, at 0° C. to rt to elevated temperature as required, to afford 112, where R13 is C(O)Rv or is C(O)ORw, respectively.
In addition to the above, for example as described in Scheme 20, compound 113 can be treated with thionyl chloride or carbon tetrabromide in the presence of triphenylphosphine, and in a suitable solvent such as THF or DCM, at rt to elevated temperatures, to afford, respectively, alkyl chlorides or bromides 114. Compound 114 can be subsequently treated with either an appropriate substituted primary or secondary amine, or with a suitable alkoxide, in a suitable solvent such as THF, DCM or DMF, at 0° C. to rt to elevated temperatures as required, to afford, compound 116 or 117, respectively. Alternatively, compound 116 can be prepared from 113 via 115, wherein 113 is treated with a suitable oxidizing agent such as Dess-Martin periodinane, or a mixture of oxalyl chloride and DMSO (Swern oxidizing conditions), in a suitable solvent such as DCM, and at appropriate temperatures, to afford 115. Compound 115 can be treated with an appropriate substituted primary or secondary amine and a reducing agent such as sodium cyanoborohydride or sodium triacetoxyborohydride, optionally in the presence of HOAc, and in a suitable solvent such as THF, DCM, MeOH or DMF, at 0° C. to rt to elevated temperatures as required, to afford 116.
In addition to the above, for example as described in Scheme 21, compounds 121 and 122 can be prepared using methodology analogous to that described in Scheme 20 for conversion of 113 to 116 and 117.
In addition to the above, for example as described in Scheme 22, compounds 126 and 127 can be prepared using methodology analogous to that described in Scheme 20 for conversion of 113 to 116 and 117.
In addition to the above, for example as described in Scheme 23, compound 128 can be treated with lithium hydroxide in aq THF to afford 129. The conversion of the carboxylic acid group of 129 to the carboxamide group of 130 can be accomplished by a variety of standard methods, including treatment with an appropriate substituted primary or secondary amine in the presence of coupling reagents such as HATU, EDCI and HOBt, DCC and the like, and in a suitable solvent such as DMF or DMA, or alternatively via the acid chloride by treatment of the acid with thionyl chloride or phosphoryl chloride or the like, followed by the addition of an appropriate substituted primary or secondary amine in the presence of an organic base such as pyridine, TEA or DIEA. Compounds 133 and 136 can be prepared from 131 or 134, respectively, using methodology analogous to that described in Scheme 23 for conversion of 128 to 130.
Aminoazole or azolyl amine intermediates employed herein may be obtained either via commercial sources or prepared using methods known to those skilled in the art. Scheme 24 illustrates representative methods that may be employed for the preparation of additional aminoazoles or azolyl amines. For example, nitroazoles 137 may be converted to aminoazoles 138 via treatment with a suitable reducing agent such as SnCl2 in a suitable solvent such as DCE or EtOH optionally in the presence of HCl, with heating. Alternatively, treatment of 137 with activated iron or zinc metal in HOAc with heating will afford 138. Alternatively, treatment of 137 with palladium metal on activated carbon in the presence of ≧1 atmosphere pressure of hydrogen gas, in a suitable solvent such as MeOH, EtOH, or EtOAc or mixtures of these, at rt or with heating as required, will afford 138. Alternatively, treatment of 137 with sodium hydrosulfite in a suitable solvent mixture such as THF and water at rt or with heating as required, will afford 138. Alternatively, aminoazoles 138 may also be obtained from azole carboxylic acids 139 via initial treatment with diphenylphosphoryl azide in the presence of an organic base such as TEA, and in a suitable solvent such as toluene or THF, and with heating from 50° C. to 150° C. as required, followed by hydrolysis. Alternatively, treatment of 139 with diphenylphosphoryl azide in the presence of an organic base such as TEA, and in the presence of excess tert-butanol, and in a suitable solvent such as toluene or THF, and with heating from 50° C. to 150° C. as required, will afford a tert-butylcarbamoyl azole intermediate, which upon treatment with an acid such as TFA or HCl, and in a suitable solvent, will afford 138 Aminoazoles 138 may also be obtained from azolyl bromides or iodides 140, bearing (as required) suitable protecting groups on any azole ring N—H positions, via initial treatment with a suitable amino containing reagent (where P=protecting group), such as benzophenone imine, 2,4-dimethoxybenzylamine, or tert-butyl carbamate, and in the presence of a catalytic amount of a suitable organopalladium-complex, and optionally in the presence of a suitable phosphine-ligand, and optionally in the presence of a suitable base, and in a suitable solvent with heating or under microwave conditions as required, to afford intermediate 141. Subsequent N-deprotection of intermediate 141 (including azole ring N-deprotection, where required), employing appropriate methods known to those skilled in the art will afford 138. Conversion of aminoazoles 138 to alkylated aminoazoles 142 may be achieved via treatment of 138 with an appropriate aldehyde or ketone substrate, in the presence of a suitable Lewis acid such as TMSCl or TiCl4 and a reducing agent such as sodium (triacetoxy)borohydride or sodium cyanoborohydride, in a suitable organic solvent such as DCM, DCE, THF, or MeOH, optionally in the presence of HOAc, at rt or with heating as required. Alternatively, 142 may be obtained via treatment of 138 with an alkyl halide in the presence of a suitable organic base such as pyridine or DIEA, and sodium or potassium iodide, and in a suitable solvent such as DMF or THF, at rt or with heating as required. Nitroazoles 137, azole carboxylic acids 139, and azole bromides or iodides 140 may be obtained from commercial sources or prepared using methods known to those skilled in the art.
The subject matter has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Thus, it will be appreciated by those of skill in the art that conditions such as choice of solvent, temperature of reaction, volumes, reaction time may vary while still producing the desired compounds. In addition, one of skill in the art will also appreciate that many of the reagents provided in the following examples may be substituted with other suitable reagents. See, e.g., Smith & March, Advanced Organic Chemistry, 5th ed. (2001). Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations and/or methods of use provided herein, may be made without departing from the spirit and scope thereof U.S. patents and publications referenced herein are incorporated by reference.
The embodiments described above are intended to be merely exemplary, and those skilled in the art will recognize, or will be able to ascertain using no more than routine experimentation, numerous equivalents of specific compounds, materials, and procedures. All such equivalents are considered to be within the scope of the claimed subject matter and are encompassed by the appended claims.
Step A:
A mixture 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (560 mg, 2 mmol), 1-(4-methoxybenzyl)-1H-pyrazol-5-amine from Example 2 Step A (610 mg, 3 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (231 mg, 0.4 mmol), tris(dibenzylidenacetone)dipalladium (0) (183 mg, 0.2 mmol) and sodium tert-butoxide (288 mg, 3 mmol) in toluene (15 mL) was stirred and heated at 90° C. for 15 h. After cooling to rt, the mixture was partitioned between DCM and water. The layers were separated and the aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 15-50% EtOAc/hexanes to afford 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as an oil (314 mg, 35%). LC-MS (ESI) m/z 447 (M+H)+.
Step B:
A stirred solution of 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (314 mg, 0.70 mmol) in TFA (10 mL) was heated at 65° C. for 4 h. After concentration under reduced pressure, the residue was dissolved in DCM and washed with saturated aq sodium hydrogen carbonate. The organic layer was separated, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by trituration with a mixture of diethyl ether and DCM to afford 2-(4-fluorophenylthio)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (165 mg, 72%). LC-MS (ESI) m/z 327 (M+H)+.
Step C:
To a stirred solution of 2-(4-fluorophenylthio)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (165 mg, 0.5 mmol) in DMF (6 mL) at 0° C. was added a solution of 70% m-CPBA (112 mg, 0.5 mmol) in DMF (2 mL). The mixture was stirred at 0° C. for 3 h. The solvent was removed under reduced pressure and the residue was purified by preparative reverse-phase HPLC eluting with 55% to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford (R, 5)-2-(4-fluorophenylsulfinyl)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a solid (31 mg, 18%). 1H NMR (300 MHz, DMSO-d6) δ 12.08 (br s, 1H), 10.43 (br s, 1H), 7.82 (dd, J=8.7, 5.3 Hz, 2H), 7.67 (d, J=2.1 Hz, 1H), 7.39-7.28 (m, 4H), 6.86-6.81 (m, 2H). LCMS (ESI) m/z 343 (M+H)+.
Step A:
To a stirred solution of crotonitrile (10.06 g, 150 mmol) in THF at rt was added hydrazine monohydrate (7.76 g, 155 mmol) and the resulting mixture was stirred at rt for 2 h. p-Methoxybenzaldehyde (21.10 g, 155 mmol) was added and the mixture was stirred at rt for 3 h. The solvent was removed under reduced pressure to obtain an oily residue, which was treated with sodium tert-butoxide (14.41 g, 150 mmol) in n-butanol (100 mL) and the resulting mixture was heated at 120° C. for 3 h. The mixture was poured into 1N aq HCl (300 mL) and extracted with diethyl ether (3×100 mL). The aqueous phase was basified with aq 1N sodium hydroxide and extracted with diethyl ether (3×120 mL). The latter organic layers were combined, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 40-60% EtOAc/hexanes to afford 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine (8.64 g, 26%) as a solid.
1H NMR (300 MHz, CDCl3) δ 7.12 (d, J=8.5 Hz, 2H), 6.86 (d, J=8.7 Hz, 2H), 5.37 (s, 1H), 5.08 (s, 2H), 3.79 (s, 3H), 3.31 (s, 2H), 2.19 (s, 3H). LCMS (ESI) m/z 218 (M+H)+.
Step B:
2-(4-Fluorophenylthio)-N-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared following a procedure analogous to that described in Example 1 Step A, substituting 1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-amine for the 1-(4-methoxybenzyl)-1H-pyrazol-5-amine used in Example 1. The residue was purified by silica gel flash chromatography eluting with 30-40% EtOAc/hexanes to afford 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (438 mg, 27%). 1H NMR (300 MHz, DMSO-d6) δ 11.64 (br s, 1H), 9.29 (s, 1H), 7.63-7.58 (m, 2H), 7.24 (t, J=8.9 Hz, 2H), 7.06-7.01 (m, 3H), 6.79 (d, J=8.7 Hz, 2H), 6.29 (br s, 1H), 5.79 (s, 1H), 5.02 (s, 2H), 3.68 (s, 3H), 2.09 (s, 3H). LCMS (ESI) m/z 461 (M+H)+.
Step C:
2-(4-Fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared following a procedure analogous to that described in Example 1 Step B, substituting 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine for the 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine used in Example 1. The filtrate from trituration of the solid was further purified by silica gel chromatography, eluting with 50-80% ethyl acetate in hexanes to afford 2-(4-fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (164 mg, 51%). 1H NMR (300 MHz, DMSO-d6) δ 11.53 (br s, 1H), 9.94 (s, 1H), 7.67 (dd, J=8.6, 5.6 Hz, 2H), 7.36-7.30 (m, 2H), 7.02 (d, J=2.4 Hz, 1H), 6.79 (br s, 1H), 5.61 (s, 1H), 4.33 (br s, 1H), 2.09 (s, 3H). LCMS (ESI) m/z 341 (M+H)+.
Step D:
(R,S)-2-(4-Fluorophenylsulfinyl)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared following a procedure analogous to that described in Example 1 Step C, substituting 2-(4-fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (130 mg, 0.38 mmol) for the 2-(4-fluorophenylthio)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine used in Example 1. The residue was purified by preparative reverse-phase HPLC eluting with 50% to 60% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford (R,S)-2-(4-fluorophenylsulfinyl)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a solid (41 mg, 30%). 1H NMR (300 MHz, DMSO-d6) δ 12.06 (br s, 2H), 10.26 (br s, 1H), 7.84-7.80 (m, 2H), 7.42-7.36 (m, 2H), 7.28 (br s, 1H), 6.87 (br s, 1H), 6.39 (br s, 1H), 2.25 (s, 3H). LC-MS (ESI) m/z 357 (M+H)+.
2-(4-Fluorophenylsulfonyl)-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared following a procedure analogous to that described in Example 1 Step C, substituting 2-(4-fluorophenylthio)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine for the 2-(4-fluorophenylthio)-N-(1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine used in Example 1. The residue was purified by preparative reverse-phase HPLC eluting with 45% to 55% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) and then by silica gel flash chromatography to afford 2-(4-fluorophenylsulfonyl)-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (42 mg, 30%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.29 (br s, 2H), 10.26 (br s, 1H), 8.07-8.02 (m, 2H), 7.63 (d, J=2.3 Hz, 1H), 7.50 (t, J=8.9 Hz, 2H), 7.42-7.41 (m, 1H), 6.95 (br s, 1H), 6.56 (s, 1H). LCMS (ESI) m/z 357 (M+H)+.
To 2-(4-fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine from Example 2 Step C (185 mg, 0.54 mmol) in THF (6 mL) and DCM (6 mL) at 0° C. was added 77% m-CPBA (363 mg, 1.62 mmol). The ice bath was removed and the mixture was stirred for 3 h. Saturated aq NaHCO3 was added, and the mixture was extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 70-95% EtOAc/hexanes to afford 2-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (32 mg, 16%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.27 (br s, 1H), 12.04 (br s, 1H), 10.42 (br s, 1H), 8.06 (dd, J=8.8, 5.2 Hz, 2H), 7.57-7.51 (m, 2H), 7.40 (br s, 1H), 6.96 (br s, 1H), 5.93 (s, 1H), 2.20 (s, 3H). LCMS (ESI) m/z 373 (M+H)+.
Step A:
A stirred mixture of 2-(4-fluorophenylthio)-N-(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine from Example 1 Step A (740 mg, 1.66 mmol), di-tert-butyl dicarbonate (873 mg, 4 mmol), potassium carbonate (552 mg, 4 mmol) and 4-(dimethylamino)pyridine (30 mg, 0.24 mmol) in 1,4-dioxane (20 mL) was heated at 40° C. for 2 h. After cooling to rt, 28% aq ammonium hydroxide (6 mL) and MeOH (4 mL) were added and the resulting mixture was stirred at rt for 3 h. The mixture was partitioned between DCM and water. The layers were separated and the aqueous phase was extracted with DCM. The organic phases were combined, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 25-45% EtOAc/hexanes to afford tert-butyl 2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-yl(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)carbamate (822 mg, 91%) as a solid. 1H NMR (300 MHz, CDCl3) δ 9.38 (br s, 1H), 7.48 (d, J=1.8 Hz, 1H), 7.39 (dd, J=8.7, 5.4 Hz, 2H), 7.14-7.12 (m, 1H), 7.04 (t, J=8.7 Hz, 2H), 6.94 (d, J=8.7 Hz, 2H), 6.69 (d, J=8.7 Hz, 2H), 6.33-6.31 (m, 1H), 6.04 (d, J=2.1 Hz, 1H), 4.86 (s, 2H), 3.73 (s, 3H), 1.46 (s, 9H); LCMS (ESI) m/z 547 (M+H)+ and 447 [(M+H)+-Boc].
Step B:
A stirred mixture of tert-butyl 2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-yl(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)carbamate (590 mg, 1.08 mmol), potassium carbonate (276 mg, 2 mmol), iodomethane (199 mg, 1.4 mmol) in acetone (15 mL) was heated at 50° C. for 18 h. The mixture was cooled to rt and partitioned between DCM and water. The layers were separated and the aqueous phase was extracted with DCM. The organic phases were combined, dried over MgSO4, filtered, and concentrated under reduced pressure to afford tert-butyl 2-(4-fluorophenylthio)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)carbamate (603 mg, quant.), which was used directly in the next step. LCMS (ESI) m/z 561 (M+H)+.
Step C:
A stirred mixture of tert-butyl 2-(4-fluorophenylthio)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl(1-(4-methoxybenzyl)-1H-pyrazol-5-yl)carbamate (603 mg, 1.07 mmol) and TFA (10 mL) was heated at 60° C. for 3 h. The mixture was concentrated under reduced pressure and the residue was partitioned between DCM and saturated aq sodium hydrogen carbonate. The layers were separated and the aqueous phase was extracted with DCM. The organic phases were combined, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 60-100% EtOAc/hexanes to afford 2-(4-fluorophenylthio)-7-methyl-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (217 mg, 59%). 1H NMR (300 MHz, DMSO-d6) δ 12.20 (br s, 1H), 10.05 (br s, 1H), 7.69-7.65 (m, 2H), 7.35-7.27 (m, 2H), 7.07 (s, 1H), 6.83-6.80 (m, 2H), 5.90 (s, 1H), 3.69 (s, 3H). LCMS (ESI) m/z 341 (M+H)+.
Step D:
To A stirred solution of 2-(4-fluorophenylthio)-7-methyl-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (108 mg, 0.317 mmol) in DMF (8 mL) at 0° C. was added m-CPBA (547 mg, 0.317 mmol). The mixture was stirred at 0° C. for 3 h and then purified by preparative reverse phase HPLC eluting with 45% to 55% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford (R, 5)-2-(4-fluorophenylsulfinyl)-7-methyl-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (32 mg, 28%). 1H NMR (300 MHz, DMSO-d6) δ 12.24 (br s, 1H), 10.48 (br s, 1H), 7.88-7.81 (m, 2H), 7.66 (s, 1H), 7.40-7.32 (m, 3H), 6.88 (br s, 1H), 6.81 (br s, 1H), 3.77 (s, 3H). LCMS (ESI) m/z 357 (M+H)+.
2-(4-Fluorophenylsulfonyl)-7-methyl-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine was prepared following a procedure analogous to that described in Example 5 Step D, except using excess m-CPBA in place of 1 equiv of m-CPBA used in Example 5. The resulting mixture was purified by preparative reverse phase HPLC eluting with 40% to 50% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc), and then further purified by silica gel flash chromatography eluting with 60-100% EtOAc/hexanes to afford 2-(4-fluorophenylsulfonyl)-7-methyl-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (26 mg, 22%). 1H NMR (300 MHz, DMSO-d6) δ 12.41 (br s, 1H), 10.61 (br s, 1H), 8.09-8.05 (m, 2H), 7.61 (s, 1H), 7.53-7.46 (m, 3H), 6.97 (br s, 1H), 6.45 (s, 1H), 3.77 (s, 3H). LCMS (ESI) m/z 373 (M+H)+.
Step A:
To absolute EtOH (300 mL) at rt under an argon atmosphere, was added sodium metal (10.35 g, 450 mmol) portionwise with stirreing. Once all the metal had dissolved, ethyl cyanoacetate (45.81 g, 405 mmol) was added dropwise, and the mixture was stirred at rt for 15 min. To the resulting suspension was added thiourea (33.87 g, 445 mmol), and the mixture was heated at reflux for 2 h. After cooling to rt, water (72 mL) was added followed by dimethyl sulfate (51.66 g, 410 mmol). The mixture was heated at reflux for 30 min, then allowed to cool to rt and stand for 72 h. A solid formed, which was collected by filtration, washed with EtOH, and dried under vacuum to afford 6-amino-2-(methylthio)pyrimidin-4-ol (52.97 g, 83%) as a cream-colored solid which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ 11.80 (br s, 1H), 6.43 (br s, 2H), 4.93 (s, 1H), 2.42 (s, 3H). LCMS (ESI) m/z 158 (M+H)+.
Step B:
To a stirred suspension of 6-amino-2-(methylthio)pyrimidin-4-ol (52.97 g, 337 mmol) in water (400 mL) at rt was added sodium acetate (60 g, 731 mmol) and the mixture was heated at 70° C. while 50 wt % chloroacetaldehyde/H2O (60 mL, 379 mmol) was added dropwise. Heating was continued at 70° C. for 40 min, and then the mixture was allowed to cool slowly to rt and stand for 15 h. The supernatant liquid was decanted and the solid residue was triturated with acetone to afford a 2:1 mixture (35 g) of the desired 2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol and unreacted 6-amino-2-(methylthio)pyrimidin-4-ol. To a suspension of this mixture in water (300 mL) was added sodium acetate (30 g, 366 mmol) and the mixture was heated to 70° C. while 50 wt % chloroacetaldehyde/H2O (30 mL, 190 mmol) was added dropwise. Heating was continued at 70° C. for 40 min, and then the mixture was allowed to slowly cool to rt and stand for 15 h. The supernatant liquid was decanted and the solid residue was triturated with acetone to afford 2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (21.45 g, 35%) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 12.02 (br s, 1H), 11.74 (br s, 1H), 6.89-6.91 (m, 1H), 6.34-6.36 (m, 1H), 2.09 (s, 3H). LCMS (ESI) m/z 182 (M+H)+.
Step C:
To a stirred solution of 2-(methylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (11.5 g, 63.5 mmol) in DMF (100 mL) at 0° C. was added portionwise 77% m-CPBA (35 g, 159 mmol), and the mixture was stirred at 0° C. for 1.5 h. The mixture was then allowed to warm to rt and stirred for a further 1.5 h. Additional 77% m-CPBA (4 g, 23.2 mmol) was added and the mixture was stirred at rt for a further 72 h. The solid was collected by filtration to afford a 1:1 mixture of (R, S)-2-(methylsulfinyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol and 2-(methylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4-ol as a solid (5.2 g). To the solid (5.2 g) in DMF (50 mL) were added 4-fluorothiophenol (3.85 g, 30 mmol) and DIEA (11.3 mL, 65 mmol), and the mixture was stirred at rt for 20 h. The mixture was concentrated under reduced pressure and the residue was triturated with DCM to afford 2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (4.10 g) as a solid. LCMS (ESI) m/z 262 (M+H)+.
Step D:
A stirred mixture of 2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-4-ol (520 mg, 1.99 mmol) and phosphorous oxychloride (2 mL) was heated at 110° C. for 1 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was partitioned between DCM and saturated aq sodium hydrogen carbonate. The organic layer was separated and washed with saturated aq sodium hydrogen carbonate. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to give a solid. Purification by trituration with diethyl ether, followed by silica gel flash chromatography eluting with 100% hexanes to 50% EtOAc/hexanes afforded 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine (203 mg, 37%) as a colorless solid. 1H NMR (300 MHz, CDCl3) δ 9.48 (br s, 1H), 7.59-7.67 (m, 2H), 7.08-7.15 (m, 3H), 6.52-6.55 (m, 1H). LCMS (ESI) m/z 280 (M+H)+.
Step E:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine (200 mg, 0.72 mmol) in DMF (5 mL) at 0° C., was added 60% sodium hydride/mineral oil (32 mg, 0.79 mmol). The mixture was stirred at 0° C. for 15 min, and then ethyl iodide (168 mg, 1.08 mmol) was added and the mixture was stirred at 0° C. for 30 min. The mixture was partitioned between water and EtOAc. The organic layer was separated and the aqueous layer was further extracted with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford 4-chloro-7-ethyl-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine (210 mg, 95%) as an oil, which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 7.61-7.70 (m, 2H), 7.06-7.15 (m, 3H), 6.48 (d, J=3.6 Hz, 1H), 4.07 (q, J=7.5 Hz, 2H), 1.34 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z 308 (M+H)+.
Step F:
To a stirred mixture of 4-chloro-7-ethyl-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine (210 mg, 0.68 mmol) and DCM (10 mL) at 0° C. was added 77% m-CPBA (383 mg, 1.71 mmol) and the mixture was stirred at 0° C. for 2 h. DMF (1 mL) was added, followed by further addition of 77% m-CPBA (200 mg, 0.89 mmol), and the mixture was stirred at 5° C. for 2 h. The mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether to afford 4-chloro-7-ethyl-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (155 mg, 67%) as a colorless solid. 1H NMR (300 MHz, CDCl3) δ 8.17-8.23 (m, 2H), 7.47 (d, J=3.6 Hz, 1H), 7.20-7.26 (m, 2H), 6.69 (d, J=3.6 Hz, 1H), 4.38 (q, J=7.5 Hz, 2H), 1.49 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z 340 (M+H)+.
Step G:
A mixture of 4-chloro-7-ethyl-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (25 mg, 0.074 mmol), 5-methyl-1H-pyrazole-3-amine (14 mg, 0.15 mmol), sodium iodide (22 mg, 0.15 mmol) and DIEA (19 mg, 0.15 mmol) in DMF (0.5 mL) was stirred at rt for 1 h, then heated at 60° C. for 144 h. The mixture was combined with those resulting from two additional batches on the same scale, and the resulting mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 40 min, with a flow rate of 95 mL/min), to afford 7-ethyl-2-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (8 mg, 9%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.07 (br s, 1H), 10.46 (br s, 1H), 8.06-8.10 (m, 2H), 7.51-7.57 (m, 3H), 6.98 (br m, 1H), 5.80 (s, 1H), 4.22 (q, J=7.2 Hz, 2H), 2.18 (s, 3H), 1.37 (t, J=7.2 Hz, 3H). LCMS (ESI) m/z 401 (M+H)+.
A stirred mixture of 4-chloro-7-ethyl-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step F (85 mg, 0.25 mmol), 3-aminopyrazole (42 mg, 0.5 mmol), sodium iodide (112 mg, 0.75 mmol) and DIEA (64 mg, 0.50 mmol) in DMF (2 mL) was heated at 80° C. for 45 h. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 20 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 7-ethyl-2-(4-fluorophenylsulfonyl)-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (5 mg, 5%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.40 (br s, 1H), 10.59 (br s, 1H), 8.04-8.09 (m, 2H), 7.61 (m, 1H), 7.41-7.54 (m, 3H), 6.96 (br m, 1H), 6.54 (s, 1H), 4.20 (q, J=7.2 Hz, 2H), 1.35 (t, J=7.2 Hz, 3H). LCMS (ESI) m/z 387 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (200 mg, 0.72 mmol) in DMF (4 mL) at 0° C. was added 60% sodium hydride/mineral oil (43 mg, 1.07 mmol) and the mixture was stirred at 0° C. for 15 min. A solution of methyl iodide (203 mg, 1.43 mmol) in DMF (1 mL) was added and the mixture was stirred at 0° C. for 1 h. The mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford 4-chloro-2-(4-fluorophenylthio)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (211 mg, 100%) as a yellow solid that did not require further purification. 1H NMR (300 MHz, CDCl3) δ 7.61-7.69 (m, 2H), 7.08-7.16 (m, 2H), 7.02 (d, J=3.6 Hz, 1H), 6.48 (d, J=3.6 Hz, 1H), 3.64 (s, 3H). LCMS (ESI) m/z 294 (M+H)+.
Step B:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (229 mg, 0.78 mmol) in a mixture of DCM (10 mL) and DMF (1 mL) at 0° C. was added 77% m-CPBA (524 mg, 2.34 mmol). The mixture was warmed to rt and stirred for 15 h. The mixture was concentrated under reduced pressure and the solid residue was triturated with diethyl ether to afford 4-chloro-2-(4-fluorophenylsulfonyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (193 mg, 76%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.09-8.16 (m, 2H), 8.02 (d, J=3.3 Hz, 1H), 7.50-7.57 (m, 2H), 6.82 (d, J=3.6 Hz, 1H), 3.21 (s, 3H). LCMS (ESI) m/z 326 (M+H)+.
Step C:
A mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidine (70 mg, 0.23 mmol), 5-methyl-1H-pyrazol-3-amine (45 mg, 0.46 mmol), sodium iodide (103 mg, 0.69 mmol), DIEA (59 mg, 0.46 mmol) and DMF (2 mL) was stirred at 80° C. for 48 h. The mixture was cooled to rt and purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc). Appropriate fractions from this batch and a second batch conducted on the same scale were combined and the resulting solution was concentrated under reduced pressure and lyophilized to afford 2-(4-fluorophenylsulfonyl)-7-methyl-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (67 mg, 38%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.04 (br s, 1H), 10.45 (br s, 1H), 8.04-8.11 (m, 2H), 7.50-7.57 (m, 2H), 7.45 (d, J=3.3 Hz, 1H), 6.97 (br s, 1H), 5.79 (s, 1H), 3.78 (s, 3H), 2.18 (s, 3H). LCMS (ESI) m/z 387 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (250 mg, 0.89 mmol) in DMF (4 mL) at 0° C. was added 60% sodium hydride/mineral oil (54 mg, 1.34 mmol) and the mixture was stirred at 0° C. for 15 min. A solution of 2-bromopropane (220 mg, 1.79 mmol) in DMF (1 mL) was added and the mixture was stirred for 30 min, and then sodium iodide (266 mg, 1.79 mmol) was added and the mixture warmed to rt and stirred for 15 h. The mixture was diluted with water and extracted three times with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 100% hexanes to 25% EtOAc/hexanes, to afford 4-chloro-2-(4-fluorophenylthio)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine (166 mg, 58%) as an oil. 1H NMR (300 MHz, CDCl3) δ 7.61-7.67 (m, 2H), 7.05-7.16 (m, 3H), 6.47 (d, J=3.6 Hz, 1H), 4.68 (septet, J=6.6 Hz, 1H), 1.38 (d, J=6.6 Hz, 6H). LCMS (ESI) m/z 322 (M+H)+.
Step B:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine (166 mg, 0.52 mmol) in a mixture of DCM (8 mL) and DMF (1 mL) at 0° C. was added 77% m-CPBA (347 mg, 1.55 mmol). The mixture was warmed to rt and stirred for 15 h. The mixture was concentrated under reduced pressure and the residue was dissolved in a mixture of EtOAc and diethyl ether and washed with saturated aq sodium hydrogen carbonate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 100% hexanes to 25% EtOAc/hexanes, to afford 4-chloro-2-(4-fluorophenylsulfonyl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine (76 mg, 42%). 1H NMR (300 MHz, CDCl3) δ 8.17-8.22 (m, 2H), 7.52 (d, J=3.6 Hz, 1H), 7.20-7.26 (m, 2H), 6.70 (d, J=3.6 Hz, 1H), 5.16 (septet, J=6.9 Hz, 1H), 1.53 (d, J=6.9 Hz, 6H). LCMS (ESI) m/z 354 (M+H)+.
Step C:
A mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine (76 mg, 0.22 mmol), 5-methyl-1H-pyrazol-3-amine (42 mg, 0.43 mmol), sodium iodide (96 mg, 0.65 mmol), DIEA (56 mg, 0.43 mmol) and DMF (2 mL) was stirred at 80° C. for 48 h. The mixture was cooled to rt and purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-fluorophenylsulfonyl)-7-isopropyl-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (15 mg, 16%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.04 (br s, 1H), 10.43 (br s, 1H), 8.05-8.06 (m, 2H), 7.50-7.60 (m, 3H), 6.99 (br s, 1H), 5.82 (s, 1H), 4.92 (septet, J=6.6 Hz, 1H), 2.18 (s, 3H), 1.45 (d, J=6.6 Hz, 6H). LCMS (ESI) m/z 415 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (329 mg, 1.18 mmol) in DMF (4 mL) at rt was added 60% sodium hydride/mineral oil (71 mg, 1.77 mmol). The mixture was stirred at rt for 15 min, and then sodium iodide (352 mg, 2.36 mmol) and a solution of 2-bromoethyl methyl ether (328 mg, 2.36 mmol) in DMF (4 mL) were added. The mixture was stirred at rt for 15 h. The mixture was partitioned between water and EtOAc. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0 to 25% EtOAc/hexanes to afford 4-chloro-2-(4-fluorophenylthio)-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidine (299 mg, 75%) as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ 7.67-7.74 (m, 2H), 7.59 (d, J=3.6 Hz, 1H), 7.30-7.40 (m, 2H), 6.56 (d, J=3.6 Hz, 1H), 4.19 (t, J=5.1 Hz, 2H), 3.59 (t, J=5.1 Hz, 2H), 3.13 (s, 3H). LCMS (ESI) m/z 338 (M+H)+.
Step B: To a stirred mixture of 4-chloro-2-(4-fluorophenylthio)-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidine (299 mg, 0.89 mmol) in DCM (8 mL) and DMF (2 mL) at 0° C. was added 77% m-CPBA (596 mg, 2.66 mmol) and the mixture was stirred at 0° C. for 10 min, then slowly warmed to rt and stirred for 2 h. Additional 77% m-CPBA (198 mg, 0.89 mmol) was added, and the mixture was stirred at rt for a further 15 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography eluting with 0 to 50% EtOAc/hexanes, to afford 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidine (202 mg, 62%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.09-8.14 (m, 2H), 8.05 (d, J=3.6 Hz, 1H), 7.51-7.56 (m, 2H), 6.84 (d, J=3.6 Hz, 1H), 4.44 (t, J=5.4 Hz, 2H), 3.70 (t, J=5.4 Hz, 2H), 3.16 (s, 3H). LCMS (ESI) m/z 370 (M+H)+.
Step C:
A stirred mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidine (100 mg, 0.27 mmol), 5-methyl-1H-pyrazole-3-amine (52 mg, 0.54 mmol), sodium iodide (121 mg, 0.81 mmol) and DIEA (70 mg, 0.54 mmol) in DMF (3 mL) was heated at 80° C. for 44 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc), to afford 2-(4-fluorophenylsulfonyl)-7-(2-methoxyethyl)-N-(5-methyl-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (30 mg, 26%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.06 (br s, 1H), 10.48 (br s, 1H), 8.04-8.15 (m, 2H), 7.51-7.61 (m, 2H), 7.47 (d, J=3.6 Hz, 1H), 6.97 (br m, 1H), 5.84 (s, 1H), 4.34 (t, J=5.1 Hz, 2H), 3.68 (t, J=5.1 Hz, 2H), 3.21 (s, 3H), 2.19 (s, 3H). LCMS (ESI) m/z 431 (M+H)+.
A stirred mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-methoxyethyl)-7H-pyrrolo[2,3-d]pyrimidine from Example 11 Step B (100 mg, 0.27 mmol), 3-aminopyrazole (45 mg, 0.54 mmol), sodium iodide (122 mg, 0.81 mmol), and DIEA (70 mg, 0.54 mmol) in DMF (3 mL) was heated at 80° C. for 48 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-fluorophenylsulfonyl)-7-(2-methoxyethyl)-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (21 mg, 19%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.43 (br s, 1H), 10.63 (br s, 1H), 8.03-8.09 (m, 2H), 7.61 (br m, 1H), 7.47-7.54 (m, 3H), 6.96 (br m, 1H), 6.48 (br m, 1H), 4.32 (t, J=5.1 Hz, 2H), 3.67 (t, J=5.1 Hz, 2H), 3.19 (s, 3H). LCMS (ESI) m/z 417 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (300 mg, 1.07 mmol) in DMF (5 mL) at rt was added 60% sodium hydride/mineral oil (64 mg, 1.61 mmol). The mixture was stirred at rt for 10 min, and then sodium iodide (319 mg, 2.14 mmol) and a solution of 2-bromoethanol (268 mg, 2.14 mmol) in DMF (3 mL) were added. The mixture was stirred at rt for 1 h, then was allowed to stand at 4° C. for 15 h. The mixture was then stirred and heated at 45° C. for 2.5 h, then stored at rt for 72 h. The mixture was partitioned between water and EtOAc. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0 to 25% EtOAc/hexanes to afford 2-(4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethanol (250 mg, 73%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 7.66-7.72 (m, 2H), 7.59 (d, J=3.6 Hz, 1H), 7.29-7.37 (m, 2H), 6.55 (d, J=3.6 Hz, 1H), 4.87 (t, J=5.4 Hz, 1H), 4.10 (t, J=5.4 Hz, 2H), 3.63-3.68 (m, 2H). LCMS (ESI) m/z 324 (M+H)+.
Step B:
To a stirred mixture of 2-(4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethanol (250 mg, 0.77 mmol), DCM (8 mL), and DMF (2 mL) at rt was added 77% m-CPBA (519 mg, 2.32 mmol) and the mixture was stirred at rt for 15 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography eluting with 0 to 60% EtOAc/hexanes to afford 2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethanol (129 mg, 47%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.08-8.15 (m, 3H), 7.48-7.56 (m, 2H), 6.83 (d, J=3.6 Hz, 1H), 4.92 (t, J=5.4 Hz, 1H), 4.33 (t, J=5.4 Hz, 2H), 3.72-3.78 (m, 2H). LCMS (ESI) m/z 356 (M+H)+.
Step C:
A stirred mixture of 2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethanol (129 mg, 0.36 mmol), 5-methyl-1H-pyrazole-3-amine (71 mg, 0.73 mmol), sodium iodide (162 mg, 1.09 mmol), and DIEA (94 mg, 0.73 mmol) in DMF (3 mL) was heated at 80° C. for 44 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(2-(4-fluorophenylsulfonyl)-4-(5-methyl-1H-pyrazol-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethanol (35 mg, 23%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.05 (br s, 1H), 10.45 (br s, 1H), 8.05-8.10 (m, 2H), 7.48-7.57 (m, 3H), 6.97 (br m, 1H), 5.79 (s, 1H), 4.96 (t, J=5.4 Hz, 1H), 4.24 (t, J=5.7 Hz, 2H) 3.71-3.77 (m, 2H), 2.18 (s, 3H). LCMS (ESI) m/z 417 (M+H)+.
Step A:
A stirred mixture of 1-nitropyrazole (3.45 g, 30.5 mmol) in benzonitrile (33 mL) was heated at 180° C. for 3 h. The mixture was cooled to rt, diluted with hexane and stirred at rt for 20 min. The precipitated solid was collected by filtration to afford 3-nitro-1H-pyrazole as a tan solid (3.16 g, 91%). 1H NMR (300 MHz, DMSO-d6) δ 13.94 (br s, 1H), 8.03 (d, J=2.4 Hz, 1H), 7.03 (t, J=2.4 Hz, 1H).
Step B:
To a stirred mixture of 3-nitro-1H-pyrazole (3.16 g, 27.9 mmol) in glacial acetic acid (20 mL) at 0° C. was added fuming nitric acid (2.6 mL, 58.69 mmol) dropwise, followed by acetic anhydride (6.6 mL, 69.87 mmol). The mixture was stirred and allowed to warm to rt over 3 h, then poured into ice water (50 mL) and stirred for 20 h. The mixture was extracted with EtOAc combined organic layers were dried over MgSO4, filtered and concentrated to dryness to afford 1,3-dinitro-1H-pyrazole (4.3 g, 97%). 1H NMR (300 MHz, DMSO-d6) δ 8.00 (br s, 1H), 6.44 (br s, 1H).
Step C:
A stirred mixture of 1,3-dinitro-1H-pyrazole (4.3 g, 27.20 mmol) in benzonitrile (60 mL) was heated at 180° C. for 3 h. The mixture was cooled to rt and partitioned between 1N sodium hydroxide and hexane. The organic layer was separated and the solid precipitate in the aqueous layer was filtered and triturated with toluene to afford 1.2 g of a pale yellow solid. The filtrate was neutralized with 1N HCl and extracted with EtOAc. The combined organic layers were dried over MgSO4, filtered and concentrated to dryness. The residue was purified by silica gel flash chromatography elutingwith 0-30% EtOAc/hexane and then with 0-10% DCM/MeOH. The solid was triturated with diethyl ether to afford 1.36 g of solid, which was combined with the previously obtained solid to afford 3,5-dinitro-1H-pyrazole (2.56 g, 59%). 1H NMR (300 MHz, DMSO-d6) δ 7.28 (s, 1H).
Step D:
To a stirred mixture of 3,5-dinitro-1H-pyrazole (2.5 g, 15.81 mmol) and potassium carbonate (4.36 g, 31.62 mmol) in DMF (50 mL) at 0° C. was added (2-(chloromethoxy)ethyl)trimethylsilane (3.07 mL, 17.39 mmol) and the mixture was stirred at rt for 6 h. The mixture was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography eluting with 0-20% EtOAc/hexane to afford 3,5-dinitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole as a colorless oil (2.7 g, 59%). 1H NMR (300 MHz, CDCl3) δ 7.68 (s, 1H), 6.00 (s, 2H), 3.72-3.67 (m, 2H), 0.97-0.91 (m, 2H), 0.00 (s, 9H).
Step E:
To a stirred solution of anhydrous MeOH (25 mL) was added sodium (300 mg, 13.04 mmol) portionwise. To the clear solution was added SEM-protected 3,5-dinitropyrazole from Step D (1 g, 3.47 mmol) and the mixture was stirred at 60° C. for 2 h. The mixture was allowed to cool to rt and was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0-30% EtOAc/hexane to afford a single regioisomer of SEM-protected 3-methoxy-5-nitropyrazole (SEM=((2-(trimethylsilyl)ethoxy)methyl)) as a clear oil (723 mg, 76%). 1H NMR (300 MHz, CDCl3) δ 6.23 (s, 1H), 5.41 (s, 2H), 4.02 (s, 3H), 3.70-3.65 (m, 2H), 0.96-0.91 (m, 2H), 0.00 (s, 9H).
Step F:
To a stirred solution of SEM-protected 3-methoxy-5-nitropyrazole from Step E (723 mg, 2.65 mmol) in ethanol (20 mL) was added palladium on activated carbon (100 mg) and the resulting suspension was degassed and filled with hydrogen. After stirring at rt for 1 h, additional palladium on activated carbon (200 mg) was added and the mixture degassed and filled with hydrogen. The reaction mixture was stirred at rt for 75 h, filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0-50% EtOAc/hexane and then with 0-20% DCM/MeOH to afford SEM-protected 3-amino-5-methoxypyrazole (478 mg, 74%). 1H NMR (300 MHz, DMSO-d6) δ 4.93-4.92 (m, 3H), 4.62 (s, 2H), 3.78 (s, 3H), 3.47 (t, J=8.1 Hz, 2H), 0.88 (t, J=8.1 Hz, 2H), −0.04 (s, 9H).
Step G:
A stirred mixture of 4-chloro-7-ethyl-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step F (120 mg, 0.35 mmol), SEM-protected 3-amino-5-methoxypyrazole from Step F above (128 mg, 0.53 mmol), sodium iodide (156 mg, 1.05 mmol), and DIEA (90 mg, 0.70 mmol) in DMF (3 mL) was heated at 80° C. for 24 h, then at 90° C. for 142 h. Additional SEM-protected 3-amino-5-methoxypyrazole (50 mg, 0.21 mmol) was added and the mixture was stirred at 90° C. for a further 42 h. The mixture was cooled to rt and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 100% DCM then with a gradient of 0 to 10% MeOH in DCM, to afford an oil (131 mg). The oil was dissolved in DCM (1 mL), TFA (2 mL) was added, and the mixture was stirred at rt for 2 h. The mixture was concentrated under reduced pressure and the residue was partitioned between DCM and saturated aq sodium hydrogen carbonate. The organic layer was separated and the aqueous layer was further extracted with DCM. The combined organic layers were concentrated under reduced pressure. The residue was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 7-ethyl-2-(4-fluorophenylsulfonyl)-N-(5-methoxy-1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (3 mg, 2%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.00 (br s, 0.5H), 11.30 (br s, 0.5H), 10.60 (br s, 1H), 8.04-8.10 (m, 2H), 7.46-7.60 (m, 3H), 6.60-6.70 (br m, 1H), 5.50-6.60 (br m, 1H), 4.22 (q, J=7.2 Hz, 2H), 3.81 (s, 3H), 1.35 (t, J=7.2 Hz, 3H). LCMS (ESI) m/z 417 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D) (300 mg, 1.07 mmol) in DMF (6 mL) at 0° C. was added 60% sodium hydride/mineral oil (64 mg, 1.61 mmol). The mixture was stirred at 0° C. for 15 min, and then a solution of 2-chloro-N,N-dimethylacetamide (260 mg, 2.14 mmol) in DMF (2 mL) was added. The mixture was stirred at 0° C. for 1 h. The mixture was partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0 to 60% EtOAc/hexanes to afford 2-(4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (288 mg, 74%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 7.64-7.70 (m, 2H), 7.56 (d, J=3.3 Hz, 1H), 7.29-7.48 (m, 2H), 6.56 (d, J=3.3 Hz, 1H), 5.01 (s, 2H), 3.00 (s, 3H), 2.83 (s, 3H). LCMS (ESI) m/z 365 (M+H)+.
Step B:
To a stirred mixture of 2-(4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (288 mg, 0.79 mmol) in DCM (6 mL) and DMF (1 mL) at 0° C. was added 77% m-CPBA (584 mg, 2.37 mmol) and the mixture was stirred at 0° C. for 10 min, then slowly warmed to rt and stirred for a further 4 h. Additional 77% m-CPBA (250 mg, 1.12 mmol) was added, and the mixture was stirred at rt for 2 h, then stored at 4° C. for a further 15 h. The mixture was concentrated under reduced pressure and the residue triturated with diethyl ether to afford 2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (280 mg, 89%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.06-8.12 (m, 2H), 7.93 (d, J=3.6 Hz, 1H), 7.48-7.55 (m, 2H), 6.85 (d, J=3.6 Hz, 1H), 5.27 (s, 2H), 3.12 (s, 3H), 2.85 (s, 3H). LCMS (ESI) m/z 397 (M+H)+.
Step C:
A stirred mixture of 2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (120 mg, 0.30 mmol), 5-methyl-1H-pyrazole-3-amine (59 mg, 0.61 mmol), sodium iodide (90 mg, 0.61 mmol), and DIEA (117 mg, 0.91 mmol) in DMF (3 mL) was heated at 80° C. for 68 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(2-(4-fluorophenylsulfonyl)-4-(5-methyl-1H-pyrazol-3-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (35 mg, 26%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.06 (br s, 1H), 10.48 (br s, 1H), 8.02-8.10 (m, 2H), 7.50-7.59 (m, 2H), 7.36 (d, J=3.6 Hz, 1H), 6.98 (br m, 1H), 5.73 (s, 1H), 5.14 (s, 2H), 3.12 (s, 3H), 2.87 (s, 3H), 2.18 (s, 3H). LCMS (ESI) m/z 458 (M+H)+.
A stirred mixture of 2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide from Example 15 Step B) (148 mg, 0.37 mmol), 3-aminopyrazole (62 mg, 0.75 mmol), sodium iodide (112 mg, 0.75 mmol), and DIEA (144 mg, 1.12 mmol) in DMF (3 mL) was heated at 80° C. for 46 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-(1H-pyrazol-3-ylamino)-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-N,N-dimethylacetamide (28 mg, 17%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.42 (br s, 1H), 10.62 (br s, 1H), 8.03-8.07 (m, 2H), 7.60 (br m, 1H), 7.47-7.53 (m, 2H), 7.38 (d, J=3.0 Hz, 1H), 6.97 (br m, 1H), 6.38 (br m, 1H), 5.12 (s, 2H), 3.11 (s, 3H), 2.86 (s, 3H). LCMS (ESI) m/z 444 (M+H)+.
Step A:
To a stirred solution of 2-(methylsulfonyl)ethanol (1 g, 8.05 mmol) and TEA (1.23 mL, 8.85 mmol) in DCM (10 mL) at 0° C. was added dropwise methanesulfonyl chloride (0.68 mL, 8.85 mmol). The mixture was stirred at 0° C. for 1.5 h. The mixture was poured into saturated aq sodium hydrogen carbonate and the organic layer was separated. The aqueous layer was further extracted with DCM and the combined organic layers were washed sequentially with saturated aq sodium hydrogen carbonate and 2N HCl. The organic layer was separated, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford 300 mg of a 1:1 mixture of 2-(methylsulfonyl)ethyl methanesulfonate and methylsulfonylethene as an oil. 2-(methylsulfonyl)ethyl methanesulfonate. 1H NMR (300 MHz, CDCl3) δ 4.65-4.68 (m, 2H), 3.44-3.47 (m, 2H), 3.11 (s, 3H), 3.00 (s, 3H); methylsulfonylethene: 1H NMR (300 MHz, CDCl3) δ 6.74 (dd, J=18.0, 12.0 Hz, 1H), 6.40-6.50 (d, J=18.0 Hz, 1H), 6.15 (d, J=12.0 Hz, 1H), 2.96 (s, 3H).
Step B:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 StepD) (300 mg, 1.07 mmol) in DMF (4 mL) at rt was added 60% sodium hydride/mineral oil (64 mg, 1.61 mmol). The mixture was stirred at rt for 15 min, whereupon sodium iodide (319 mg, 2.14 mmol) and the mixture of products from the previous step (300 mg) in DMF (2 mL) was added. The mixture was stirred at rt for 15 h. The mixture was partitioned between EtOAc and water. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography eluting with 0 to 100% EtOAc/hexanes to afford 4-chloro-2-(4-fluorophenylthio)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine (322 mg, 78%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 7.71-7.76 (m, 2H), 7.66 (d, J=3.0 Hz, 1H), 7.30-7.36 (m, 2H), 6.60 (d, J=3.0 Hz, 1H), 4.47 (t, J=6.0 Hz, 2H), 3.60 (t, J=6.0 Hz, 2H), 2.89 (s, 3H). LCMS (ESI) m/z 386 (M+H)+.
Step C:
To a stirred mixture of 4-chloro-2-(4-fluorophenylthio)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine (320 mg, 0.83 mmol) in DCM (6 mL) and DMF (1 mL) at 0° C. was added 77% m-CPBA (614 mg, 2.49 mmol) and the mixture was stirred at 0° C. for 10 min, then slowly warmed to rt and stirred for a further 5 h. The mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether to afford 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine (317 mg, 92%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.09-8.15 (m, 3H), 7.50-7.56 (m, 2H), 6.86 (d, J=3.0 Hz, 1H), 4.72 (t, J=6.0 Hz, 2H), 3.72 (t, J=6.0 Hz, 2H), 3.02 (s, 3H). LCMS (ESI) m/z 418 (M+H)+.
Step D:
A stirred mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine (120 mg, 0.29 mmol), 5-methyl-1H-pyrazole-3-amine (56 mg, 0.57 mmol), sodium iodide (129 mg, 0.86 mmol), and DIEA (74 mg, 0.58 mmol) in DMF (3 mL) was heated at 80° C. for 67 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (42 mg, 30%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.09 (br s, 1H), 10.55 (br s, 1H), 8.07-8.11 (m, 2H), 7.52-7.57 (m, 3H), 7.00 (br m, 1H), 5.87 (s, 1H), 4.62 (t, J=6.0 Hz, 2H), 3.71 (t, J=6.0 Hz, 2H), 3.01 (s, 3H), 2.19 (s, 3H). LCMS (ESI) m/z 479 (M+H)+.
A stirred mixture of 4-chloro-2-(4-fluorophenylsulfonyl)-7-(2-(methylsulfonyl)ethyl)-7H-pyrrolo[2,3-d]pyrimidine from Example 17 Step C (120 mg, 0.29 mmol), 3-aminopyrazole (48 mg, 0.58 mmol), sodium iodide (129 mg, 0.86 mmol) and DIEA (74 mg, 0.58 mmol) in DMF (3 mL) was heated at 80° C. for 67 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-fluorophenylsulfonyl)-7-(2-(methylsulfonyl)ethyl)-N-(1H-pyrazol-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (10 mg, 7%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.44 (br s, 1H), 10.69 (br s, 1H), 8.06-8.10 (m, 2H), 7.64 (br m, 1H), 7.47-7.54 (m, 3H), 7.00 (br m, 1H), 6.51 (br m, 1H), 4.60 (t, J=6.0 Hz, 2H), 3.68 (t, J=6.0 Hz, 2H), 2.98 (s, 3H). LCMS (ESI) m/z 465 (M+H)+.
Step A:
To a stirred solution of 4-chloro-2-(4-fluorophenylthio)-7H-pyrrolo[2,3-d]pyrimidine from Example 7 Step D (500 mg, 1.79 mmol) in DCM (10 mL) and DMF (2 mL) at 0° C. was added 77% m-CPBA (1.32 g, 5.37 mmol). A suspension was observed, which was solubilized by the addition of additional DMF (20 mL). The mixture was allowed to warm slowly to rt, then was stirred for a further 15 h. The mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether to afford 4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (497 mg, 89%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 13.26 (br s, 1H), 8.07-8.12 (m, 2H), 8.00-8.02 (m, 1H), 7.50-7.56 (m, 2H), 6.79-6.81 (m, 1H). LCMS (ESI) m/z 312 (M+H)+.
Step B:
To a stirred solution of 4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine (497 mg, 1.60 mmol) in DMF (7 mL) at 0° C. was added potassium tert-butoxide (215 mg, 1.91 mmol). The mixture was stirred at 0° C. for 15 min, and then sodium iodide (356 mg, 2.39 mmol) and a solution of 4-(2-chloroethyl)morpholine (477 mg, 3.19 mmol) in DMF (3 mL) were added. The mixture was allowed to warm slowly to rt and was stirred for 15 h. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 10 to 65% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 4-(2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethyl)morpholine (70 mg, 10%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 8.07-8.13 (m, 3H), 7.51-7.57 (m, 2H), 6.84 (d, J=3.0 Hz, 1H), 4.36 (t, J=6.0 Hz, 2H), 3.30-3.39 (m, 4H), 2.65 (t, J=6.0 Hz, 2H), 2.30-2.35 (m, 4H). LCMS (ESI) m/z 425 (M+H)+.
Step C:
A stirred mixture of 4-(2-(4-chloro-2-(4-fluorophenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)ethyl)morpholine (67 mg, 0.16 mmol), 5-methyl-1H-pyrazole-3-amine (31 mg, 0.32 mmol), sodium iodide (71 mg, 0.47 mmol), and DIEA (51 mg, 0.40 mmol) in DMF (4 mL) was heated at 80° C. for 90 h, then cooled to rt. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 10 to 65% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) to afford 2-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-7-(2-morpholinoethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (19 mg, 24%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.07 (br s, 1H), 10.53 (br s, 1H), 8.04-8.09 (m, 2H), 7.51-7.58 (m, 3H), 6.97 (br m, 1H), 5.92 (s, 1H), 4.28 (t, J=6.0 Hz, 2H), 3.30-3.50 (m, 4H), 2.64 (t, J=6.0 Hz, 2H), 2.35-2.45 (m, 4H), 2.20 (s, 3H). LCMS (ESI) m/z 486 (M+H)+.
Step A:
Methylhydrazine (5.0 g, 0.11 mol) and 4-methoxybenzaldehyde (14.8 g, 0.11 mol) were stirred in EtOH (80 mL) at rt overnight. The solution was concentrated to afford crude 1-(4-methoxybenzylidene)-2-methylhydrazine (18.0 g) which was used without further purification.
Step B:
To a solution of malononitrile (10.7 g, 0.163 mol) and triethyl orthoformate (24.1 g, 0.163 mol) in EtOH (160 mL) was added 1-(4-methoxybenzylidene)-2-methylhydrazine (17.8 g, 0.108 mol) and the mixture was stirred and heate at reflux for 30 min The mixture was cooled to rt, and the precipitated white solid was collected by filtration washing with cold EtOH (5 mL) and ether, and then dried under vacuum to afford 13.7 g of an intermediate product. To a solution of the intermediate product in EtOH (80 mL) was added hydrochloric acid (20 mL) and the mixture was stirred at 80° C. for 1 h. The mixture was concentrated under reduced pressure to give a yellow solid. The yellow solid was collected washing sequentially with DCM and diethyl ether, and then partitioned between saturated aq Na2CO3 and DCM. The organic layer was separated and concentrated under reduced pressure to afford 3-amino-1-methyl-1H-pyrazole-4-carbonitrile (6.5 g, 49%) which was used without further purification. LCMS (ESI) m/z 123 (M+H)+.
Step C
3-Amino-1-methyl-1H-pyrazole-4-carbonitrile (6.5 g, 53.2 mmol) was added to H2SO4 (13 mL) at 0° C., and then the mixture was stirred at rt for 1 h. The mixture was cooled to 0° C. and water (10 mL) was added and the pH was adjusted to 7.0-8.0 with NH4OH. The mixture was stirred at rt for 10 min, whereupon a yellow solid formed. The solid was collected by filtration washing with cold water and ether, and then dried under vacuum to afford 3-amino-1-methyl-1H-pyrazole-4-carboxamide (5.0 g, 67%) which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.23 (br s, 1H), 6.74 (br s, 1H), 5.35 (br s, 2H), 3.59 (s, 3H). LCMS (ESI) m/z 141 (M+H)+.
Step D:
A solution of 2,2-difluoro-2-(4-fluorophenyl) acetic acid (prepared according to Middleton et al., J. Org. Chem., 1980, 45(14); 2883-2887 by reaction of ethyl 2-(4-fluorophenyl)-2-oxoacetate with (diethylamino)sulfur trifluoride followed by ester saponification) (136 mg, 0.71 mmol) and HATU (380 mg, 0.86 mmol) in THF (1.5 mL) was stirred at rt for 10 min. 3-Amino-1-methyl-1H-pyrazole-4-carboxamide (100 mg, 0.71 mmol) and TEA (87 mg, 0.86 mmol) were added and the mixture was stirred at rt overnight. The mixture was filtered and the filtrate was concentrated. The residue was dissolved in EtOAc and washed with aq NH4Cl and brine. The organic layer was separated and concentrated under reduced pressure to afford 3-(2,2-difluoro-2-(4-fluorophenyl)acetamido)-1-methyl-1H-pyrazole-4-carboxamide (170 mg, 76%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 11.29 (s, 1H), 8.15 (s, 1H), 7.71-7.75 (m, 3H), 7.41 (t, 2H), 7.32 (br s, 1H), 3.81 (s, 3H). LCMS (ESI) m/z 311 (M−H)−.
Step E:
A solution of 3-(2,2-difluoro-2-(4-fluorophenyl)acetamido)-1-methyl-1H-pyrazole-4-carboxamide (600 mg, 1.92 mmol) in HOAc (36 mL) was stirred at 130° C. for 5 h. The mixture was concentrated and the residue was purified by silica gel chromatography eluting with 50/1 to 20/1 DCM/MeOH to afford 6-(difluoro(4-fluorophenyl)methyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-ol (425 mg, 69%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.57 (s, 1H), 8.55 (s, 1H), 7.71-7.75 (m, 2H), 7.38 (t, 2H), 4.00 (s, 3H). LCMS (ESI) m/z 295 (M+H)+.
Step F:
A solution of 6-(difluoro(4-fluorophenyl)methyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-4-ol (50 mg, 0.17 mmol) in phosphorous oxychloride (1 mL) was stirred at 90° C. for 2 h. The mixture was concentrated, the pH was adjusted to 7-8 with aq NaHCO3 and the mixture was extracted with EtOAc. The organic layer was concentrated to afford 4-chloro-6-(difluoro(4-fluorophenyl)methyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine (50 mg, 94%) as a yellow solid, which was used without further purification. LCMS (ESI) m/z 313 (M+H)+.
Step G:
To a solution of 4-chloro-6-(difluoro(4-fluorophenyl)methyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine (200 mg, 0.64 mmol) in DMF (3 mL) was added 5-methyl-1H-pyrazol-3-amine (94 mg, 0.96 mmol) and 4M HCl/dioxane (0.08 mL, 0.32 mmol). The solution was stirred at 70° C. for 2 h. Water (30 mL) was added and the precipitated solid was collected by filtration, washed with Et2O and 50:1 Et2O/MeOH, and dried under vacuum. The solid was purified by preparative HPLC (Phenomenex C-18 reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(4-fluorophenyl)methyl)-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine (8 mg, 3%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.14 (br s, 1H), 10.97 (br s, 1H), 8.59 (br s, 1H), 7.58-7.78 (m, 2H), 7.30-7.35 (m, 2H), 6.35 (br s, 1H), 4.13 (s, 3H), 2.22 (s, 3H). LCMS (ESI) m/z 374 (M+H)+.
Step A:
To a solution of 4-chloro-6-(difluoro(4-fluorophenyl)methyl)-2-methyl-2H-pyrazolo[3,4-d]pyrimidine from Example 20 Step F (200 mg, 0.64 mmol) in DMF (2 mL) were added 1H-pyrazol-3-amine (110 mg, 1.28 mmol) and 4M HCl/dioxane (0.08 mL, 0.32 mmol). The solution was stirred at 80° C. for 1 h. Water (30 mL) was added and the precipitated solid was collected by filtration, washed sequentially with saturated aq K2CO3, MeOH, EtOAc, and ether, then dried under vacuum to afford 6-(difluoro(4-fluorophenyl)methyl)-2-methyl-N-(1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine (95 mg, 41%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 12.49 (br s, 1H), 11.07-11.10 (m, 1H), 8.62 (br s, 1H), 7.66-7.70 (m, 3H), 7.30-7.35 (m, 2H), 6.80 (br s, 1H), 4.14 (s, 3H). LCMS (ESI) m/z 358 (M−H)−.
Step A:
To a solution of 3-amino-1-methyl-1H-pyrazole-4-carboxamide from Example 20 Step C (100 mg, 0.71 mmol) in HOAc (0.6 mL) were added ethyl carbonocyanidate (77.8 mg, 0.79 mmol) and concentrated HCl (0.06 mL). The mixture was stirred at 100° C. for 5 h. The mixture was concentrated and the residue was purified by silica gel chromatography eluting with 100/1 to 50/1 DCM:MeOH to afford ethyl 4-hydroxy-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-6-carboxylate (58 mg, 36% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 12.06 (br s, 1H), 8.59 (s, 1H), 4.36 (q, J=7.2 Hz, 2H), 4.06 (s, 3H), 1.35 (t, J=7.2 Hz, 3H). LCMS (ESI) m/z 223 (M+H)+.
Step B:
A solution of ethyl 4-hydroxy-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-6-carboxylate (50 mg, 0.23 mmol) in phosphorous oxychloride (1 mL) was stirred at 85° C. for 2 h. The mixture was concentrated under reduced pressure and aq NaHCO3 was added to give a solution with pH 7-8. The mixture was extracted with EtOAc and the organic layer was concentrated to afford ethyl 4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-6-carboxylate (20 mg, 35%), which was used without further purification. 1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 1H), 4.40 (q, J=7.2 Hz, 2H), 4.31 (s, 3H), 1.37 (t, J=7.2 Hz, 3H).
Step C
To ethyl 4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidine-6-carboxylate (400 mg, 1.66 mmol) in THF (40 mL) at −30° C. under argon was added 1M 4-fluorophenylmagnesium bromide/THF (1.82 mL, 1.82 mmol) and the mixture was stirred at −30° C. for 1 h. HOAc (1 mL) was added and the mixture was concentrated onto Celite. The mixture was chromatographed on silica gel eluting with 0-50% EtOAc/DCM to afford (4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)(4-fluorophenyl)methanone (136 mg, 28%).
Step D:
To (4-chloro-2-methyl-2H-pyrazolo[3,4-d]pyrimidin-6-yl)(4-fluorophenyl)methanone (70 mg, 0.24 mmol) in DMF (3 mL) were added 5-methyl-1H-pyrazol-3-amine (120 mg, 1.23 mmol), TEA (0.067 mL, 0.48 mmol), and KI (20 mg, 0.12 mmol). The mixture was stirred at rt for 4 h, then diluted with EtOAc and washed with brine. The organic layer was separated and concentrated under reduced pressure. To the residue in THF (10 mL) and MeOH (10 mL) at 0° C. was added sodium borohydride (50 mg, 1.32 mmol) and the mixture was stirred at 0° C. for 1.5 h. Then 2N HCl (0.5 mL) was added and the mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (Varian diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford (R,S)-(4-fluorophenyl)(2-methyl-4-(5-methyl-1H-pyrazol-3-ylamino)-2H-pyrazolo[3,4-d]pyrimidin-6-yl)methanol as its acetate salt (59 mg, 67%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.03 (br s, 1H), 10.67 (br s, 1H), 8.49 (br s, 1H), 7.52 (t, J=6.4 Hz, 2H), 7.13 (t, J=8.4 Hz, 2H), 6.45 (br s, 1H), 5.68 (br s, 1H), 5.58 (br s, 1H), 4.08 (s, 3H), 2.24 (s, 3H), 1.91 (s, 3H). LCMS (ESI) m/z 354 (M+H)+.
Step A:
To a solution of 5-methyl-1H-pyrazol-3-amine (550 mg, 5.67 mmol), DIEA (0.906 mL, 5.2 mmol), and KI (392 mg, 2.36 mmol) in DMF (10 mL) was added 2,4,6-trichloropyrimidine-5-carbaldehyde (1 g, 4.73 mmol). The mixture was stirred at rt for 3 h, then water was added and the mixture was stirred for 20 min at rt. The precipitated solid was collected by filtration to afford 2,4-dichloro-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine-5-carbaldehyde (1.4 g) as a yellow solid that was used without further purification. LCMS (ESI) m/z 272 (M+H)+.
Step B:
To 2,4-dichloro-6-(5-methyl-1H-pyrazol-3-ylamino)pyrimidine-5-carbaldehyde (500 mg, 1.83 mmol) and DIEA (0.352 mL, 2.02 mmol) in dioxane (20 mL) was added 2-hydrazinylethanol (0.124 mL, 1.83 mmol). The mixture was stirred at rt for 45 min, then at 100° C. for 10 min, and then at rt overnight. The mixture was concentrated under reduced pressure onto Celite and purified by silica gel chromatography eluting with 2-15% MeOH in DCM. The residue was further purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 2-(6-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethanol (95 mg, 17%) as an orange solid. 1H NMR (300 MHz, DMSO-d6) δ 12.26 (br s, 1H), 11.12 (br s, 1H), 8.42 (br s, 1H), 6.58 (br s, 1H), 4.87 (d, J=4.9 Hz, 1H), 4.20-4.43 (m, 2H), 3.80 (d, J=4.9 Hz, 2H), 2.28 (s, 3H).
Step C:
To 2-(6-chloro-4-(5-methyl-1H-pyrazol-3-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethanol (40 mg, 0.14 mmol) and sodium 4-fluorobenzenesulfinate (247 mg, 1.36 mmol) was added DMSO (1 mL). The mixture was stirred at 140° C. for 3 days, and then filtered, washing with EtOAc. The filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC (Phenomenex C-18 reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 2-(6-(4-fluorophenylsulfonyl)-4-(5-methyl-1H-pyrazol-3-ylamino)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethanol (2 mg, 4%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.22 (br s, 1H), 11.31 (br s, 1H), 8.50 (s, 1H), 8.10 (dd, J=5.2, 8.8 Hz, 2H), 7.58 (t, J=8.7 Hz, 2H), 5.69 (br s, 1H), 4.89 (t, J=5.5 Hz, 1H), 4.26-4.50 (m, 2H), 3.84 (d, J=5.5 Hz, 2H), 2.18 (s, 3H). LCMS (ESI) m/z 418 (M+H)+.
Step A:
A mixture of ethyl 2-cyano-3-ethoxyacrylate (9.01 g, 53 mmol), ethylhydrazine oxalate (8 g, 53 mmol) and sodium acetate (4.37 g, 53 mmol) in EtOH (100 mL) was heated at 80° C. overnight. The mixture was concentrated under reduced pressure and then water was added and the mixture was extracted with EtOAc. The organic layer was separated and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with 0-4% MeOH in DCM to afford a mixture of ethyl 5-amino-1-ethyl-1H-pyrazole-4-carboxylate and ethyl 3-amino-1-ethyl-1H-pyrazole-4-carboxylate (6.7 g, 68%) as a yellow oil, which was used without further purification. LCMS (ESI) m/z 184 (M+H)+.
Step B:
To a mixture of ethyl 5-amino-1-ethyl-1H-pyrazole-4-carboxylate and ethyl 3-amino-1-ethyl-1H-pyrazole-4-carboxylate (2.75 g, 15 mmol) in acetone (20 mL) was added benzoyl isothiocyanate (2.02 mL, 15 mmol) and the mixture was stirred overnight at rt. The mixture was concentrated under reduced pressure and the residue was triturated with diethyl ether to afford a mixture of ethyl 5-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate and ethyl 3-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate (2.86 g, 55%) as a yellow solid, which was used without further purification. LCMS (ESI) m/z 347 (M+H)+.
Step C:
To a mixture of ethyl 5-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate and ethyl 3-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate (2.5 g, 7.22 mmol) in EtOH (30 mL) was added sodium tert-butoxide (2.1 g, 21.67 mmol) and the mixture was stirred for 4 h at rt. Water was then added followed by addition of 4 N HCl until the pH reached 5. The precipitated solid was collected by filtration washing with water and diethyl ether to afford a mixture of 1-ethyl-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-ethyl-6-mercapto-2H-pyrazolo[3,4-d]pyrimidin-4-ol (1.19 g, 84%) as a solid. LCMS (ESI) m/z 197 (M+H)+.
Step D:
To a mixture of 1-ethyl-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-ethyl-6-mercapto-2H-pyrazolo[3,4-d]pyrimidin-4-ol (600 mg, 3.06 mmol), were added 1-fluoro-4-iodobenzene (0.425 mL, 3.67 mmol), cesium carbonate (1.3 g, 3.97 mmol), copper powder (115 mg, 1.84 mmol) and DMF (12 mL). The mixture was heated at 160° C. in a microwave synthesizer for 1 h. The mixture was cooled and then HOAc (0.44 mL) and MeOH (5 mL) were added and the mixture was stirred at rt for 2 min. The mixture was filtered through Celite washing with MeOH. The filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford a mixture of 1-ethyl-6-(4-fluorophenylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-ethyl-6-(4-fluorophenylthio)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (340 mg, 36%) as a solid, which was used without further purification. LCMS (ESI) m/z 291 (M+H)+.
Step E:
To a mixture of 1-ethyl-6-(4-fluorophenylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-ethyl-6-(4-fluorophenylthio)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (250 mg, 0.86 mmol) was added phosphorous oxychloride (4 mL). The mixture was heated at 95° C. for 1 h and then concentrated under reduced pressure. The residue was partitioned between saturated NaHCO3 and EtOAc. The organic layer was separated and concentrated under reduced pressure onto Celite and then purified by silica gel chromatography eluting with 5-40% EtOAc/hexanes to afford 4-chloro-1-ethyl-6-(4-fluorophenylthio)-1H-pyrazolo[3,4-d]pyrimidine (220 mg, 83%). 1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.63 (dd, J=5.6, 8.2 Hz, 2H), 7.02-7.24 (m, 2H), 4.26 (q, J=7.2 Hz, 2H), 1.40 (t, J=7.3 Hz, 3H).
Step F:
To 4-chloro-1-ethyl-6-(4-fluorophenylthio)-1H-pyrazolo[3,4-d]pyrimidine (210 mg, 0.67 mmol) in DCM (10 mL) was added 70% m-CPBA (360 mg, 1.48 mmol) and the mixture was stirred at rt overnight. The mixture was evaporated onto Celite and then purified by silica gel chromatography eluting with 0-40% EtOAc/hexanes to afford 4-chloro-1-ethyl-6-(4-fluorophenylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine (200 mg, 87%). LCMS (ESI) m/z 341 (M+H)+.
Step G:
A mixture of 5-methyl-1H-pyrazol-3-amine (74 mg, 0.76 mmol), DIEA (0.049 mL, 0.28 mmol), and KI (37 mg, 0.22 mmol) in DMF (3 mL) was added to 4-chloro-1-ethyl-6-(4-fluorophenylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine (80 mg, 0.23 mmol) and the mixture was stirred at rt overnight. HOAc (0.1 mL) was added and the mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 1-ethyl-6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (40 mg, 43%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.22 (br s, 1H), 11.34 (br s, 1H), 8.50 (s, 1H), 8.01-8.21 (m, 2H), 7.58 (t, J=8.8 Hz, 2H), 5.71 (s, 1H), 4.39 (q, J=6.9 Hz, 2H), 2.18 (s, 3H), 1.42 (t, J=7.1 Hz, 3H). LCMS (ESI) m/z 402 (M+H)+.
Step A:
To 2,4,6-trichloropyrimidine-5-carbaldehyde (2 g, 9.46 mmol) in EtOH (25 mL) at −78° C. under argon were added tert-butylhydrazine hydrochloride (1.18 g, 9.46 mmol) and TEA (6 mL, 42.57 mmol) dropwise. The mixture was stirred at −78° C. for 2 h, then at 0° C. for 3 h. The mixture was then concentrated under reduced pressure onto Celite and purified by silica gel chromatography eluting with 0-1% MeOH in DCM to afford 1-tert-butyl-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1.7 g, 73%) as an oil that solidified upon standing. LCMS (ESI) m/z 245 (M+H)+.
Step B:
1-tert-Butyl-4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine (1 g, 4.06 mmol) was added to a mixture of 5-methyl-1H-pyrazol-3-amine (550 mg, 5.67 mmol), DIEA (0.85 mL, 4.87 mmol), and KI (360 mg, 2.16 mmol) in DMF (7 mL), and the mixture was stirred at rt overnight. Water was added to the mixture and the precipitated solid was collected by filtration washing with water to afford 1-tert-butyl-6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.53 g, 88%) as a white solid, which was used without further purification. LCMS (ESI) m/z 306 (M+H)+.
Step C:
To a mixture of 1-tert-butyl-6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (75 mg, 0.24 mmol) in DMSO (1 mL) was added sodium 4-fluorobenzenesulfinate (135 mg, 0.73 mmol) and the mixture was heated at 140° C. in a sealed tube overnight. The mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 1-tert-butyl-6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (15 mg, 15%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.24 (br s, 1H), 11.30 (br s, 1H), 8.47 (br s, 1H), 8.11 (dd, J=5.1, 8.7 Hz, 2H), 7.40-7.71 (m, 2H), 6.04 (s, 1H), 2.22 (s, 3H), 1.64 (br s, 9H). LCMS (ESI) m/z 430 (M+H)+.
Step A:
To a mixture of 2,2-difluoro-2-(4-fluorophenyl) acetic acid prepared as described in Example 20 Step D (163 mg, 1.16 mmol) and 5-amino-1-methyl-1H-pyrazole-4-carboxamide (264 mg, 1.38 mmol) was added trimethylsilyl polyphosphate (4 mL). The mixture was stirred and heated at 130° C. in an oil bath for 30 hours. The mixture was allowed to cool to rt and then partitioned between water (15 mL) and EtOAc (15 mL). The organic layer was separated, washed with water (20 mL) and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was triturated with DCM to afford 6-(difluoro(4-fluorophenyl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (135 mg, 39%). 1H NMR (300 MHz, DMSO-d6) δ 13.01-13.08 (m, 1H), 8.10-8.15 (m, 1H), 7.73-7.82 (m, 2H), 7.34-7.46 (m, 1H), 5.75-5.79 (m, 1H), 3.87-3.92 (m, 3H). LCMS (ESI) m/z 295 (M+H)+.
Step B:
A mixture of 6-(difluoro(4-fluorophenyl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (224 mg, 0.71 mmol) and phosphorous oxychloride (4 mL) was stirred at 95° C. for 1 h. The mixture was concentrated under reduced pressure and diluted with EtOAc. The mixture was washed with saturated aq NaHCO3, and the organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to give an oil that solidified upon standing. To this solid was added a solution of 5-methyl-1H-pyrazol-3-amine (224 mg, 2.3 mmol), DIEA (0.16 mL, 0.92 mmol), and potassium iodide (330 mg, 1.99 mmol) in DMF (4 mL), and the solution was stirred at rt overnight. HOAc (0.2 mmol) was added and the mixture was purified by preparative HPLC (Varian diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(4-fluorophenyl)methyl)-1-methyl-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (33 mg, 11%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.11 (br s, 1H), 11.03 (br s, 1H), 8.43 (br s, 1H), 7.69 (dd, J=5.5, 8.7 Hz, 2H), 7.35 (t, J=8.9 Hz, 2H), 6.19 (br s, 1H), 3.96 (s, 3H), 2.21 (s, 3H). LCMS (ESI) m/z 374 (M+H)+.
Step A:
To a mixture of (R)-1-[(SP)-2-(dicyclohexylphosphino)ferrocenyl]ethyldi-tert-butylphosphine (14 mg, 0.025 mmol), palladium acetate (6 mg, 0.025 mmol), potassium tert-butoxide (173 mg, 1.54 mmol), 4-fluorobenzenethiol (0.15 mL, 1.41 mmol) and 1-tert-butyl-6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine from Example 25 Step B (366 mg, 1.18 mmol) was added DME (4 mL) and the reaction vessel evacuated and flushed with argon (3×). The mixture was heated in a sealed vessel at 110° C. for 5 h and then at 120° C. for 2 h. The mixture was cooled and HOAc (0.2 mL) was added. The mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 1-tert-butyl-6-(4-fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (180 mg, 38%). LCMS (ESI) m/z 398 (M+H)+.
Step B:
To 1-tert-butyl-6-(4-fluorophenylthio)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (121 mg, 0.3 mmol) was added formic acid (4 mL) and the mixture was heated to 100° C. overnight. Concentrated HCl (0.05 mL) was added and the mixture was stirred at 100° C. for 3 h. Additional concentrated HCl (0.15 mL) was then added and the mixture was stirred at 100° C. overnight. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford a white solid. The solid was dissolved in MeOH (4 mL) and water (4 mL) and then oxone (320 mg) was added. The mixture was stirred for 4 h at rt, and then additional oxone (200 mg) was added. The mixture was stirred at rt for 6 h and then MeOH (4 mL) was added and the mixture was filtered. The filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC (Phenomenex C-18 reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (2 mg, 2%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 14.09 (br s, 1H), 12.22 (br s, 1H), 11.30 (br s, 1H), 8.51 (br s, 1H), 8.09 (dd, J=5.1, 8.7 Hz, 2H), 7.57 (t, J=8.8 Hz, 2H), 5.87 (br s, 1H), 2.20 (s, 3H). LCMS (ESI) m/z 374 (M+H)+.
Step A:
To 2,4,6-trichloropyrimidine-5-carbaldehyde (0.693 g, 3.27 mmol) in EtOH (10 mL) at −78° C. under argon was added (tetrahydro-2H-pyran-4-yl)hydrazine hydrochloride (0.5 g, 3.27 mmol) followed by dropwise addition of TEA (2.05 mL, 14.7 mmol). The mixture was stirred at −78° C. for 1 h, then at 0° C. for 2 h. The mixture was then concentrated under reduced pressure onto Celite and purified by silica gel chromatography eluting with DCM to afford 4,6-dichloro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine (440 mg, 49%). LCMS (ESI) m/z 273 (M+H)+.
Step B:
4,6-Dichloro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidine (320 mg, 1.17 mmol) was added to a mixture of 5-methyl-1H-pyrazol-3-amine (200 mg, 2.06 mmol), DIEA (0.264 mL, 1.52 mmol), and KI (200 mg, 1.2 mmol) in DMF (4 mL). The mixture was stirred at rt for 2 h, and then partitioned between water and EtOAc. The organic layer washed with saturated aqueous NaCl dried over Na2SO4, and concentrated under reduced pressure to afford 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (340 mg, 87%) as a solid, which was used without further purification. LCMS (ESI) m/z 334 (M+H)+.
Step C:
To a mixture of 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (120 mg, 0.36 mmol) and 15-crown-5 (0.04 mL) in DMSO (2 mL) was added sodium 4-fluorobenzenesulfinate (130 mg, 0.72 mmol) and the mixture was heated at 140° C. in a sealed tube overnight. The mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (30 mg, 18%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.21 (br s, 1H), 11.35 (s, 1H), 8.53 (s, 1H), 8.11 (dd, J=5.2, 8.8 Hz, 2H), 7.58 (t, J=8.7 Hz, 2H), 5.62 (s, 1H), 4.88-4.96 (m, 1H), 3.99-4.02 (m, 2H), 3.55-3.62 (m, 2H), 2.03-2.30 (m, 5H), 1.82-1.96 (m, 2H). LCMS (ESI) m/z 458 (M+H)+.
Step A:
To 2,4,6-trichloropyrimidine-5-carbaldehyde (582 mg, 2.75 mmol) in EtOH (7 mL) at −78° C. under argon was added 4-(2-hydrazinylethyl)morpholine hydrochloride (0.5 g, 2.75 mmol) followed by dropwise addition of TEA (1.72 mL, 12.37 mmol). The mixture was stirred at −78° C. for 2 h, then at 0° C. for 2 h. The mixture was concentrated under reduced pressure onto Celite and purified by silica gel chromatography eluting with 0-12% MeOH in DCM to afford 4-(2-(4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)morpholine (242 mg, 29%) as a solid. LCMS (ESI) m/z 302 (M+H)+.
Step B:
4-(2-(4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)morpholine (242 mg, 0.8 mmol) was added to a mixture of 5-methyl-1H-pyrazol-3-amine (141 mg, 1.45 mmol), DIEA (0.21 mL, 1.2 mmol), and KI (100 mg, 0.6 mmol) in DMF (3 mL). The mixture was stirred at rt overnight. HOAc (0.2 mL) was added and the mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (200 mg, 69%) as a solid. LCMS (ESI) m/z 363 (M+H)+.
Step C:
To a mixture of 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (150 mg, 0.35 mmol) and 15-crown-5 (0.04 mL) in DMSO (3 mL) was added sodium 4-fluorobenzenesulfinate (195 mg, 1.07 mmol) and the mixture was heated at 140° C. in a sealed tube for 5 h. After addition of HOAc (0.3 mL) the mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O). The product was then further purified by silica gel chromatography 0-15% MeOH in DCM to afford 6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (17 mg, 10%) as a solid. 1H NMR (300 MHz, Methanol-d4) δ 8.29 (br s, 1H), 8.05-8.18 (m, 2H), 7.63-7.67 (m, 1H), 7.42 (t, J=8.7 Hz, 2H), 7.10-7.16 (m, 1H), 6.11 (br s, 1H), 4.56 (br s, 2H), 3.53 (d, J=4.0 Hz, 4H), 2.84 (br s, 2H), 2.49 (br s, 4H), 2.30 (s, 3H). LCMS (ESI) m/z 487 (M+H)+.
Step A:
To a solution of 5-amino-1H-pyrazole-4-carbonitrile (5.02 g, 46.4 mmol) in DMF (20 mL) were added (chloromethyl)benzene (6.0 mL, 52.1 mmol) and potassium carbonate (7.40 g, 55.9 mmol), and the mixture was stirred in a 70° C. oil bath for 110 minutes. The mixture was then partitioned between water (100 mL) and EtOAc (100 mL) and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a mixture of 3-amino-1-benzyl-1H-pyrazole-4-carbonitrile and 5-amino-1-benzyl-1H-pyrazole-4-carbonitrile (8.74 g, 95%) which was used without further purification. LCMS (ESI) m/z 199 (M+H)+.
Step B:
To concentrated H2SO4 (10 mL) at 0° C. was added a mixture of 5-amino-1-benzyl-1H-pyrazole-4-carbonitrile and 3-amino-1-benzyl-1H-pyrazole-4-carbonitrile (2.04 g, 10.3 mmol). The resulting mixture was allowed to warm to rt and was stirred for 2 h. Ice was added followed by EtOAc, and the mixture was neutralized with K2CO3 and filtered. The organic layer of the filtrated was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a mixture of 5-amino-1-benzyl-1H-pyrazole-4-carboxamide and 3-amino-1-benzyl-1H-pyrazole-4-carboxamide (1.23 g, 55%) which was used without further purification. LCMS (ESI) m/z 217 (M+H)+.
Step C:
To a mixture of 5-amino-1-benzyl-1H-pyrazole-4-carboxamide and 3-amino-1-benzyl-1H-pyrazole-4-carboxamide (250 mg, 1.15 mmol) were added 2,2-difluoro-2-(4-fluorophenyl) acetic acid prepared as described in Example 20 Step D (264 mg, 1.38 mmol) and trimethylsilyl polyphosphate (7 mL), and the mixture was heated at 130° C. overnight. The solution was cooled and equal volumes of EtOAc and water were added and the mixture was stirred for 30 min. The organic layer was separated, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a mixture of 1-benzyl-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-benzyl-6-(difluoro(4-fluorophenyl)methyl)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (208 mg, 49%) as a crude oil which was used without further purification. LCMS (ESI) m/z 371 (M+H)+.
Step D:
To a mixture of 1-benzyl-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol and 2-benzyl-6-(difluoro(4-fluorophenyl)methyl)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (208 mg, 0.56 mmol) was added phosphorous oxychloride (4 mL) and the mixture was heated at 95° C. overnight. The solution was cooled and concentrated under reduced pressure. Toluene was added and the solution was again concentrated under reduced pressure. The residue was diluted with EtOAc, washed with saturated NaHCO3, dried over Na2SO4, filtered, and concentrated onto Celite. The mixture was purified by silica gel chromatography eluting with 10-100% EtOAc/hexanes to afford a mixture of 1-benzyl-4-chloro-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidine and 2-benzyl-4-chloro-6-(difluoro(4-fluorophenyl)methyl)-2H-pyrazolo[3,4-d]pyrimidine (54 mg, 25%) as an oil, which was used without further purification. LCMS (ESI) m/z 389 (M+H)+.
Step E:
To a mixture of 1-benzyl-4-chloro-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidine and 2-benzyl-4-chloro-6-(difluoro(4-fluorophenyl)methyl)-2H-pyrazolo[3,4-d]pyrimidine (54 mg, 0.14 mmol) was added a solution of 5-methyl-1H-pyrazol-3-amine (47 mg, 0.48 mmol), DIEA (0.036 mL, 0.21 mmol), KI (48 mg, 0.29 mmol) in DMF (2 mL) and the mixture was stirred at rt overnight. Water (30 mL) was added, and the mixture was stirred for 30 min. The precipitated solid was collected by filtration to afford a mixture of 1-benzyl-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine and 2-benzyl-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine (58 mg, 92%), which was used without further purification. LCMS (ESI) m/z 450 (M+H)+.
Step F:
To a mixture of 1-benzyl-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine and 2-benzyl-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine (58 mg, 0.13 mmol) in EtOH (5 mL) was added 10% palladium on carbon (20 mg) and the mixture was stirred under a hydrogen atmosphere at rt for 3 h. The mixture was then heated at 60° C. under a hydrogen atmosphere overnight. Then 20% palladium hydroxide on carbon (25 mg) and EtOAc (3 mL) were added and the mixture was stirred under an atmosphere of hydrogen at 65° C. overnight. The mixture was filtered through Celite and the filtrate was purified by preparative HPLC (Phenomenex C-18 reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.5 mg, 3%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 13.82 (br s, 1H), 12.15 (br s, 1H), 10.98 (br s, 1H), 8.46 (br s, 1H), 7.68 (dd, J=5.4, 8.6 Hz, 2H), 7.35 (t, J=8.8 Hz, 2H), 6.28 (br s, 1H), 2.22 (s, 3H). LCMS (ESI) m/z 360 (M+H)+.
Step A:
To 2,4,6-trichloropyrimidine-5-carbaldehyde (2 g, 9.45 mmol) in EtOH (25 mL) at −78° C. under argon was added phenylhydrazine (0.93 mL, 9.45 mmol) followed by dropwise addition of TEA (4.6 mL, 33 mmol). The mixture was stirred at −78° C. for 0.5 h, then at 0° C. for 2 h. Water was added and the precipitated solid was collected by filtration to afford 4,6-dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (2.23 g, 88%), which was used without further purification. LCMS (ESI) m/z 265 (M+H)+.
Step B:
4,6-Dichloro-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine (1 g, 3.77 mmol) was added to a mixture of 5-methyl-1H-pyrazol-3-amine (510 mg, 5.25 mmol), DIEA (1 mL, 5.84 mmol), and KI (470 mg, 2.83 mmol) in DMF (10 mL). The mixture was stirred at rt for 2 h. Water was added and the solid was collected by filtration washing with diethyl ether to afford 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1.5 g) as a tan solid, which was used without further purification. LCMS (ESI) m/z 326 (M+H)+.
Step C:
To a mixture of 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (300 mg, 0.92 mmol) and 15-crown-5 (0.04 mL) in DMSO (5 mL) was added sodium 4-fluorobenzenesulfinate (340 mg, 1.84 mmol) and the mixture was heated at 130° C. in a sealed tube for 2 h. The mixture was purified by preparative HPLC (Varian Diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(4-fluorophenylsulfonyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (70 mg, 16%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.29 (br s, 1H), 11.55 (s, 1H), 8.76 (s, 1H), 8.14 (dd, J=5.2, 8.8 Hz, 2H), 8.05 (d, J=7.9 Hz, 2H), 7.52-7.68 (m, 4H), 7.35-7.46 (m, 1H), 5.95 (s, 1H), 2.22 (s, 3H). LCMS (ESI) m/z 450 (M+H)+.
Step A:
To 2-hydrazinylethanol (7.46 g, 98 mmol) in EtOH (20 mL) was added 2-(ethoxymethylene)malononitrile (8.88 g, 72 mmol) and the solution was stirred at 80° C. for 1 h. The mixture was stored at 4° C. overnight, and the solid was collected by filtration washing with EtOH and diethyl ether to afford 5-amino-1-(2-hydroxyethyl)-1H-pyrazole-4-carbonitrile as a yellow solid (8.36 g, 76%), which was used without further purification. LCMS (ESI) m/z 153 (M+H)+.
Step B:
To a solution of 5-amino-1-(2-hydroxyethyl)-1H-pyrazole-4-carbonitrile (5 g, 32 mmol) and triphenylphosphine (10.3 g, 39 mmol) in DCM (50 mL) was added carbon tetrachloride (16 mL) dropwise, and the mixture was stirred at rt for 3 days. The reaction mixture was concentrated under reduced pressure onto Celite, and then purified by silica gel chromatography eluting with 50-100% EtOAc/hexanes to afford 5-amino-1-(2-chloroethyl)-1H-pyrazole-4-carbonitrile (2.97 g, 54%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 7.59 (s, 1H), 6.70 (s, 2H), 4.24 (t, J=6.0 Hz, 2H), 3.88 (t, J=5.9 Hz, 2H).
Step C:
To 5-amino-1-(2-chloroethyl)-1H-pyrazole-4-carbonitrile (500 mg, 2.94 mmol) was added concentrated H2SO4 and the mixture was stirred at rt for 2 h. The solution was then cooled to 0° C. and 50% aqueous NH4OH (15 mL) was added slowly. The mixture was stirred at 0° C. for 5 min and then the solid was collected by filtration washing with cold water and diethyl ether to afford 5-amino-1-(2-chloroethyl)-1H-pyrazole-4-carboxamide as a white solid (487 mg, 88%). 1H NMR (300 MHz, DMSO-d6) δ 7.68 (s, 1H), 6.51-7.47 (m, 2H), 6.30 (br s, 2H), 4.20 (t, J=6.1 Hz, 2H), 3.74-4.00 (m, 2H). LCMS (ESI) m/z 189 (M+H)+.
Step D:
To 5-amino-1-(2-chloroethyl)-1H-pyrazole-4-carboxamide (300 mg, 1.58 mmol) and 2,2-difluoro-2-(4-fluorophenyl) acetic acid prepared as described in Example 20 Step D (362 mg, 1.90 mmol) was added trimethylsilyl polyphosphate (7 mL) and the mixture was heated at 130° C. overnight. The solution was cooled and equal volumes of EtOAc and water were added, and then the mixture was stirred for 30 min. The organic layer was separated, washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 1-(2-chloroethyl)-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (585 mg) as a crude solid which was used without further purification. LCMS (ESI) m/z 343 (M+H)+.
Step E:
To 1-(2-chloroethyl)-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol (100 mg, 0.29 mmol) were added DIEA (0.1 mL, 0.58 mmol) and phosphorous oxychloride (2 mL) and the mixture was heated at 95° C. overnight. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with saturated aqueous NaHCO3, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford the 4-chloro intermediate. To this intermediate was added a solution of 5-methyl-1H-pyrazol-3-amine (75 mg, 0.77 mmol) and DIEA (0.075 mL, 0.78 mmol) in DMF (2 mL) and the mixture was stirred at rt for 2 h. The mixture was then diluted with water and EtOAc. The organic layer was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a crude oil. To this oil were added NMP (3 mL), morpholine (0.1 mL, 1.14 mmol) and KI (100 mg, 0.60 mmol) and the mixture was stirred at 60° C. overnight. Additional morpholine (0.1 mL, 1.14 mmol) was added and the mixture was stirred at 100° C. overnight. HOAc (0.6 mL) was added and the mixture was purified by preparative HPLC (Varian diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (27 mg, 20%). 1H NMR (300 MHz, DMSO-d6) δ 12.15 (br s, 1H), 11.03 (br s, 1H), 8.33-8.57 (m, 1H), 7.68 (dd, J=5.5, 8.7 Hz, 2H), 7.36 (t, J=8.9 Hz, 2H), 6.16-6.36 (m, 1H), 4.30-4.55 (m, 2H), 3.37 (d, J=4.1 Hz, 4H), 2.75 (t, J=5.7 Hz, 2H), 2.38 (br s, 4H), 2.22 (s, 3H). LCMS (ESI) m/z 473 (M+H)+.
Step A:
To 1-(2-chloroethyl)-6-(difluoro(4-fluorophenyl)methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol from Example 32 Step D (350 mg, 1.02 mmol) were added DIEA (0.35 mL, 2.04 mmol) and phosphorous oxychloride (5 mL) and the mixture was heated at 100° C. overnight. The mixture was concentrated under reduced pressure and then toluene was added and evaporated. The residue was diluted with EtOAc, washed with saturated NaHCO3, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford a crude intermediate (330 mg). To this intermediate was added a solution of 5-methyl-1H-pyrazol-3-amine (240 mg, 0.25 mmol) and DIEA (0.24 mL, 1.35 mmol) in DMF (4 mL) and the mixture was stirred at rt for 1 h. The mixture was diluted with water and EtOAc, and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography eluting with 0-15% MeOH in DCM to afford 1-(2-chloroethyl)-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (220 mg, 51%) as a solid. LCMS (ESI) m/z 422 (M+H)+.
Step B:
To 1-(2-chloroethyl)-6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (68 mg, 0.16 mmol) were added MeOH (4 mL) and 25% NaOMe/MeOH (0.18 mL, 8 mmol). The mixture was stirred at rt for 1 h, and then potassium iodide (100 mg, 0.60 mmol) was added and the mixture was heated at 50° C. overnight. The mixture was concentrated under reduced pressure and then THF (4 mL), 15-crown-5 (0.05 mL, 0.25 mmol) and sodium methoxide (50 mg, 0.93 mmol) were added. The mixture was heated at 55° C. for 6 h, then cooled to rt and stirred overnight. The solution was concentrated under reduced pressure, followed by the addition of HOAc (0.5 mL) and DMSO (4 mL). This mixture was purified by preparative HPLC (Varian diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-vinyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1 mg, 2%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.20 (br s, 1H), 11.21 (br s, 1H), 8.61 (br s, 1H), 7.71 (dd, J=5.4, 8.6 Hz, 2H), 7.54 (dd, J=9.0, 15.6 Hz, 1H), 7.36 (t, J=8.8 Hz, 2H), 6.21 (br s, 1H), 5.84 (d, J=15.6 Hz, 1H), 5.05 (d, J=8.9 Hz, 1H), 2.21 (br s, 3H). LCMS (ESI) m/z 386 (M+H)+.
Step A:
To a mixture of 2-bromo-5-fluoropyridine (2 g, 11.36 mmol) and ethyl 2-bromo-2,2-difluoroacetate (1.6 mL, 12.5 mmol) in DMSO (4 mL) was added copper powder (1.6 g, 24.98 mmol) and the mixture was stirred at 50° C. overnight in a sealed flask. The mixture was diluted with DMSO (10 mL) and then filtered through Celite. Water and EtOAc were added to the filtrate and the mixture was shaken and again filtered through Celite. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford ethyl 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate (1.5 g, 60%) as a yellow oil which was used without further purification. 1H NMR (300 MHz, CDCl3) δ 8.50 (d, J=2.4 Hz, 1H), 7.76-7.80 (m, 1H), 7.54-7.60 (m, 1H), 4.38 (q, J=7.1 Hz, 2H), 1.34 (t, J=7.1 Hz, 3H).
Step B:
To ethyl 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate (560 mg, 2.55 mmol) in a mixture of MeOH (5 mL) and THF (5 mL) at rt was added 1 M NaOH (2.8 mL, 2.8 mmol). The mixture was stirred for 10 min and then concentrated to dryness to afford crude sodium 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate (548 mg) which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ 8.54 (d, J=2.4 Hz, 1H), 7.76-7.82 (m, 2H), 7.63-7.68 (m, 1H).
Step C:
To 5-amino-1-methyl-1H-pyrazole-4-carboxamide (2 g, 14.3 mmol) and sodium 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate (3.64 g, 17.12 mmol) was added trimethylsilyl polyphosphate (20 mL) and the mixture was heated at 130° C. overnight. The solution was cooled, equal volumes of EtOAc and water were added, and the mixture was stirred for 30 min. The organic layer was washed with brine, separated, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was dissolved in DCM and extracted with 1 N aqueous NaOH. The aqueous layer was washed with DCM and then acidified with 4 N HCl and extracted with EtOAc. The organic layer was separated, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 6-(difluoro(5-fluoropyridin-2-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (1.85 g, 44%) as a solid, which was used without further purification. 1H NMR (300 MHz, DMSO-d6) δ 11.67 (s, 1H), 8.77 (s, 1H), 7.95-8.21 (m, 3H), 3.74 (s, 3H).
Step D:
To 6-(difluoro(5-fluoropyridin-2-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-ol (200 mg, 0.68 mmol) were added phosphorous oxybromide (1.9 g, 6.66 mmol), toluene (1 mL) and DIEA (0.24 mL, 1.35 mmol), and the mixture was heated to 120° C. for 2 h. The mixture was cooled, diluted with EtOAc, and washed with saturated NaHCO3, dried over Na2SO4, and concentrated under reduced pressure to afford 230 mg of a solid. 180 mg of the solid was purified by silica gel chromatography eluting with 20-80% EtOAc/hexanes to afford 4-bromo-6-(difluoro(5-fluoropyridin-2-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (90 mg) as a white solid. 1H NMR (300 MHz, CDCl3) δ 8.43 (d, J=2.6 Hz, 1H), 8.15 (s, 1H), 8.01 (dd, J=4.1, 8.7 Hz, 1H), 7.61 (dt, J=2.7, 8.3 Hz, 1H), 4.19 (s, 3H); LCMS (ESI) m/z 358 and 360 (M+H)+.
Step E:
To a solution of 5-methyl-1H-pyrazol-3-amine (81 mg, 0.83 mmol) and DIEA (0.08 mL, 0.46 mmol) in DMF (2 mL) at 0° C. was added a solution of 4-bromo-6-(difluoro(5-fluoropyridin-2-yl)methyl)-1-methyl-1H-pyrazolo[3,4-d]pyrimidine (80 mg, 0.3 mmol) in DMF (2 mL). The solution was allowed to warm to rt and was stirred overnight. The mixture was purified by preparative HPLC (Varian diphenyl reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 6-(difluoro(5-fluoropyridin-2-yl)methyl)-1-methyl-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (36 mg, 32%) as a solid. 1H NMR (300 MHz, DMSO-d6) δ 12.12 (br s, 1H), 11.01 (br s, 1H), 8.67 (s, 1H), 8.43 (br s, 1H), 8.00 (d, J=5.3 Hz, 2H), 5.88 (s, 1H), 3.97 (s, 3H), 2.15 (s, 3H). LCMS (ESI) m/z 375 (M+H)+.
Step A:
A mixture of 4-amino-2-(methylthio)thiazole-5-carbonitrile (500 mg, 2.92 mmol) and concentrated sulfuric acid (3 mL) was stirred at rt for 1 h. Ice was added with stirring, the mixture was diluted with water, and the resulting solid was collected by filtration and dried under vacuum to afford 4-amino-2-(methylthio)thiazole-5-carboxamide (380 mg, 68%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 6.95 (br s, 2H), 2.64 (s, 3H). LCMS (ESI) m/z 190 (M+H)+.
Step B:
A stirred mixture of 4-amino-2-(methylthio)thiazole-5-carboxamide (380 mg, 2.01 mmol), 2,2-difluoro-2-(4-fluorophenyl)acetic acid prepared as described in Example 20 Step D (458 mg, 2.41 mmol) and trimethylsilyl polyphosphate (3 mL) was heated at 120° C. for 20 h. After cooling to rt, the mixture was partitioned between 50% MeOH/H2O and EtOAc. The separated aqueous layer was extracted with EtOAc and the combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The solid residue was triturated with diethyl ether to afford 5-(difluoro(4-fluorophenyl)methyl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7(6H)-one (476 mg, 69%) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 13.75 (br s, 1H), 7.72-7.77 (m, 2H), 7.37-7.43 (m, 2H), 2.80 (s, 3H). LCMS (ESI) m/z 344 (M+H)+ and 366 (M+H+Na)+.
Step C:
A stirred mixture of 5-(difluoro(4-fluorophenyl)methyl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7(6H)-one (476 mg, 1.39 mmol) and phosphorous oxychloride (3 mL) was heated at 100° C. for 1.5 h. After cooling to rt, the mixture was concentrated under reduced pressure. The residue was partitioned between saturated aqueous sodium hydrogen carbonate and EtOAc. The separated aqueous layer was extracted with EtOAc and the combined organic layers were washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to afford 7-chloro-5-(difluoro(4-fluorophenyl)methyl)-2-(methylthio)thiazolo[4,5-d]pyrimidine (406 mg, 81%) as a tan solid which did not require further purification. 1H NMR (300 MHz, DMSO-d6) δ 7.68-7.73 (m, 2H), 7.33-7.39 (m, 2H), 2.90 (s, 3H). LCMS (ESI) m/z 362 (M+H)+.
Step D:
A mixture of 7-chloro-5-(difluoro(4-fluorophenyl)methyl)-2-(methylthio)thiazolo[4,5-d]pyrimidine (150 mg, 0.42 mmol), 5-methyl-1H-pyrazol-3-amine (80 mg, 0.83 mmol), potassium iodide (138 mg, 0.83 mmol), DIEA (108 mg, 0.83 mmol) and DMF (2 mL), was stirred at rt for 15 h. Water (20 mL) was added and the mixture was stirred at rt for 10 min. The resulting solid was collected by filtration and purified by trituration with diethyl ether to afford 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7-amine (80 mg, 46%) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 12.31 (br s, 1H), 10.62 (br s, 1H), 7.64-7.75 (m, 2H), 7.29-7.42 (m, 2H), 6.11 (s, 1H), 2.79 (s, 3H), 2.23 (s, 3H). LCMS (ESI) m/z 423 (M+H)+.
Step A:
To a stirred solution of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7-amine (prepared according to the procedure described in Example 35) (400 mg, 0.95 mmol) in a mixture of DCM (4 mL) and DMF (4 mL) at 0° C., was added 70% m-CPBA (234 mg, 0.95 mmol). After stirring at 0° C. for 20 min, the mixture was allowed to warm to rt and stirred for 1 h. Additional 70% m-CPBA (234 mg, 0.95 mmol) was added and the mixture was stirred at rt for a further 1.5 h. A mixture of water and saturated aqueous sodium hydrogen carbonate was added and the mixture was stirred at rt for 10 min, before EtOAc was added and the mixture was stirred for a further 10 min. The mixture was transferred to a separatory funnel and the organic layer was separated. The aqueous layer was further extracted with EtOAc and the combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by trituration with 5% DCM in diethyl ether to afford 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (195 mg, 47%) as an orange solid. 1H NMR (300 MHz, DMSO-d6) δ 12.31 (br s, 1H), 11.26 (br s, 1H), 7.65-7.77 (m, 2H), 7.29-7.43 (m, 2H), 6.20 (br s, 1H), 3.09 (s, 3H), 2.26 (s, 3H). LCMS (ESI) m/z 439 (M+H)+.
Step B:
To a stirred solution of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (90 mg, 0.21 mmol) in DMA (2 mL) at rt, was added a solution of pyrrolidine (57 mg, 0.80 mmol) in DMA (0.5 mL) and the mixture was stirred for 10 min. The mixture was concentrated under reduced pressure and the residue was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 40 min, with a flow rate of 95 mL/min) to afford 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(pyrrolidin-1-yl)thiazolo[4,5-d]pyrimidin-7-amine (17 mg, 18%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.18 (br s, 1H), 9.96 (br s, 1H), 7.57-7.71 (m, 2H), 7.27-7.40 (m, 2H), 6.04 (s, 1H), 3.43-3.64 (m, 4H), 2.20 (s, 3H), 1.93-2.07 (m, 4H). LCMS (ESI) m/z 446 (M+H)+.
5-(Difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-morpholinothiazolo[4,5-d]pyrimidin-7-amine was prepared as a colorless solid (34 mg, 32%) using a procedure analogous to that described in Example 36, Step B, substituting morpholine for the pyrrolidine used in Example 36, Step B. 1H NMR (300 MHz, DMSO-d6) δ 12.20 (br s, 1H), 10.07 (br s, 1H), 7.59-7.72 (m, 2H), 7.27-7.42 (m, 2H), 6.04 (s, 1H), 3.67-3.82 (m, 4H), 3.52-3.64 (m, 4H), 2.21 (s, 3H). LCMS (ESI) m/z 462 (M+H)+.
5-(Difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(4-methylpiperazin-1-yl)thiazolo[4,5-d]pyrimidin-7-amine was prepared as a colorless solid (30 mg, 34%) using a procedure analogous to that described in Example 36, Step B, substituting 1-methylpiperazine for the pyrrolidine used in Example 36, Step B. 1H NMR (300 MHz, DMSO-d6) δ 12.17 (br s, 1H), 10.05 (br s, 1H), 7.59-7.70 (m, 2H), 7.26-7.41 (m, 2H), 6.04 (s, 1H), 3.55-3.65 (m, 4H), 2.40-2.50 (m, 4H), 2.23 (s, 3H), 2.21 (s, 3H). LCMS (ESI) m/z 475 (M+H)+.
A mixture of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (prepared according to the procedure described in Example 36, step A) (80 mg, 0.18 mmol) and potassium carbonate (80 mg, 0.58 mmol) in MeOH (2.5 mL), was stirred at rt for 15 min. The mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 25 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 40 min, with a flow rate of 95 mL/min) to afford 5-(difluoro(4-fluorophenyl)methyl)-2-methoxy-N-(5-methyl-1H-pyrazol-3-yl)thiazolo[4,5-d]pyrimidin-7-amine (23 mg, 32%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.29 (br s, 1H), 10.43 (br s, 1H), 7.62-7.72 (m, 2H), 7.29-7.42 (m, 2H), 6.08 (s, 1H), 4.17 (s, 3H), 2.22 (s, 3H). LCMS (ESI) m/z 407 (M+H)+.
A mixture of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (prepared according to the procedure described in Example 36, step A) (100 mg, 0.23 mmol) and potassium cyanide (30 mg, 0.46 mmol) in DMA (2.5 mL), was stirred at rt for 1 h 40 min. Additional potassium cyanide (15 mg, 0.23 mmol) was added and the mixture was stirred at rt for an additional 40 min. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 20 to 65% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 35 min, with a flow rate of 95 mL/min) to afford 5-(difluoro(4-fluorophenyl)methyl)-7-(5-methyl-1H-pyrazol-3-ylamino)thiazolo[4,5-d]pyrimidine-2-carbonitrile (15 mg, 16%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.17-12.88 (br m, 1H), 10.82-11.77 (br m, 1H), 7.65-7.80 (m, 2H), 7.27-7.50 (m, 2H), 6.28 (br s, 1H), 2.25 (s, 3H). LCMS (ESI) m/z 402 (M+H)+.
To a stirred solution of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (prepared according to the procedure described in Example 36, step A) (100 mg, 0.23 mmol) in THF (4 mL) at 0° C. under an argon atmosphere, was added dropwise 1.5M benzylmagnesium chloride/THF (0.6 mL, 0.90 mmol). The mixture was stirred at 0° C. for 20 min. The reaction was quenched by addition of water (0.5 mL) and the mixture was stirred at rt for 10 min. The mixture was concentrated under reduced pressure and the residue was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 20 to 80% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 40 min, with a flow rate of 95 mL/min) to afford 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)thiazolo[4,5-d]pyrimidin-7-amine (6 mg, 7%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.35 (br s, 1H), 10.85 (br s, 1H), 9.68 (s, 1H), 7.63-7.77 (m, 2H), 7.28-7.45 (m, 2H), 6.14 (s, 1H), 2.23 (s, 3H). LCMS (ESI) m/z 377 (M+H)+.
A mixture of 5-(difluoro(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-(methylsulfinyl)thiazolo[4,5-d]pyrimidin-7-amine (prepared according to the procedure described in Example 36 Step A) (80 mg, 0.18 mmol) and 2M methylamine/THF (1 mL, 2.0 mmol) was stirred at rt for 15 min. The mixture was purified by preparative reverse-phase HPLC (diphenyl column) eluting with a gradient of 10 to 65% acetonitrile (containing 0.05% HOAc) in water (containing 0.05% HOAc) (over 40 min, with a flow rate of 95 mL/min) to afford 5-(difluoro(4-fluorophenyl)methyl)-N2-methyl-N7-(5-methyl-1H-pyrazol-3-yl)thiazolo[4,5-d]pyrimidine-2,7-diamine (21 mg, 29%) as a colorless solid. 1H NMR (300 MHz, DMSO-d6) δ 12.17 (br s, 1H), 9.85 (br s, 1H), 8.64 (br s, 1H), 7.59-7.70 (m, 2H), 7.28-7.41 (m, 2H), 6.04 (s, 1H), 2.94 (d, J=2.1 Hz, 3H), 2.20 (s, 3H). LCMS (ESI) m/z 406 (M+H)+.
Step A:
To a mixture of 5-methyl-1H-pyrazol-3-amine (1.44 g, 14.84 mmol), DIEA (2.19 mL, 12.57 mmol) and KI (380 mg, 2.28 mmol) in DMF (13 mL) was added 4,6-dichloro-2-(methylthio)pyrimidine-5-carbaldehyde (2.55 g, 11.43 mmol). The mixture was stirred at rt for 3 h and then water was added. The suspended solid was collected by filtration and dried to afford crude 4-chloro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-(methylthio)pyrimidine-5-carbaldehyde (3.74 g, quantitative) as a light orange powder, which was used without further purification.
Step B:
To a mixture of crude 4-chloro-6-((5-methyl-1H-pyrazol-3-yl)amino)-2-(methylthio)pyrimidine-5-carbaldehyde (610 mg, 2.15 mmol) and DIEA (1.16 mL, 6.66 mmol) in dioxane (20 mL) was added ethylhydrazine oxalate (323 mg, 2.15 mmol). The mixture was stirred at rt for 20 min, then at 100° C. overnight. The mixture was concentrated under reduced pressure onto Celite and the residue was purified by silica gel chromatography eluting with 0-10% MeOH/DCM to afford 1-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (340 mg, 55%) as a yellow solid. LCMS (ESI) m/z 290 (M+H)+.
Step C:
To 1-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-6-(methylthio)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (202 mg, 0.7 mmol) in DCM (15 mL) was added 70% 3-chloroperbenzoic acid (345 mg, 1.53 mmol) and the mixture was stirred for 1 h. An additional amount of 70% 3-chloroperbenzoic acid (90 mg) was added and the mixture was stirred for 1 h at rt. The mixture was diluted with DCM and then aq sodium thiosulfate and saturated aqq sodium bicarbonate were added. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford a solid (280 mg). To 20 mg of this solid in DMF (0.8 mL) were added K2CO3 (15 mg, 0.093 mmol) and 4-fluorobenzenethiol (0.01 mL, 0.093 mmol) and the mixture was heated in a microwave synthesizer at 80° C. for 10 min, and then at 85° C. for 10 min. The mixture was purified by preparative HPLC (Phenomenex C-18 reverse phase column, eluted with gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 1-ethyl-6-((4-fluorophenyl)thio)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (5 mg, 27%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.35 (t, J=7.16 Hz, 3H) 2.07 (s, 3H) 4.23 (d, J=7.16 Hz, 2H) 5.40 (br. s., 1H) 7.24-7.47 (m, 2H) 7.71 (dd, J=8.57, 5.56 Hz, 2H) 8.31 (br. s., 1H) 10.74 (br. s., 1H) 12.01 (br. s., 1H); LCMS (ESI) m/z 370 (M+H)+.
Step A:
To 3-amino-1H-pyrazole-4-carbonitrile (4.32 g, 40 mmol) in DMF (30 mL) were added K2CO3 (6.6 g, 48 mmol) and bromocyclopentane (7.15 g, 48 mmol). The mixture was heated at 80° C. overnight and then filtered. The filtrate was concentrated under reduced pressure and the residue was partitioned between water and EtOAc. The organic layer was washed with brine, dried over sodium sulfate, and concentrated under reduced pressure. The residue was triturated with cold DCM then the solid was collected by filtration to afford 3-amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile (1.75 g, 25%) as a brown solid. 1H NMR (300 MHz, DMSO-d6) δ ppm 1.47-2.14 (m, 8H) 4.45 (quin, J=6.88 Hz, 1H) 5.54 (s, 2H) 8.12 (s, 1H).
Step B:
To 3-amino-1-cyclopentyl-1H-pyrazole-4-carbonitrile (1.5 g, 8.5 mmol) was added concentrated sulfuric acid (4 mL) and the mixture was stirred at rt for 2 h. Ice was added, followed by the slow addition of 50% NH4OH until the pH was >7. The cold suspension was then filtered and the collected solid was washed with water and Et2O to afford 3-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide (850 mg, 52%) as a tan solid. LCMS (ESI) m/z 195 (M+H)+.
Step C:
To a mixture of 3-amino-1-cyclopentyl-1H-pyrazole-4-carboxamide (650 mg, 3.35 mmol) and sodium 2,2-difluoro-2-(5-fluoropyridin-2-yl)acetate from Example 34 step B (860 mg, 4 mmol) was added trimethylsilyl polyphosphate (5 mL) and the mixture was heated at 120° C. overnight. The mixture was allowed to cool, equal volumes of EtOAc and water were added, and the mixture was stirred for 1 h. The organic layer was separated, washed with brine, dried over Na2SO4, and concentrated under reduced pressure to afford crude 2-cyclopentyl-6-(difluoro(5-fluoropyridin-2-yl)methyl)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (1.22 g, quantitative) as an oil that was used without further purification. LCMS (ESI) m/z 350 (M+H)+.
Step D:
To crude 2-cyclopentyl-6-(difluoro(5-fluoropyridin-2-yl)methyl)-2H-pyrazolo[3,4-d]pyrimidin-4-ol (320 mg, 0.91 mmol) were added phosphoryl tribromide (3.3 g), toluene (4 mL), and DIEA (0.32 mL, 1.82 mmol). The mixture was heated at 115° C. for 0.75 h, then at 90° C. overnight. The mixture was allowed to cool and was then partitioned between EtOAc and saturated aq sodium bicarbonate. The organic layer was dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography eluting with 15-80% EtOAc/hexanes. To the residue was added a solution of 5-methyl-1H-pyrazol-3-amine (113 mg, 1.16 mmol) in THF (3 mL) and the mixture was stirred at rt for 3 days. The mixture was purified by preparative HPLC (Varian diphenyl reverse phase column, eluting with a gradient of solvent B=0.05% HOAc/ACN and solvent A=0.05% HOAc/H2O) to afford 2-cyclopentyl-6-(difluoro(5-fluoropyridin-2-yl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-2H-pyrazolo[3,4-d]pyrimidin-4-amine (38 mg, 10%). 1H NMR (300 MHz, DMSO-d6) δ ppm 1.63-1.78 (m, 2H) 1.79-1.91 (m, 2H) 1.93-2.09 (m, 2H) 2.18 (s, 5H) 4.88-5.12 (m, 1H) 6.09 (br. s., 1H) 7.85-8.11 (m, 2H) 8.57-8.79 (m, 2H) 10.88 (br. s., 1H) 12.11 (br. s., 1H); LCMS (ESI) m/z 429 (M+H)+.
Competition binding assays used herein were developed, validated and performed as described in Fabian et al., Nature Biotechnology 2005, 23, 329-336. Kinases were produced as fusions to T7 phage (See, Fabian et al. or WO04/015142) or alternatively, the kinases were expressed in HEK-293 cells and subsequently tagged with DNA for PCR detection (See, WO08/005,310). For the binding assays, streptavidin-coated magnetic beads were treated with biotinylated affinity ligands for 30 min at rt to generate affinity resins. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinase, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17×PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 100× stocks in DMSO and rapidly diluted into the aqueous environment. DMSO was added to control assays lacking a test compound. Primary screen interactions were performed in polypropylene 384-well plates in a final volume of 34 μL, while Kd determinations were performed in polystyrene 96-well plates in a final volume of 135 μL. The assay plates were incubated at room temperature with shaking for 1 hour, long enough for binding reactions to reach equilibrium, and the affinity beads were washed extensively with wash buffer (1×PBS, 0.05% Tween 20) to remove unbound protein. The beads were then resuspended in elution buffer (1×PBS, 0.05% Tween 20, 2 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by quantitative PCR. Each kinase was tested individually against each compound. Kds were determined using eleven serial threefold dilutions. A selectivity score, which is a quantitative measure of selectivity of a compound against a panel of enzymes, may be calculated for a compound by dividing the number of enzymes for which a compound meets a set criteria, (for example, a binding constant of 100 nM or less), by the total number of enzymes tested. A kinase selectivity score, S10, for example, may be calculated for each compound by dividing the number of kinases for which a compound at a certain concentration (for example, 10 μM) displayed inhibition of 90% or greater compared to negative control lacking inhibitors (DMSO only), divided by the number of distinct kinases tested excluding mutant variants, typically 359 or 386.
In one embodiment, the compounds provided herein were found to have Kds of less than about 20 μM against JAK2. In another embodiment, the compounds provided herein were found to have Kds of less than about 10 μM against JAK2. In another embodiment, the compounds provided herein were found to have Kds of less than about 1 μM against JAK2.
In another embodiment, the compounds provided herein were found to have Kds of less than about 20 μM against JAK3. In another embodiment, the compounds provided herein were found to have Kds of less than about 10 μM against JAK3. In another embodiment, the compounds provided herein were found to have Kds of less than about 1 μM against JAK3.
CSTF-1 cells are derived from the human erythroleukemia cell line that is growth dependent on GM-CSF and has an intact GM-CSFR/JAK2/STAT5 pathway. The cell line contains stably integrated beta-lactamase reporter gene under the control of the regulatory factor 1 (irf 1) response element recognized by the activated transcription factor STAT5. csTF-1 cells (Invitrogen K1219) were washed with assay media (97% OPTIMEM/0.5% dialyzed FBS/0.1 mM NEAA/1 mM Na pyr/P/S) and seeded in the same media at 5×105 cell/mL in T150 flask. After 16 hour incubation, cells were seeded at 2×105 cell/well in 50 μl volume, into Costar, clear bottom, 96-well assay plates. Serial dilutions of compounds were added to the plates with final DMSO concentration at 0.5% and GM-CSF at 2 ng/mL and the plates were then incubated at 30° C. and 5% CO2 for 4 hours. The plates were brought to room temperature before adding Substrate Mixture according to manufacturer's protocol (Invitrogen, Catalog #K1085). The assay plates containing the substrate mixture were incubated in the dark at room temperature for 2 hours. Blue and green fluorescence was measured with excitation at 409 nm and emission at 460 nm (for blue) and excitation at 409 nm and emission at 530 nm (for green) using Spectra Max Gemini EM. The compounds provided herein were found to have IC50 of less than about 5 μM. In another embodiment, the compounds provided herein were found to have activity IC50 of less than about 500 nM.
The compounds provided herein were found to have the following activity shown in Table 1:
In Table 1,
CSTF-1 reporter assay IC50 (nM): A≦100, 100<B≦500, C>500;
In certain embodiments, the compounds provided herein bind to JAK2 kinase with higher specificity as compared to non-mutant and non-JAK family kinases. For certain compounds provided herein, binding constants for less than 10 non-mutant and non-JAK family kinases are within 100-fold of the binding constant for JAK2 kinase for compounds provided herein. For certain compounds provided herein, binding constants for less than 8 non-mutant and non-JAK family kinases are within 100-fold of the binding constant for JAK2 kinase for compounds provided herein. For certain compounds provided herein, binding constants for 6 non-mutant and non-JAK family kinases are within 100-fold of the binding constant for JAK2 kinase.
Since modifications will be apparent to those of skill in the art, it is intended that the claimed subject matter be limited only by the scope of the appended claims.
This application claims the benefit of the priority of U.S. Provisional Application No. 61/379,306, filed Sep. 1, 2010, the disclosure of which is incorporated herein by reference in its entirety.
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/US11/49911 | 8/31/2011 | WO | 00 | 7/18/2013 |
| Number | Date | Country | |
|---|---|---|---|
| 61379306 | Sep 2010 | US |
